Approved prescription drug products with therapeutic equivalence evaluations.

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

http://hdl.handle.net/2027/mdp.39015072931762

HathiTrust

www.hathitrust.org

Public Domain, Google-digitized

http://www.hathitrust.org/access_use#pd-google

We have determined this work to be in the public domain, meaning that it is not subject to copyright. Users are free to copy, use, and redistribute the work in part or in whole. It is possible that current copyright holders, heirs or the estate of the authors of individual portions of the work, such as illustrations or photographs, assert copyrights over these portions. Depending on the nature of subsequent use that is made, additional rights may need to be obtained independently of anything we can address. The digital images and OCR of this work were produced by Google, Inc. (indicated by a watermark on each page in the PageTurner). Google requests that the images and OCR not be re-hosted, redistributed or used commercially. The images are provided for educational, scholarly, non-commercial purposes.

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

The University of Michigan Pharmacy Library

CUMULATIVE SUPPLEMENT 10

AUG'84 - JUN'85

SERIAL



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

5TH EDITION

THE UNIVERSITY OF MICHIGAN
PHARMACY LIBRARY
SEP 23 1985

REFERENCE

UNIVERSITY OF MICHIGAN
LIBRARIES
SEP 11 1985
DEPOSITED BY
UNITED STATES OF AMERICA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUGS AND BIOLOGICS

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google
Digitized by Google
Original from
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 5th Edition (the List), to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature, are identified by the term "list." The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1984. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Original from UNIVERSITY OF MICHIGAN
Digitized by Google
Generated for Sheerer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT> (DELETE) to the left of the line containing the overstruck print. The >DLT> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (¤) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the Drug Product List.

Products	Federal Register Reference
dicyclomine hydrochloride	JUN 22, 1984 (49 FR 25681)
isosorbide dinitrate	AUG 3, 1984 (49 FR 31151)
nandrolone decanoate	JUL 15, 1983 (48 FR 32395)

(continued)

Original from UNIVERSITY OF MICHIGAN

Products	Federal Register Reference
(continued)	
neomycin sulfate with either: dexamethasone sodium phosphate, fluocinolone acetonide, flurandrenolide, hydrocortisone, or methylprednisolone acetate. [topical anti-infectives for dermatologic use]	MAR 26, 1984 (49 FR 11888)
neomycin sulfate, polymyxin B sulfate, bacitracin zinc, and hydrocortisone [topical ointment]	MAY 4, 1984 (49 FR 19147)
nitroglycerin (capsule,controlled release;oral)	SEP 7, 1984 (49 FR 35428)
nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
parenteral multivitamin products	SEP 17, 1984 (49 FR 36446)
phenazopyridine hydrochloride and sulfamethoxazole	JUL 29, 1983 (48 FR 34516)
sulfanilamide and aminacrine	AUG 22, 1983 (48 FR 38097)
tranylcypromine sulfate	MAR 22, 1984 (49 FR 10708)

C. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

Former Applicant (Name)	New Applicant (Name)	New Abbreviated Name
OHIO MEDICAL ANESTHETICS	ANAQUEST	ANAQUEST

D. ADDENDUM: DRUG PRICE COMPETITION AND PATENT TERM RESTORATION

The addendum of this supplement provides information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984."

Original from UNIVERSITY OF MICHIGAN
Digitized by Google
Generated for Sheerer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google

E. DISCONTINUED APPROVED PRODUCT IDENTIFIER ("∂")

The Drug Price Competition and Patent Term Restoration Act of 1984 requires the FDA to make publicly available an alphabetical list of approved drug products, with the application number and approval date, for each product approved January 1, 1982 and thereafter, and an indication whether *in vitro* and/or *in vivo* bioequivalence studies are required for ANDA approval. This publication, *Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 5th Edition*, and its monthly supplements is being used to satisfy this new requirement. The Agency will no longer delete products from this publication when an applicant discontinues marketing for economic reasons, as it had done in the past. The only cause for product removal from the publication will be for safety reasons. Products discontinued from marketing will be flagged in the Cumulative Supplement and future editions of this publication with the "∂" symbol to designate their nonmarketed status.

Original from
UNIVERSITY OF MICHIGAN

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '84. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods.

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '84 (BASELINE)	OCT '84	JAN '85	APR '85
DRUG PRODUCTS LISTED	7415	7609	7746	7890
SINGLE SOURCE	2005 (27.0%)	2045 (26.9%)	2077 (26.8%)	2078 (26.3%)
MULTISOURCE(1)	5410 (72.9%)	5564 (73.1%)	5669 (73.2%)	5812 (73.7%)
THERAPEUTICALLY EQUIVALENT	4393 (59.2%)	4497 (59.1%)	4598 (59.4%)	4709 (59.6%)
NOT THERAPEUTICALLY EQUIVALENT	999 (13.4%)	1032 (13.5%)	1038 (13.4%)	1068 (13.5%)
EXCEPTIONS(2)	18 (0.3%)	26 (0.3%)	23 (0.3%)	26 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	-	4	9	2
NUMBER OF APPLICANTS	295	300	304	307

B. ACTIVITY FOR SUPPLEMENT NUMBER 10

	MAY '85	JUNE '85	CUMULATIVE
DRUG PRODUCTS ADDED:	40	43	83
NEWLY APPROVED	37	42	79
DESI EFFECTIVE	3	1	4
REMARKETED	0	0	0
DRUG PRODUCTS REMOVED:	28	24	52
WITHDRAWN APPROVAL	0	0	0
RX TO OTC SWITCH	0	0	0
DISCONTINUED MARKETING	28	24	52
NET GAIN IN DRUG PRODUCTS	12	19	31
SINGLE SOURCE PRODUCTS APPROVED	12	7	19
MULTISOURCE DRUG PRODUCTS APPROVED	28	36	64
NEW MOLECULAR ENTITIES APPROVED:	3	0	3
AS THE ENTITY	3	0	3
AS A SALT, ESTER OR DERIVATIVE OF THE ENTITY	0	0	0

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (i.e., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE I-5 OF THE LIST)

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

ACEBUTOLOL HYDROCHLORIDE (PAGE 3-1)

CAPSULE; ORAL
SECTRAL
IVES LABS/AMHO — EQ 200MG BASE* — N 18917
EQ 400MG BASE* — N 18917

ACETAMINOPHEN; BUTALBITAL (PAGE 3-1)

> ADD > CAPSULE; ORAL
> ADD > BUTALBITAL AND ACETAMINOPHEN
> ADD > AB DM GRAHAM LABS — 650MG;50MG* — N 88991
> ADD > PHRENILIN FORTE
> ADD > AB CARNRICK/GW CARNRICK — 650MG;50MG* — N 88831

TABLET; ORAL
BUTALBITAL AND ACETAMINOPHEN
AB DANBURY PHARMACAL — 325MG;50MG* — N 87550
> ADD > PHRENILIN
> ADD > AB CARNRICK/GW CARNRICK — 325MG;50MG* — N 87811

ACETAMINOPHEN; BUTALBITAL; CAFFEINE (PAGE 3-1)

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE
AB DM GRAHAM LABS — 325MG;50MG;40MG* — N 88758
AB — 325MG;50MG;40MG* — N 88765
> ADD > AB — 325MG;50MG;40MG* — N 89023
AB — 325MG;50MG;40MG* — N 89067
> ADD > AB — 325MG;50MG;40MG* — N 89102
ESGIC
AB GILBERT LABORATORIES — 325MG;50MG;40MG* — N 88825

TABLET; ORAL
> ADD > BUTALBITAL ASPIRIN AND CAFFEINE
> ADD > AB QUANTUM PHARMICS — 325MG;50MG;40MG* — N 88972
ESGIC
AB GILBERT LABORATORIES — 325MG;50MG;40MG* — N 87629
FIORICET
AB SANDOZ PHARMS/SANDOZ — 325MG;50MG;40MG* — N 88616
REPAN
AB DM GRAHAM LABS — 325MG;50MG;40MG* — N 87804

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
AA ZENITH LABORATORIES — 300MG;60MG — N 87083
ACETAMINOPHEN W/ CODEINE #2
AA LEMMON — 300MG;15MG* — N 88627

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

TABLET; ORAL
ACETAMINOPHEN W/ CODEINE #3
AA LEMMON — 300MG;30MG* — N 88628
ACETAMINOPHEN W/ CODEINE #4
AA LEMMON — 300MG;60MG* — N 88629
/ACETAMINOPHEN W/ CODEINE PHOSPHATE #4/
/AA/ /ZENITH LABORATORIES/ /300MG;60MG/ /N 87083/

ACETAMINOPHEN; HYDROCODONE BITARTRATE (PAGE 3-2)

CAPSULE; ORAL
ACETAMINOPHEN AND HYDROCODONE BITARTRATE
AA CENTRAL PHARMS — 500MG;5MG* — N 88898

TABLET; ORAL
ACETAMINOPHEN AND HYDROCODONE BITARTRATE
/AA/ /CENTRAL PHARMS/ /500MG;5MG/ /N 87757/
CO-GESIC
AA CENTRAL PHARMS — 500MG;5MG — N 87757
HYDROCODONE BITARTRATE W/ ACETAMINOPHEN
AA BARR LABORATORIES — 500MG;5MG* — N 88577

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

CAPSULE; ORAL
TYLOX
MCNEIL PHARM — 500MG;5MG* — N 88790
TYLOX-325
MCNEIL PHARM — 325MG;5MG* — N 88246

TABLET; ORAL
/CODACET/
OXYCET
AA HALSEY DRUG — 325MG;5MG* — N 87463

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE (PAGE 3-2)

TABLET; ORAL
DARVOCET-N 100
> ADD > AA ELI LILLY — 650MG;100MG — N 17122
DARVOCET-N 50
> ADD > AA ELI LILLY — 325MG;50MG — N 17122
> ADD > PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN
> ADD > AA BARR LABORATORIES — 325MG;50MG* — N 70115
> ADD > AA — 650MG;100MG* — N 70116
> ADD > AA MYLAN PHARMS — 650MG:100MG* — N 70145
> ADD > PROVOCET 100
> ADD > AA LEMMON — 650MG;100MG* — N 70107

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

ACETIC ACID, GLACIAL (PAGE 3-3)

SOLUTION/DROPS; OTIC
ACETIC ACID
AT THAMES PHARMACAL 2%* N 88638

ACETIC ACID, GLACIAL; HYDROCORTISONE (PAGE 3-3)

SOLUTION/DROPS; OTIC
HYDROCORTISONE AND ACETIC ACID
AT THAMES PHARMACAL 2%;1%* N 88759

ACYCLOVIR (PAGE 3-4)

CAPSULE; ORAL
ZOVIRAX
BURROUGHS WELLCOME 200MG* N 18828

ALBUTEROL SULFATE (PAGE 3-5)

SYRUP; ORAL
PROVENTIL
SCHERING EQ 2MG BASE/5ML* N 18062

ALLOPURINOL (PAGE 3-5)

TABLET; ORAL
ALLOPURINOL
AB BOLAR PHARMACEUTICAL 100MG* N 18241
AB 300MG* N 18241
AB CHELSEA LABORATORIES 100MG* N 18785
AB 300MG* N 18785
AB DANBURY PHARMACAL 100MG* N 18832
AB 300MG* N 18877

AMDINOCILLIN (PAGE 3-6)

INJECTABLE; INJECTION
COACTIN
HOFFMANN-LA ROCHE 250MG/VIAL* N 50565
500MG/VIAL* N 50565
1GM/VIAL* N 50565

AMIKACIN SULFATE (PAGE 3-6)

INJECTABLE; INJECTION
AMIKIN
BRISTOL LABS/B-M EQ 50MG BASE/ML* N 62562
EQ 250MG BASE/ML* N 62562

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION
BRANCHAMIN 4%
TRAVENOL LABS 4%* N 18678
BRANCHAMIN 4% IN PLASTIC CONTAINER
TRAVENOL LABS 4%* N 18684
TRAVASOL 10% W/O ELECTROLYTES IN PLASTIC CONTAINER
TRAVENOL LABS 10%* N 18931
TRAVASOL 5.5% W/O ELECTROLYTES IN PLASTIC CONTAINER
TRAVENOL LABS 5.5%* N 18931
TRAVASOL 8.5% W/O ELECTROLYTES IN PLASTIC CONTAINER
TRAVENOL LABS 8.5%* N 18931

AMINO ACIDS; DEXTROSE (PAGE 3-7)

INJECTABLE; INJECTION
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT LABORATORIES 3.5%;5GM/100ML N 19120
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT LABORATORIES 3.5%;25GM/100ML N 19118
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT LABORATORIES 4.25%;25GM/100ML N 19119

AMINOPHYLLINE (PAGE 3-8)

INJECTABLE; INJECTION
AMINOPHYLLINE
AP SOLOPAK LABORATORIES 25MG/ML* N 88429
AP 25MG/ML* N 88749

TABLET; ORAL
AMINOPHYLLINE
/BP/ /CORD LABORATORIES/ /200MG/ /N 85261/
AB CORD LABORATORIES 200MG N 85261

AMINOPHYLLINE; SODIUM CHLORIDE (PAGE 3-9)

INJECTABLE; INJECTION
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
AP ABBOTT LABORATORIES 100MG/100ML;450MG/100ML* N 88147
AP 200ML/100ML;450MG/100ML* N 88147
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 100MG/100ML;450MG/100ML* N 18924
AP 200MG/100ML;450MG/100ML* N 18924
400MG/100ML;450MG/100ML* N 18924
500MG/100ML;450MG/100ML* N 18924
/AMINOPHYLLINE 0.05% IN SODIUM CHLORIDE 0.45%/
/ABBOTT LABORATORIES//50MG/100ML;450MG/100ML/ /N 88147/
/AMINOPHYLLINE 0.1% IN SODIUM CHLORIDE 0.45%/
/AP/ /ABBOTT LABORATORIES//100MG/100ML;450MG/100ML*/ /N 88147/
/AMINOPHYLLINE 0.2% IN SODIUM CHLORIDE 0.45%/
/AP/ /ABBOTT LABORATORIES//200MG/100ML;450MG/100ML*/ /N 88147/

Generated for Shearrer, Cynthia D. (University of Missouri-Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

AMITRIPTYLINE HYDROCHLORIDE (PAGE 3-10)

TABLET; ORAL
AMITRIPTYLINE HCL

	BP	AM THERAPEUTICS	25MG*	N 88672
	BP		50MG*	N 88673
	BP		75MG*	N 88674
	BP		100MG*	N 88675
	BP	PAR PHARMACEUTICAL	10MG*	N 88697
	BP		25MG*	N 88698
	BP		50MG*	N 88699
	BP		75MG*	N 88700
	BP		100MG*	N 88701
	BP		150MG*	N 88702
> ADD >	AB	∂ PUREPAC/KALIPHARMA	10MG	N 88084
> ADD >	AB	∂	25MG	N 88085
> ADD >	AB	∂	50MG	N 88105
> ADD >	AB	∂	75MG	N 88106
> ADD >	AB	∂	100MG	N 88107
	~~BP~~	~~SIDMAK LABORATORIES~~	~~10MGH~~	~~N 88883~~
	~~BP~~		~~25MGH~~	~~N 88884~~
	~~BP~~		~~50MGH~~	~~N 88885~~
	~~BP~~		~~75MGH~~	~~N 88886~~
	~~BP~~		~~100MGH~~	~~N 88887~~
	~~BP~~		~~150MGH~~	~~N 88888~~
	AB	SIDMAK LABORATORIES	10MG*	N 88883
	AB		25MG*	N 88884
	AB		50MG*	N 88885
	AB		75MG*	N 88886
	AB		100MG*	N 88887
	AB		150MG*	N 88888
	BP	SUPERPHARM	10MG*	N 88853
	BP		25MG*	N 88854
	BP		50MG*	N 88855
	BP		75MG*	N 88856
	BP		100MG*	N 88857

AMMONIUM LACTATE (PAGE 3-12)

LOTION; TOPICAL
AMMONIUM LACTATE

BRISTOL-MYERS	EQ 12% ACID*	N 19155

AMOXICILLIN (PAGE 3-12)

CAPSULE; ORAL
UTIMOX

> ADD >	AB	∂ PARKE-DAVIS/W-L	250MG	N 62107
> ADD >	AB	∂	500MG	N 62107

AMOXICILLIN; POTASSIUM CLAVULANATE (PAGE 3-13)

POWDER FOR RECONSTITUTION; ORAL
AUGMENTIN '125'
BEECHAM LABS/BEECHAM 125MG/5ML;
EQ 31.25MG ACID/5ML* N 50575
AUGMENTIN '250'
BEECHAM LABS/BEECHAM 250MG/5ML;EQ 62.5MG ACID/5ML* N 50575

TABLET; ORAL
AUGMENTIN '250'
BEECHAM LABS/BEECHAM 250MG;EQ 125MG ACID* N 50564
AUGMENTIN '500'
BEECHAM LABS/BEECHAM 500MG;EQ 125MG ACID* N 50564

AMPHETAMINE SULFATE (PAGE 3-13)

TABLET; ORAL
AMPHETAMINE SULFATE

LANNETT	5MG*	N 83901
	10MG*	N 83901

AMPICILLIN SODIUM (PAGE 3-14)

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP	ELI LILLY	EQ 500MG BASE/VIAL*	N 62565
AP		EQ 1GM BASE/VIAL*	N 62565

AMPICILLIN/AMPICILLIN TRIHYDRATE (PAGE 3-14)

CAPSULE; ORAL
AMPICILLIN

AB	∂ DRUMMER/PHOENIX	EQ 250MG BASE	N 61387
AB	∂	EQ 500MG BASE	N 61387

ASPIRIN; BUTALBITAL; CAFFEINE (PAGE 3-16)

CAPSULE; ORAL
BUTALBITAL W/ ASPIRIN AND CAFFEINE
CHELSEA LABORATORIES 325MG;50MG;40MG* N 86231

TABLET; ORAL
BUTALBITAL COMPOUND

AB	ZENITH LABORATORIES	325MG;50MG;40MG*	N 85441

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

CAPSULE; ORAL
PROPOXYPHENE COMPOUND 65

AA	LEMMON	389MG;32.4MG;65MG*	N 89025
AA	ZENITH LABORATORIES	389MG;32.4MG;65MG*	N 83077

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

CAPSULE; ORAL
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE
AA CHELSEA LABORATORIES 389MG;32.4MG;65MG* N 85732

ASPIRIN; METHOCARBAMOL (PAGE 3-17)

TABLET; ORAL
/METHOCARBAMOL W/ ASPIRIN/
METHOCARBAMOL AND ASPIRIN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE (PAGE 3-18)

TABLET; ORAL
LOGEN
AA SUPERPHARM 0.025MG;2.5MG* N 88962

AURANOFIN (PAGE 3-18)

CAPSULE; ORAL
RIDAURA
SK&F LABORATORIES 3MG* N 18689

BACITRACIN ZINC, HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-20)

> ADD > OINTMENT; TOPICAL
> ADD > CORTISPORIN
> ADD > BURROUGHS WELLCOME 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;
> ADD > 5,000 UNITS/GM* N 50168

BENZOYL PEROXIDE; ERYTHROMYCIN (PAGE 3-21)

GEL; TOPICAL
BENZAMYCIN
DERMIK/RORER 5%;3%* N 50557

/BENZTHIAZIDE; RESERPINE/(PAGE 3-21)

/TABLET; ORAL/
/EXNA-R/
/AH ROBINS/ /50MG;0.125MG/ /N 14861/

BENZTROPINE MESYLATE (PAGE 3-21)

TABLET; ORAL
BENZTROPINE MESYLATE
BP PAR PHARMACEUTICAL 0.5MG* N 88877
BP 1MG* N 88894
BP 2MG* N 88895

BETAMETHASONE DIPROPIONATE (PAGE 3-22)

OINTMENT; TOPICAL
ALPHATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.05% BASE* N 19143
BETAMETHASONE DIPROPIONATE
AB E FOUGERA/BYK-GLDN EQ 0.05% BASE* N 19141
AB PHARMADERM/BYK-GLDN EQ 0.05% BASE* N 19140
DIPROLENE
BX SCHERING EQ 0.05% BASE* N 18741
DIPROSONE
AB SCHERING EQ 0.05% BASE* N 17691

BETAMETHASONE VALERATE (PAGE 3-22)

CREAM; TOPICAL
BETAMETHASONE VALERATE
AB THAMES PHARMACAL EQ 0.1% BASE* N 70062
BETATREX
/AP/ /SAVAGE LABS/BYK-GLDN/EQ 0.1% BASE/ /N 18862/
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE N 18862
VALNAC
AB NMC LABORATORIES EQ 0.1% BASE* N 70050

LOTION; TOPICAL
> ADD > BETA-VAL
> ADD > AB LEMMON EQ 0.1% BASE* N 70072

OINTMENT; TOPICAL
VALNAC
AB NMC LABORATORIES EQ 0.1% BASE* N 70051

BITOLTEROL MESYLATE (PAGE 3-24)

AEROSOL; INHALATION
TORNALATE
WINTHROP-BREON/STERL 0.37MG/INH* N 18770

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE (PAGE 3-24)

SYRUP; ORAL
AMBAY
AA BAY LABORATORIES 12.5MG/5ML;10MG/5ML* N 88626
AMBENYL
AA MARION LABORATORIES 12.5MG/5ML;10MG/5ML N 09319
BROMANYL
AA NATL PHARM MFG/BARRE 12.5MG/5ML;10MG/5ML* N 88343

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-25)

SYRUP; ORAL

	BIPHETANE DC			
AA	BAY LABORATORIES	2MG/5ML;10MG/5ML; 12.5MG/5ML*		N 88904
	BROMANATE DC			
AA	NATL PHARM MFG/BARRE	2MG/5ML;10MG/5ML; 12.5MG/5ML*		N 88723
	DIMETANE-DC			
AA	AH ROBINS	2MG/5ML;10MG/5ML 12.5MG/5ML		N 11694

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE (PAGE 3-25)

SYRUP; ORAL

> ADD >	**BIPHETANE DX**			
> ADD > AA	BAY LABORATORIES	2MG/5ML;10MG/5ML;30MG/5ML*		N 88811
	BROMANATE DM			
AA	NATL PHARM MFG/BARRE	2MG/5ML;10MG/5ML;30MG/5ML*		N 88722
	DIMETANE-DX			
AA	AH ROBINS	2MG/5ML;10MG/5ML;30MG/5ML		N 11694
AA		2MG/5ML;10MG/5ML;30MG/5ML		N 19279

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-25)

ELIXIR; ORAL

	BIPHETAP			
AA	BAY LABORATORIES	4MG/5ML;25MG/5ML*		N 88687
	BROMANATE			
AA	NATL PHARM MFG/BARRE	4MG/5ML;25MG/5ML*		N 88688
	/ELIXIR, DIMETAPP/			
	/AH ROBINS/	/4MG/5ML;25MG/5ML/		/N 13087/
	/TABLET, CONTROLLED RELEASE; ORAL/			
	/DIMETAPP/			
	/AH ROBINS/	/12MG;75MG/		/N 12436/

BUMETANIDE (PAGE 3-25)

TABLET; ORAL

	BUMEX			
> ADD >	HOFFMANN-LA ROCHE	2MG*		N 18225

/**BUPRENORPHINE HYDROCHLORIDE**/ (PAGE 3-26)

	/INJECTABLE; INJECTION/			
	/BUPRENEX/			
	/NORWICH EATON/P&G/	/EQ 0.3MG BASE/ML/		/N 18401/

BUTABARBITAL SODIUM (PAGE 3-26)

ELIXIR; ORAL

	/SODIUM BUTABARBITAL/			
	BUTABARBITAL SODIUM			

TABLET; ORAL

	BUTABARBITAL SODIUM			
AA	LEMMON	15MG*		N 88632
AA		30MG*		N 88631

CALCITONIN (PAGE 3-27)

INJECTABLE; INJECTION

	CALCIMAR			
	/ARMOUR PHARM/	/200 MRC UNITS/ML/		/N 17769/
		/400 MRC UNITS/ML/		/N 17769/
	ARMOUR PHARM	200 IU/ML		N 17769
		400 IU/VIAL		N 17497

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-28)

SOLUTION; INTRAPERITONEAL

	DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER			
AT	DELMED	25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML*		N 18883
	DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER			
AT	DELMED	25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML*		N 18883
	DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER			
AT	DELMED	25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML*		N 18883
	DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER			
AT	DELMED	25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML*		N 18883
	DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER			
AT	DELMED	25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML*		N 18883
	DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER			
AT	DELMED	25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML*		N 18883
	DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER			
AT	TRAVENOL LABS	25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML*		N 17512
	DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER			
AT	TRAVENOL LABS	25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML*		N 17512

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-28)

SOLUTION; INTRAPERITONEAL
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
AT TRAVENOL LABS 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML* N 17512

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-29)

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
AP TRAVENOL LABS 20MG/100ML;5GM/100ML; 105MG/100ML;600MG/100ML; 310MG/100ML* N 19367
AP 20MG/100ML;5GM/100ML; 179MG/100ML;600MG/100ML; 310MG/100ML* N 19367
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
AP TRAVENOL LABS 20MG/100ML;5GM/100ML; 254MG/100ML;600MG/100ML; 310MG/100ML* N 19367
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
AP TRAVENOL LABS 20MG/100ML;5GM/100ML; 179MG/100ML;600MG/100ML; 310MG/100ML* N 19367
AP 20MG/100ML;5GM/100ML; 328MG/100ML;600MG/100ML; 310MG/100ML* N 19367
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
AP TRAVENOL LABS 20MG/100ML;5GM/100ML; 254MG/100ML;600MG/100ML; 310MG/100ML* N 19367
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
AP TRAVENOL LABS 20MG/100ML;5GM/100ML; 328MG/100ML;600MG/100ML; 310MG/100ML* N 19367
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
AP TRAVENOL LABS 20MG/100ML;5GM/100ML; 105MG/100ML;600MG/100ML; 310MG/100ML* N 19367

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-29)

INJECTABLE; INJECTION
~~/PLASMA-LYTE IN PLASTIC CONTAINER/~~
PLASMA-LYTE R IN PLASTIC CONTAINER

CALCIUM GLUCEPTATE (PAGE 3-30)

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE
~~/AP/ /INTL MEDICATION SYS//EQ 90MG CALCIUM/5ML/ /N 87455/~~

CAPTOPRIL (PAGE 3-31)

TABLET; ORAL
CAPOTEN
ER SQUIBB AND SONS 12.5MG* N18343

CAPTOPRIL; HYDROCHLOROTHIAZIDE (PAGE 3-31)

TABLET; ORAL
CAPOZIDE 25/15
ER SQUIBB AND SONS 25MG;15MG* N 18709
CAPOZIDE 25/25
ER SQUIBB AND SONS 25MG;25MG* N 18709
CAPOZIDE 50/15
ER SQUIBB AND SONS 50MG;15MG* N 18709
CAPOZIDE 50/25
ER SQUIBB AND SONS 50MG;25MG* N 18709

CARBACHOL (PAGE 3-31)

~~/SOLUTION/DROPS; OPHTHALMIC/~~
INJECTABLE; INJECTION

CEFAZOLIN SODIUM; DEXTROSE (PAGE 3-33)

INJECTABLE; INJECTION
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER
TRAVENOL LABS EQ 10MG BASE/ML;50MG/ML* N 50566
EQ 20MG BASE/ML;50MG/ML* N 50566

CEFORAMIDE (PAGE 3-33)

INJECTABLE; INJECTION
PRECEF
BRISTOL LABS/B-M 500MG/VIAL* N 62579
1GM/VIAL* N 62579
2GM/VIAL* N 62579
10GM/VIAL* N 62579
20GM/VIAL* N 62579

CEFOTAXIME SODIUM (PAGE 3-33)

INJECTABLE; INJECTION
CLAFORAN
HOECHST-ROUSSEL ~~/EQ 500MG BASE/VIAL/ /N 50547/~~
EQ 10GM BASE/VIAL* N 50547

Generated for Shearrer, Cynthia D. (University of Missouri-Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

CEFOTAXIME SODIUM; DEXTROSE (PAGE 3-33)

INJECTABLE; INJECTION
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

HOECHST-ROUSSEL	EQ 20MG BASE/ML;50MG/ML*	N 50596
	EQ 40MG BASE/ML;50MG/ML*	N 50596

CEFOTAXIME SODIUM; SODIUM CHLORIDE (PAGE 3-33)

INJECTABLE; INJECTION
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOECHST-ROUSSEL	EQ 20MG BASE/ML;9MG/ML*	N 50596
	EQ 40MG BASE/ML;9MG/ML*	N 50596

CEFOXITIN SODIUM (PAGE 3-33)

INJECTABLE; INJECTION
MEFOXIN

MS&D/MERCK	EQ 10GM BASE/VIAL*	N 50517

CEFOXITIN SODIUM; DEXTROSE (PAGE 3-33)

INJECTABLE; INJECTION
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

MS&D/MERCK	EQ 20MG BASE/ML;50MG/ML*	N 50581
	EQ 40MG BASE/ML;50MG/ML*	N 50581

CEFOXITIN SODIUM; SODIUM CHLORIDE (PAGE 3-33)

INJECTABLE; INJECTION
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MS&D/MERCK	EQ 20MG BASE/ML;9MG/ML*	N 50581
	EQ 40MG BASE/ML;9MG/ML*	N 50581

CEFTIZOXIME SODIUM; DEXTROSE (PAGE 3-33)

INJECTABLE; INJECTION
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

SK&F LABORATORIES	EQ 20MG BASE/ML;50MG/ML*	N 50589
	EQ 40MG BASE/ML;50MG/ML*	N 50589

CEFTRIAXONE SODIUM (PAGE 3-33)

INJECTABLE; INJECTION
ROCEPHIN

HOFFMANN-LA ROCHE	EQ 250MG BASE/VIAL*	N 50585
	EQ 250MG BASE/VIAL*	N 62510
	EQ 500MG BASE/VIAL*	N 50585
	EQ 500MG BASE/VIAL*	N 62510
	EQ 1GM BASE/VIAL*	N 50585
	EQ 1GM BASE/VIAL*	N 62510

CEFTRIAXONE SODIUM (PAGE 3-33)

INJECTABLE; INJECTION
ROCEPHIN

HOFFMANN-LA ROCHE	EQ 2GM BASE/VIAL*	N 50585
	EQ 10GM BASE/VIAL*	N 50585

CELLULOSE SODIUM PHOSPHATE (PAGE 3-34)

POWDER; ORAL
CALCIBIND

MISSION PHARMACAL	300GM/BOT*	N 18757

CEPHALOTHIN SODIUM (PAGE 3-34)

INJECTABLE; INJECTION
CEPHALOTHIN

AP	INTL MEDICATION SYS	EQ 1GM BASE/VIAL*	N 62426
AP		EQ 2GM BASE/VIAL*	N 62426
AP		EQ 4GM BASE/VIAL*	N 62426
		EQ 500MG BASE/VIAL*	N 62426

CHLORDIAZEPOXIDE HYDROCHLORIDE (PAGE 3-37)

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL

AB	LEMMON	5MG*	N 88705
AB		10MG*	N 88706
AB		25MG*	N 88707
AB	SUPERPHARM	5MG*	N 88987
AB		10MG*	N 88986
AB		25MG*	N 88988

CHLOROTHIAZIDE (PAGE 3-38)

TABLET; ORAL
CHLOROTHIAZIDE

AB	@ DRUMMER/PHOENIX	250MG	N 85485

CHLORPHENTERMINE HYDROCHLORIDE (PAGE 3-40)

TABLET; ORAL
PRE-SATE

>ADD>	@ PARKE-DAVIS/W-L	EQ 65MG BASE	N 14696

CHLORPROMAZINE HYDROCHLORIDE (PAGE 3-40)

CONCENTRATE; ORAL
CHLORPROMAZINE HCL

/AA/	ROXANE LABORATORIES	30MG/ML	N 88157
/AA/		100MG/ML	N 88158

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

CHLORPROMAZINE HYDROCHLORIDE (PAGE 3-40)

CONCENTRATE; ORAL
CHLORPROMAZINE HCL INTENSOL

AA	ROXANE LABORATORIES	30MG/ML	N 88157
AA		100MG/ML	N 88158

TABLET; ORAL
CHLORPROMAZINE HCL

BP	CORD LABORATORIES	10MG	N 80439
BP		25MG	N 80439
BP		50MG	N 80439
BP		100MG	N 80439
BP		200MG	N 80439
	/SONAZINE/		
/BP/	/CORD LABORATORIES/	/10MG/	/N 80439/
/BP/		/25MG/	/N 80439/
/BP/		/50MG/	/N 80439/
/BP/		/100MG/	/N 80439/
/BP/		/200MG/	/N 80439/

CHLORPROPAMIDE (PAGE 3-42)

TABLET; ORAL
CHLORPROPAMIDE

AB	BARR LABORATORIES	100MG*	N 88812
AB		250MG*	N 88813
AB	CHELSEA LABORATORIES	100MG*	N 86865
AB	COLMED LABORATORIES	100MG*	N 88708
AB		250MG*	N 88709
AB	CORD LABORATORIES	100MG*	N 88725
AB		250MG*	N 88726
AB	DANBURY PHARMACAL	100MG*	N 88852
AB		250MG*	N 88826
AB	DURAMED PHARMS	100MG*	N 88918
AB		250MG*	N 88919
AB	LEMMON	100MG*	N 88768
AB	SIDMAK LABORATORIES	100MG*	N 88921
AB		250MG*	N 88922
AB	SUPERPHARM	100MG*	N 88694
AB		250MG*	N 88695
AB	ZENITH LABORATORIES	100MG*	N 88840
	GLUCAMIDE		
AB	LEMMON	250MG*	N 88641

CHLORTHALIDONE (PAGE 3-42)

TABLET; ORAL
CHLORTHALIDONE

> ADD >	AB	∂ DRUMMER/PHOENIX	50MG	N 87118
	AB	LEMMON	50MG*	N 88651

CHYMOPAPAIN (PAGE 3-43)

INJECTABLE; INJECTION
CHYMODIACTIN

SMITH LABORATORIES	4,000 UNITS/VIAL*	N 18663

CISPLATIN (PAGE 3-44)

INJECTABLE; INJECTION
/PLATINOL/

/BRISTOL LABS/B-M/	/10MG/ML/	/N 18057/
	/50MG/VIAL/	/N 18057/

PLATINOL-AQ

BRISTOL LABS/B-M	0.5MG/ML	N 18057

CLEMASTINE FUMARATE (PAGE 3-44)

SYRUP; ORAL
TAVIST

> ADD >	DORSEY LABS/SANDOZ	EQ 0.5MG BASE/5ML*	N 18675

CLOMIPHENE CITRATE (PAGE 3-45)

TABLET; ORAL
CLOMID

/BP/	/MERRELL DOW/DOW CHEM/	/50MG/	/N 16131/
AB	MERRELL DOW/DOW CHEM	50MG	N 16131
	CLOMIPHENE CITRATE		
/BP/	/PLANTEX/IKAPHARM/	/50MG/	/N 18361/
AB	PLANTEX/IKAPHARM	50MG	N 18361

CLONIDINE (PAGE 3-45)

FILM, CONTROLLED RELEASE; PERCUTANEOUS
CATAPRES-TTS-1

BOEHRINGER INGELHEIM	2.5MG*	N 18891

CATAPRES-TTS-2

BOEHRINGER INGELHEIM	5MG*	N 18891

CATAPRES-TTS-3

BOEHRINGER INGELHEIM	7.5MG*	N 18891

CLOTRIMAZOLE (PAGE 3-45)

TABLET; VAGINAL
MYCELEX-G

MILES PHARMS/MILES	500MG*	N 19069

Generated for Shearrer, Cynthia D. (University of Missouri-Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-46)

SYRUP; ORAL
PHENERGAN VC W/ CODEINE
AA WYETH LABS/AMHO 10MG/5ML;5MG/5ML;6.25MG/5ML N 08306
PROMETH VC W/ CODEINE
AA NATL PHARM MFG/BARRE 10MG/5ML;5MG/5ML;6.25MG/5ML* N 88764
PROMETHAZINE VC W/ CODEINE
AA BAY LABORATORIES 10MG/5ML;5MG/5ML;6.25MG/5ML* N 88896

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-46)

SYRUP; ORAL
PHENERGAN W/ CODEINE
AA WYETH LABS/AMHO 10MG/5ML;6.25MG/5ML N 08306
PROMETH W/ CODEINE
AA NATL PHARM MFG/BARRE 10MG/5ML;6.25MG/5ML* N 88763
PROMETHAZINE W/ CODEINE
AA BAY LABORATORIES 10MG/5ML;6.25MG/5ML* N 88875

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-46)

SYRUP; ORAL
ACTIFED W/ CODEINE
AA BURROUGHS WELLCOME 10MG/5ML;30MG/5ML;1.25MG/5ML N 12575
PSEUDODINE C
AA BAY LABORATORIES 10MG/5ML;30MG/5ML;1.25MG/5ML* N 88833
TRIACIN-C
AA NATL PHARM MFG/BARRE 10MG/5ML;30MG/5ML;1.25MG/5ML* N 88704

COLCHICINE; PROBENECID (PAGE 3-47)

TABLET; ORAL
PROBENECID AND COLCHICINE
BP DRUMMER/PHOENIX 0.5MG;500MG N 86130
PROBENECID W/ COLCHICINE
/BP/ /DRUMMER/PHOENIX/ /0.5MG;500MG/ /N 86130/

CORTICOTROPIN (PAGE 3-47)

INJECTABLE; INJECTION
CORTICOTROPIN
AP CARTER-GLOGAU LABS 40 UNITS/VIAL* N 88772

CORTISONE ACETATE (PAGE 3-47)

TABLET; ORAL
CORTISONE ACETATE
BP ∂ VITARINE/PHOENIX 25MG N 80333

CROMOLYN SODIUM (PAGE 3-48)

SOLUTION/DROPS; OPHTHALMIC
OPTICROM
FISONS 4%* N 18155

CYCLOPHOSPHAMIDE (PAGE 3-50)

INJECTABLE; INJECTION
CYTOXAN
/AP/ /MEAD JOHNSON/B-M/ /100MG/VIAL/ /N 12142/
/AP/ /200MG/VIAL/ /N 12142/
/AP/ /500MG/VIAL/ /N 12142/
/AP/ /1GM/VIAL/ /N 12142/
/2GM/VIAL/ /N 12142/
AP BRISTOL LABS/B-M 100MG/VIAL N 12142
AP 200MG/VIAL N 12142
AP 500MG/VIAL N 12142
AP 1GM/VIAL N 12142
2GM/VIAL N 12142

TABLET; ORAL
CYTOXAN
/MEAD JOHNSON/B-M/ /25MG/ /N 12141/
/50MG/ /N 12141/
CYTOXAN
BRISTOL LABS/B-M 25MG N 12141
50MG N 12141

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-51)

TABLET; ORAL
CYPROHEPTADINE HCL
AA AM THERAPEUTICS 4MG* N 88798
> ADD > AA ∂ DRUMMER PHOENIX 4MG N 87284

DESERPIDINE; METHYCLOTHIAZIDE (PAGE 3-52)

TABLET; ORAL
ENDURONYL
BP ABBOTT LABORATORIES 0.25MG;5MG N 12775
ENDURONYL FORTE
BP ABBOTT LABORATORIES 0.5MG;5MG N 12775
METHYCLOTHIAZIDE AND DESERPIDINE
BP BOLAR PHARMACEUTICAL 0.25MG;5MG* N 88486
BP 0.5MG;5MG* N 88452

DESONIDE (PAGE 3-53)

CREAM; TOPICAL
DESOWEN
AB OWEN LABS/DERM PRODS 0.05%* N 19048
TRIDESILON
AB MILES PHARMS/MILES 0.05% N 17010

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

DESOXIMETASONE (PAGE 3-53)

OINTMENT; TOPICAL
TOPICORT
HOECHST-ROUSSEL 0.05%* N 18594

DEXAMETHASONE (PAGE 3-53)

/CREAM; TOPICAL/
/HEXADROL/
/ORGANON/ARZONA/ /0.04%/ /N 13304/

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-55)

OINTMENT; OPHTHALMIC
DEXACIDIN
AT COOPERVISION PHARMS 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM* N 62566

SUSPENSION/DROPS; OPHTHALMIC
DEXACIDIN
AT COOPERVISION PHARMS 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML* N 62544

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-55)

SOLUTION/DROPS; OPHTHALMIC
DEXAMETHASONE SODIUM PHOSPHATE
AT CARTER-GLOGAU LABS EQ 0.1% PHOSPHATE* N 88771

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE (PAGE 3-56)

SOLUTION/DROPS; OPHTHALMIC
NEODECADRON
AT MS&D/MERCK EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML N 50322
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE
AT PHARMAFAIR EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML* N 62539

/**DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE**/(PAGE 3-56)

/TABLET; ORAL/
/DISOPHROL/
/SCHERING/ /2MG;60MG/ /N 12394/

DEXTROAMPHETAMINE SULFATE (PAGE 3-56)

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE
AA ∂ VITARINE/PHOENIX 5MG N 84986
AA ∂ 10MG N 85892

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-57)

SYRUP; ORAL
PHENERGAN W/ DEXTROMETHORPHAN
AA WYETH LABS/AMHO 15MG/5ML;6.25MG/5ML N 11265
PROMETH W/ DEXTROMETHORPHAN
AA NATL PHARM MFG/BARRE 15MG/5ML;6.25MG/5ML* N 88762
PROMETHAZINE DM
AA BAY LABORATORIES 15MG/5ML;6.25MG/5ML* N 88864

DEXTROSE (PAGE 3-57)

INJECTABLE; INJECTION
DEXTROSE 30% IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 30GM/100ML* N 19345
AP TRAVENOL LABS 30GM/100ML N 17521
DEXTROSE 38.5% IN PLASTIC CONTAINER
ABBOTT LABORATORIES 38.5GM/100ML* N 18923
DEXTROSE 5% IN PLASTIC CONTAINER
/AP/ /ABBOTT LABORATORIES/ /5GM/100ML/ /N 16367/
AP ABBOTT LABORATORIES 50MG/ML N 16367
DEXTROSE 60% IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 60GM/100ML* N 19346

DEXTROSE; HEPARIN SODIUM (PAGE 3-58)

INJECTABLE; INJECTION
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%
AP ABBOTT LABORATORIES 5GM/100ML;10,000 UNITS/100ML* N 18911
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 5GM/100ML;10,000 UNITS/100ML* N 19339
HEPARIN SODIUM 1000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 5GM/100ML;200 UNITS/100ML* N 19130
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%
ABBOTT LABORATORIES 5GM/100ML;5,000 UNITS/100ML* N 18911
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 5GM/100ML;5,000 UNITS/100ML* N 19339
HEPARIN SODIUM 2000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 5GM/100ML;200 UNITS/100ML* N 19130
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
AP ABBOTT LABORATORIES 5GM/100ML;10,000 UNITS/100ML* N 18911
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 5GM/100ML;5,000 UNITS/100ML* N 19339
AP 5GM/100ML;10,000 UNITS/100ML* N 19339
HEPARIN SODIUM 25000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 5GM/100ML;5,000 UNITS/100ML* N 19134
HEPARIN SODIUM 5000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
AM MCGAW/AM HOSP 5GM/100ML;1,000 UNITS/100ML* 9130

Generated for Shearrer, Cynthia D. (University of Missouri-Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

DEXTROSE; LIDOCAINE HYDROCHLORIDE (PAGE 3-58)

INJECTABLE; INJECTION

LIDOCAINE HCL W/ DEXTROSE

AP	ABBOTT LABORATORIES	7.5%;5%	N 83914
	~~XYLOCAINE HCL W/ DEXTROSE~~		
	XYLOCAINE W/ DEXTROSE		
	ASTRA PHARM PRODS	7.5%;1.5%	N 16297

XYLOCAINE W/ GLUCOSE

AP	ASTRA PHARM PRODS	7.5%;5%	N 10496

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE (PAGE 3-58)

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

	AM MCGAW/AM HOSP	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML*	N 19025

DEXTROSE; OXYTOCIN (PAGE 3-59)

INJECTABLE; INJECTION

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

AP	ABBOTT LABORATORIES	5GM/100ML;1 USP UNIT/100ML*	N 19185
AP		5GM/100ML;2 USP UNITS/100ML*	N 19185

OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

AP	ABBOTT LABORATORIES	5GM/100ML;2 USP UNITS/100ML*	N 19185

OXYTOCIN 5 USP UNITS IN DEXTROSE 5%

AP	ABBOTT LABORATORIES	5GM/100ML;1 USP UNIT/100ML*	N 19185

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE (PAGE 3-60)

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	TRAVENOL LABS	5GM/100ML;75MG/100ML; 900MG/100ML*	N 19308
AP		5GM/100ML;150MG/100ML; 900MG/100ML*	N 19308

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	TRAVENOL LABS	5GM/100ML;150MG/100ML; 900MG/100ML*	N 19308
AP		5GM/100ML;300MG/100ML; 900MG/100ML*	N 19308

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	TRAVENOL LABS	5GM/100ML;224MG/100ML; 900MG/100ML*	N 19308

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	TRAVENOL LABS	5GM/100ML;300MG/100ML; 900MG/100ML*	N 19308

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE (PAGE 3-60)

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	TRAVENOL LABS	5GM/100ML;150MG/100ML; 900MG/100ML*	N 19308

DEXTROSE; THEOPHYLLINE (PAGE 3-62)

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	TRAVENOL LABS	5GM/100ML;40MG/100ML	N 18649
AP		5GM/100ML;80MG/100ML	N 18649
AP		5GM/100ML;160MG/100ML	N 18649
AP		5GM/100ML;200MG/100ML	N 18649
AP		5GM/100ML;400MG/100ML	N 18649

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT LABORATORIES	5GM/100ML;40MG/100ML*	N 19211
AP		5GM/100ML;80MG/100ML*	N 19211
AP		5GM/100ML;160MG/100ML*	N 19211
AP		5GM/100ML;200MG/100ML*	N 19211
AP		5GM/100ML;400MG/100ML*	N 19211

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	AM MCGAW/AM HOSP	5GM/100ML;40MG/100ML*	N 19083

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	AM MCGAW/AM HOSP	5GM/100ML;80MG/100ML*	N 19083

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	AM MCGAW/AM HOSP	5GM/100ML;160MG/100ML*	N 19083

THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	AM MCGAW/AM HOSP	5GM/100ML;200MG/100ML*	N 19212

THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	AM MCGAW/AM HOSP	5GM/100ML;400MG/100ML*	N 19212

DIATRIZOATE MEGLUMINE (3-62)

INJECTABLE; INJECTION

~~HYPAQUE~~

~~AP~~	~~WINTHROP LABS/STERL~~	~~30%~~	~~N 16403~~
~~AP~~		~~60%~~	~~N 16403~~

HYPAQUE MEGLUMINE 30%

AP	WINTHROP-BREON/STERL	30%	N 16403

HYPAQUE MEGLUMINE 60%

AP	WINTHROP-BREON/STERL	60%	N 16403

SOLUTION; URETHRAL

>ADD>	CYSTOGRAFIN DILUTE		
>ADD>	ER SQUIBB AND SONS	18%*	N 10040

HYPAQUE-CYSTO

~~AT~~	~~WINTHROP LABS/STERL~~	~~30%~~	~~N 16403~~
AT	WINTHROP-BREON/STERL	30%	N 16403

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

DIATRIZOATE SODIUM (PAGE 3-63)

INJECTABLE; INJECTION
HYPAQUE
~~/AP/ /WINTHROP LABS/STERL//50%/ /N 09992/~~
~~/25%/ /N 09561/~~
AP WINTHROP-BREON/STERL 50% N 09561
25% N 09561

SOLUTION; URETERAL
HYPAQUE
~~/WINTHROP LABS/STERL//20%/ /N 09561/~~
WINTHROP-BREON/STERL 20% N 09561

DICYCLOMINE HYDROCHLORIDE (PAGE 3-64)

CAPSULE; ORAL
BENTYL
MERRELL DOW/DOW CHEM 10MG* N 07409

INJECTABLE; INJECTION
BENTYL
MERRELL DOW/DOW CHEM 10MG/ML* N 08370

SYRUP; ORAL
BENTYL
MERRELL DOW/DOW CHEM 10MG/5ML* N 07961

TABLET; ORAL
BENTYL
MERRELL DOW/DOW CHEM 20MG* N 07409

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-65)

TABLET; ORAL
DIETHYLPROPION HCL
AA LEMMON 25MG* N 88642

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

INJECTABLE; INJECTION
EMBOLEX
SANDOZ PHARMS/SANDOZ 0.5MG/0.5ML;2,500 UNITS/0.5ML;
5.33MG/0.5ML* N 18885
0.5MG/0.7ML;5,000 UNITS/0.7ML;
7.46MG/0.7ML* N 18885

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-67)

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
AA SUPERPHARM 25MG* N 89040
AA 50MG* N 89041

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-67)

ELIXIR; ORAL
DIPHENHYDRAMINE HCL
AA NASKA PHARMACAL 12.5MG/5ML* N 88680

DISOPYRAMIDE PHOSPHATE (PAGE 3-68)

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE
AB BIOCRAFT LABS EQ 100MG BASE* N 70101
AB EQ 150MG BASE* N 70102
AB DANBURY PHARMACAL EQ 100MG BASE* N 70173
AB EQ 150MG BASE* N 70174
> ADD > AB MYLAN PHARMS EQ 100MG BASE* N 70138
> ADD > AB EQ 150MG BASE* N 70139
NORPACE
AB SEARLE PHARMS EQ 100MG BASE N 17447
AB EQ 150MG BASE N 17447

DISULFIRAM (PAGE 3-68)

TABLET; ORAL
DISULFIRAM
BX PAR PHARMACEUTICAL 250MG* N 88792
BX 500MG* N 88793

DIVALPROEX SODIUM (PAGE 3-69)

TABLET, ENTERIC COATED; ORAL
DEPAKOTE
ABBOTT LABORATORIES EQ 125MG BASE* N 18723

DOPAMINE HYDROCHLORIDE (PAGE 3-69)

INJECTABLE; INJECTION
DOPAMINE HCL
> ADD > AP INVENEX LABS/LIFE 40MG/ML* N 70012
> ADD > AP 80MG/ML* N 70013
AP LYPHOMED 40MG/ML* N 70058
AP 80MG/ML* N 70059

DOXORUBICIN HYDROCHLORIDE (PAGE 3-69)

INJECTABLE; INJECTION
ADRIAMYCIN
FARMITALIA CARLO ERB 20MG/VIAL* N 50467

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

DOXYCYCLINE HYCLATE (PAGE 3-70)

CAPSULE; ORAL
- **DOXY-LEMMON**
  - AB LEMMON — EQ 50MG BASE* — N 62497
- **DOXYCYCLINE HYCLATE**
  - AB HALSEY DRUG — EQ 50MG BASE* — N 62119
  - AB — EQ 100MG BASE* — N 62119
  - AB PAR PHARMACEUTICAL — EQ 50MG BASE* — N 62434
  - AB SUPERPHARM — EQ 50MG BASE* — N 62469
  - AB — EQ 100MG BASE* — N 62469
  - AB WEST-WARD — EQ 50MG BASE* — N 62396
  - AB ZENITH LABORATORIES — EQ 50MG BASE* — N 62500
  - AB — EQ 100MG BASE* — N 62500

TABLET; ORAL
- **DOXY-LEMMON**
  - AB LEMMON — EQ 100MG BASE* — N 62581
- **DOXYCYCLINE HYCLATE**
  - AB SUPERPHARM — EQ 100MG BASE* — N 62494
  - AB ZENITH LABORATORIES — EQ 100MG BASE* — N 62505

DOXYLAMINE SUCCINATE (PAGE 3-70)

TABLET; ORAL
- **DECAPRYN**
  - AA MERRELL DOW/DOW CHEM — 25MG — N 06412
- **DOXYLAMINE SUCCINATE**
  - AA QUANTUM PHARMICS — 25MG* — N 88603

DRONABINOL (PAGE 3-70)

CAPSULE; ORAL
- MARINOL
  - UNIMED — 2.5MG* — N 18651
  - — 5MG* — N 18651
  - — 10MG* — N 18651

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE (PAGE 3-72)

INJECTABLE; INJECTION
- LIGNOSPAN FORTE
  - DEPROCO — EQ 0.02MG BASE/ML;2%* — N 88389
- LIGNOSPAN STANDARD
  - DEPROCO — EQ 0.01MG BASE/ML;2%* — N 88390

ERGOCALCIFEROL (PAGE 3-72)

CAPSULE; ORAL
- **DRISDOL**
  - AA ~~WINTHROP LABS/STERL~~ — ~~50,000 IU~~ — ~~N 03444~~
  - AA WINTHROP-BREON/STERL — 50,000 IU — N 03444
- **VITAMIN D**
  - > ADD > AA VITARINE/PHOENIX — 50,000 IU — N 84053

ERYTHROMYCIN (PAGE 3-73)

OINTMENT; TOPICAL
- AKNE-MYCIN
  - HERMAL PHARM LABS — 2%* — N 50584

SOLUTION; TOPICAL
- **SANSAC**
  - AT OWEN LABS/DERM PRODS — 2%* — N 62522

SWAB; TOPICAL
- ERYCETTE
  - ORTHO PHARMACEUTICAL — 2%* — N 50594

ERYTHROMYCIN ETHYLSUCCINATE (PAGE 3-74)

SUSPENSION; ORAL
- **ERYTHROMYCIN ETHYLSUCCINATE**
  - AB PHARMAFAIR — EQ 200MG BASE/5ML* — N 62559
  - AB — EQ 400MG BASE/5ML* — N 62558

ERYTHROMYCIN LACTOBIONATE (PAGE 3-75)

INJECTABLE; INJECTION
- **ERYTHROMYCIN**
  - AP ELKINS-SINN/AHROBINS — EQ 500MG BASE/VIAL* — N 62563
  - AP — EQ 1GM BASE/VIAL* — N 62563
- **ERYTHROMYCIN LACTOBIONATE**
  - AP ABBOTT LABORATORIES — EQ 500MG BASE/VIAL — N 50182
  - AP — EQ 1GM BASE/VIAL — N 50182

ESTROGENS, CONJUGATED (PAGE 3-76)

TABLET; ORAL
- CONJUGATED ESTROGENS
  - BS ZENITH LABORATORIES — 0.3MG* — N 88569

ETHACRYNATE SODIUM (PAGE 3-78)

INJECTABLE; INJECTION
- EDECRIN
  - > DLT > ~~MS&D/MERCK~~ — ~~EQ 50MG BASE/VIAL~~ — ~~N 16093~~
  - > ADD > MS&D/MERCK — EQ 50MG ACID/VIAL — N 16093

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE (PAGE 3-78)

TABLET; ORAL-21
- ~~DEMULEN~~
- DEMULEN 1/50-21

TABLET; ORAL-28
- ~~DEMULEN-28~~
- DEMULEN 1/50-28

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

ETHINYL ESTRADIOL; LEVONORGESTREL (PAGE 3-78)

TABLET; ORAL-21
TRIPHASIL-21
WYETH LABS/AMHO 0.03MG,0.04MG,0.03MG; 0.05MG,0.075MG,0.125MG* N 19192

TABLET; ORAL-28
TRIPHASIL-28
WYETH LABS/AMHO 0.03MG,0.04MG,0.03MG; 0.05MG,0.075MG,0.125MG* N 19190

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE (PAGE 3-79)

TABLET; ORAL-21
/LOESTRIN 1.5/30/
LOESTRIN 21 1.5/30

ETIDRONATE DISODIUM (PAGE 3-81)

TABLET; ORAL
DIDRONEL
NORWICH EATON/P&G 400MG* N 17831

FENTANYL CITRATE (PAGE 3-81)

INJECTABLE; INJECTION
FENTANYL CITRATE
AP ABBOTT LABORATORIES EQ 0.05MG BASE/ML* N 19115

FLUNISOLIDE (PAGE 3-82)

AEROSOL; INHALATION
BRONALIDE
SYNTEX LABS/SYNTEX 0.025MG/INH* N 18340

FLUOCINOLONE ACETONIDE (PAGE 3-82)

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
AT BAY LABORATORIES 0.01%* N 88757
AT 0.025%* N 88756
AT PHARMAFAIR 0.01%* N 88499
AT 0.025%* N 88506
FLUONID
AT HERBERT LABS/ALLERGN 0.025%* N 87156
/AT/ /MARION LABORATORIES//0.01%/ /N 80434/
/AT/ /0.025%/ /N 80434/

FLUOCINOLONE ACETONIDE (PAGE 3-82)

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
AT BAY LABORATORIES 0.025%* N 88742
FLUONID
AT HERBERT LABS/ALLERGN 0.025%* N 87157
/AT/ /MARION LABORATORIES//0.025%/ /N 80433/

SOLUTION; TOPICAL
FLUONID
/AT/ /MARION LABORATORIES//0.01%/ /N 80432/

FLUOROMETHOLONE (PAGE 3-83)

SUSPENSION/DROPS; OPHTHALMIC
FML
ALLERGAN PHARMS 0.1%* N 16851

FLUOROURACIL (PAGE 3-83)

INJECTABLE; INJECTION
FLUOROURACIL
AP SOLOPAK LABORATORIES 50MG/ML* N 88766
AP 50MG/ML* N 88767

FLUPHENAZINE HYDROCHLORIDE (PAGE 3-84)

TABLET; ORAL
PERMITIL
> ADD > BP ∂ SCHERING 2.5MG N 12034

FLUPREDNISOLONE (PAGE 3-84)

TABLET; ORAL
ALPHADROL
∂ UPJOHN 1.5MG N 12259

/**FOLLICLE STIMULATING HORMONE; LUTEINIZING HORMONE**/(PAGE 3-85)

/INJECTABLE; INJECTION/
/PERGONAL/
/SERONO LABS/ /75 IU/AMP;75 IU/AMP/ /N 17646/

FUROSEMIDE (PAGE 3-86)

TABLET; ORAL
FUROSEMIDE
AB CORD LABORATORIES 80MG* N 18569
AB LEDERLE LABS/AM CYAN 80MG* N 18415
AB PARKE-DAVIS/W-L 80MG* N 18419

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

FUROSEMIDE (PAGE 3-86)

TABLET; ORAL
LASIX

AB	HOECHST-ROUSSEL	80MG	N 16273

GENTAMICIN SULFATE (PAGE 3-86)

INJECTABLE; INJECTION
GENTAMICIN SULFATE

> ADD >	AP	SOLOPAK LABORATORIES	EQ 10MG BASE/ML*	N 62507
> ADD >	AP		EQ 40MG BASE/ML*	N 62507

OINTMENT; TOPICAL
GENTAMICIN SULFATE

AT	E FOUGERA/BYK-GLDN	EQ 1MG BASE/GM*	N 62533
AT	PHARMADERM/BYK-GLDN	EQ 1MG BASE/GM*	N 62534

SOLUTION/DROPS; OPHTHALMIC
GENOPTIC

AT	ALLERGAN PHARMS	EQ 3MG BASE/ML*	N 62452

GLUTETHIMIDE (PAGE 3-88)

TABLET; ORAL
GLUTETHIMIDE

> ADD >	AA	@ DRUMMER/PHOENIX	500MG	N 87297
	/AA/	/ZENITH LABORATORIES/	/500MG/	/N 83683/

GONADOTROPIN, CHORIONIC (PAGE 3-89)

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

AP	CARTER-GLOGAU LABS	15,000 UNITS/VIAL*	N 17016
		2,000 UNITS/VIAL*	N 17016
AP	LYPHOMED	15,000 UNITS/VIAL	N 17067

GUANETHIDINE MONOSULFATE (PAGE 3-90)

TABLET; ORAL
GUANETHIDINE MONOSULFATE

AB	BOLAR PHARMACEUTICAL	EQ 10MG SULFATE*	N 86113
AB		EQ 25MG SULFATE*	N 86114
	ISMELIN		
	/CIBA/CIBA-GEIGY/	/10MG/	/N 12329/
		/25MG/	/N 12329/
AB	CIBA/CIBA-GEIGY	EQ 10MG SULFATE	N 12329
AB		EQ 25MG SULFATE	N 12329

HALCINONIDE (PAGE 3-90)

CREAM; TOPICAL
/**HALCIDERM**/
HALOG-E

HEPARIN SODIUM (PAGE 3-91)

INJECTABLE; INJECTABLE
HEP-FLUSH 10

AP	LYPHOMED	10 UNITS/ML*	N 17651

HEPARIN LOCK FLUSH

AP	LYPHOMED	100 UNITS/ML*	N 17651
AP	SOLOPAK LABORATORIES	10 UNITS/ML*	N 88457
AP		10 UNITS/ML*	N 88580
AP		100 UNITS/ML*	N 88581

HEPARIN SODIUM

/AP/	ELKINS-SINN/AHROBINS/	/20,000 UNITS/ML/	/N 17037/
/AP/		/40,000 UNITS/ML/	/N 17037/
		/250 UNITS/ML/	/N 17037/
> ADD > AP	ORGANON/AKZONA	1,000 UNITS/ML*	N 00552
> ADD > AP		5,000 UNITS/ML*	N 00552
> ADD > AP		10,000 UNITS/ML*	N 00552
> DLT >	/LIQUAEMIN/		
> DLT >/AP/	/ORGANON/AKZONA/	/40,000 UNITS/ML/	/N 00552/
> ADD >	**LIQUAEMIN SODIUM**		
> ADD > AP	ORGANON/AKZONA	1,000 UNITS/ML	N 00552
> ADD > AP		5,000 UNITS/ML	N 00552
> ADD > AP		10,000 UNITS/ML	N 00552
> ADD > AP		20,000 UNITS/ML	N 00552
> ADD > AP		40,000 UNITS/ML	N 00552
> DLT >	/LIQUAEMIN SODIUM "10"/		
> DLT >/AP/	/ORGANON/AKZONA/	/1,000 UNITS/ML/	/N 00552/
> DLT >	/LIQUAEMIN SODIUM "100"/		
> DLT >/AP/	/ORGANON/AKZONA/	/10,000 UNITS/ML/	/N 00552/
> DLT >	/LIQUAEMIN SODIUM "200"/		
> DLT >/AP/	/ORGANON/AKZONA/	/20,000 UNITS/ML/	/N 00552/
> DLT >	/LIQUAEMIN SODIUM "50"/		
> DLT >/AP/	/ORGANON/AKZONA/	/5,000 UNITS/ML/	/N 00552/

HEPARIN SODIUM; SODIUM CHLORIDE (PAGE 3-93)

INJECTABLE; INJECTION
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%

	ABBOTT LABORATORIES	10,000 UNITS/100ML; 900MG/100ML*	N 18911

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%

AP	ABBOTT LABORATORIES	10,000 UNITS/100ML; 450MG/100ML*	N 18911

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%

AP	ABBOTT LABORATORIES	5,000 UNITS/100ML; 900MG/100ML*	N 18911

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%

AP	ABBOTT LABORATORIES	5,000 UNITS/100ML; 900MG/100ML*	N 18911

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

HEPARIN SODIUM; SODIUM CHLORIDE - IN PLASTIC (PAGE 3-93)

INJECTABLE; INJECTION

	HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.45%		
AP	ABBOTT LABORATORIES	100 UNITS/ML;4.5MG/ML*	N 18911
	HEPARIN SODIUM 1000 UNITS IN SODIUM CHLORIDE 0.9%		
AP	AM MCGAW/AM HOSP	200 UNITS/100ML;900MG/100ML*	N 19042
	HEPARIN SODIUM 2000 UNITS IN SODIUM CHLORIDE 0.9%		
AP	AM MCGAW/AM HOSP	200 UNITS/100ML;900MG/100ML*	N 19042
	HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.9%		
AP	AM MCGAW/AM HOSP	5,000 UNITS/100ML;	
AP		900MG/100ML*	N 19135
	HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.9%		
AP	ABBOTT LABORATORIES	1,000 UNITS/100ML;900MG/100ML	N 18916
AP	AM MCGAW/AM HOSP	1,000 UNITS/100ML;	
		900MG/100ML*	N 19042

HEXACHLOROPHENE (PAGE 3-94)

EMULSION; TOPICAL

	TURGEX		
AT	XTTRIUM LABS	3%*	N 19055

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE (PAGE 3-95)

SYRUP; ORAL

	/~~HYDROCODONE/~~		
	HYDROCODONE COMPOUND		
> ADD >	**HYDROPANE**		
> ADD > AA	HALSEY DRUG	1.5MG/5ML;5MG/5ML*	N 88066

HYDRALAZINE HYDROCHLORIDE (PAGE 3-95)

TABLET; ORAL

	HYDRALAZINE HCL		
AA	AMIDE PHARMACEUTICAL	25MG*	N 88560
AA		50MG*	N 88649
AA	ASCOT HOSP PHARMS	25MG*	N 88310
AA		50MG*	N 88311
AA	BARR LABORATORIES	10MG*	N 88728
AA		100MG*	N 88729
AA	CAMALL	10MG*	N 88846
AA		25MG*	N 88847
AA		50MG*	N 88848
AA		100MG*	N 88849
AA	◑ DRUMMER/PHOENIX	25MG	N 86088
AA	SUPERPHARM	10MG*	N 88787
AA		25MG*	N 88788
AA		50MG*	N 88789

HYDROCHLOROTHIAZIDE (PAGE 3-96)

TABLET; ORAL

	HYDROCHLOROTHIAZIDE		
AB	LEMMON	25MG*	N 88924
AB		50MG*	N 88923
AB	SUPERPHARM	25MG*	N 88827
AB		50MG*	N 88828
AB		100MG*	N 88829

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE (PAGE 3-98)

TABLET; ORAL

LOPRESSOR HCT 100/25		
GEIGY/CIBA-GEIGY	25MG;100MG*	N 18303
LOPRESSOR HCT 100/50		
GEIGY/CIBA-GEIGY	50MG;100MG*	N 18303
LOPRESSOR HCT 50/25		
GEIGY/CIBA-GEIGY	25MG;50MG*	N 18303

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE (PAGE 3-98)

TABLET; ORAL

/~~INDERIDE/~~			
/~~AYERST LABS/AMHO/~~		/~~25MG;40MG/~~	/~~N 18031/~~
		/~~25MG;80MG/~~	/~~N 18031/~~
INDERIDE-40/25			
AYERST LABS/AMHO		25MG;40MG	N 18031
INDERIDE-80/25			
AYERST LABS/AHMO		25MG;80MG	N 18031

HYDROCHLOROTHIAZIDE; RESERPINE (PAGE 3-98)

TABLET; ORAL

	HYDROCHLOROTHIAZIDE W/ RESERPINE		
> DLT > /~~BP/~~	/~~BARR LABORATORIES/~~	/~~25MG;0.125MG/~~	/~~N 84580/~~
> DLT > /~~BP/~~		/~~50MG;0.125MG/~~	/~~N 84579/~~
	RESERPINE AND HYDROCHLOROTHIAZIDE		
> ADD > BP	BARR LABORATORIES	25MG;0.125MG	N 84580
> ADD > BP		50MG;0.125MG	N 84579

HYDROCHLOROTHIZIDE; SPIRONOLACTONE (PAGE 3-98)

TABLET; ORAL

	SPIRONOLACTONE + HYDROCHLOROTHIAZIDE		
AB	ASCOT HOSP PHARMS	25MG;25MG*	N 88025
	SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE		
> ADD > AB	◑ PUREPAC/KALIPHARMA	25MG;25MG	N 88054

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE (PAGE 3-98)

TABLET; ORAL
/TIMOLIDE/
TIMOLIDE 10-25

HYDROCHLOROTHIAZIDE; TRIAMTERENE (PAGE 3-98)

TABLET; ORAL
MAXZIDE

	MYLAN PHARMS	50MG;75MG*	N 19129

HYDROCORTISONE (PAGE 3-99)

CREAM; TOPICAL

	HYDROCORTISONE		
AT	THAMES PHARMACAL	2.5%*	N 88799
	HYTONE		
/AT/	DERMIK/RORER-AMCHEM	/0.5%/	N 80472

OINTMENT; TOPICAL

	HYTONE		
/AT/	DERMIK/RORER-AMCHEM	/0.5%/	N 80474

POWDER; FOR RX COMPOUNDING

	H-CORT		
/AA/	/PARAMEX LABORATORIES/	/100%/	/N 87834/
AA	TORCH LABORATORIES	100%	N 87834

HYDROCORTISONE ACETATE (PAGE 3-102)

/AEROSOL; TOPICAL/
/EPIFOAM/
/REED&CARNRICK PHARMS/1%/ /N 86457/

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE (PAGE 3-103)

AEROSOL; TOPICAL
EPIFOAM

	REED&CARNRICK PHARMS	1%;1%	N 86457

HYDROFLUMETHIAZIDE (PAGE 3-104)

TABLET; ORAL

	HYDROFLUMETHIAZIDE		
AB	CHELSEA LABORATORIES	50MG*	N 88528
AB	PAR PHARMACEUTICAL	50MG*	N 88850

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-104)

TABLET; ORAL
RESERPINE AND HYDROFLUMETHIAZIDE

BP	ZENITH LABORATORIES	50MG;0.125MG*	N 88932

HYDROXYZINE HYDROCHLORIDE (PAGE 3-105)

TABLET; ORAL

	HYDROXYZINE HCL		
AB	PUREPAC/KALIPHARMA	10MG*	N 88120
AB		25MG*	N 88121
AB		50MG*	N 88122
AB	SUPERPHARM	10MG*	N 88794
AB		25MG*	N 88795
AB		50MG*	N 88796

HYDROXYZINE PAMOATE (PAGE 3-106)

CAPSULE; ORAL

	HY-PAM "25"		
AB	LEMMON	EQ 25MG HCL*	N 88713

IBUPROFEN (PAGE 3-106)

TABLET; ORAL

		IBUPROFEN		
> ADD >	AB	BOOTS PHARMACEUTICAL	600MG*	N 70556
		RUFEN		
	AB	BOOTS PHARMACEUTICAL	400MG*	N 70083
	AB		600MG*	N 70088
	AB		600MG*	N 70099

IMIPRAMINE HYDROCHLORIDE (PAGE 3-107)

TABLET; ORAL

	IMIPRAMINE HCL		
AB	∂ DRUMMER/PHOENIX	10MG	N 85200
	SK-PRAMINE		
/AB/	/SK&F LABORATORIES/	/10MG/	/N 18083/
/AB/		/25MG/	/N 18083/
/BP/		/50MG/	/N 18083/
AB	SK&F LABORATORIES	10MG	N 83827
AB		25MG	N 83827
BP		50MG	N 83827

INDOMETHACIN (PAGE 3-108)

CAPSULE; ORAL

	INDOMETHACIN		
AB	PAR PHARMACEUTICAL	25MG*	N 18829
AB		50MG*	N 18829

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

INDOMETHACIN (PAGE 3-108)

CAPSULE; ORAL
INDOMETHACIN
AB PARKE-DAVIS/W-L 25MG* N 18806
AB 50MG* N 18806
> ADD > AB ROXANE LABORATORIES 25MG* N 70353
> ADD > AB 50MG* N 70354

SUPPOSITORY; RECTAL
INDOCIN
MS&D RES LABS/MERCK 50MG* N 17814

INDOMETHACIN SODIUM TRIHYDRATE (PAGE 3-108)

INJECTABLE; INJECTION
INDOCIN I.V.
MS&D/MERCK EQ 1MG BASE/VIAL* N 18878

IODOHIPPURATE SODIUM, I-123 (PAGE 3-109)

INJECTABLE; INJECTION
NEPHROFLOW
MEDI-PHYSICS 1MCI/ML* N 18289

IOPANOIC ACID (PAGE 3-109)

TABLET; ORAL
TELEPAQUE
/WINTHROP LABS/STERL//500MG/ /N 08032/
WINTHROP-BREON/STERL 500MG N 08032

ISOETHARINE MESYLATE (PAGE 3-110)

AEROSOL; INHALATION
BRONKOMETER
/BREON LABS/STERLING//0.61%/ /N 12339/
BN BREON LABS/STERLING 0.34MG/INH N 12339
ISOETHARINE MESYLATE
BN NATL PHARM MFG/BARRE 0.34MG/INH* N 87858

KANAMYCIN SULFATE (PAGE 3-112)

INJECTABLE; INJECTION
KANAMYCIN SULFATE
AP CARTER-GLOGAU LABS EQ 1GM BASE/3ML* N 62520
KANTREX
AP BRISTOL LABS/B-M EQ 75MG BASE/2ML* N 62564
AP EQ 500MG BASE/2ML* N 62564
AP EQ 1GM BASE/3ML* N 62564

LABETALOL HYDROCHLORIDE (PAGE 3-113)

INJECTABLE; INJECTION
NORMODYNE
SCHERING 5MG/ML* N 18686

TABLET; ORAL
NORMODYNE
AB SCHERING 200MG* N 18687
AB 300MG* N 18687
AB 400MG* N 18687
TRANDATE
AB GLAXO 200MG* N 18716
AB 300MG* N 18716
AB 400MG* N 18716
> ADD > 100MG* N 18716

LEUPROLIDE ACETATE (PAGE 3-113)

INJECTABLE; INJECTION
LUPRON
TAP PHARMACEUTICALS 1MG/0.2ML* N 19010

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE (PAGE 3-114)

INJECTABLE; INJECTION
SCANDONEST L
AP DEPROCO 0.05MG/ML;2%* N 88388

LEVOTHYROXINE SODIUM; LIOTHYRONINE SODIUM (PAGE 3-114)

TABLET; ORAL
THYROLAR-5
> ADD > @ ARMOUR PHARM 0.25MG;0.065MG N 16807

LIDOCAINE (PAGE 3-114)

AEROSOL; ORAL
XYLOCAINE
ASTRA PHARM PRODS 10%* N 14394

LIDOCAINE HYDROCHLORIDE (PAGE 3-115)

INJECTABLE; INJECTION
XYLOCAINE
ASTRA PHARM PRODS /5%/ /N 10496/

SOLUTION; ORAL
> DLT > /LIDOCAINE HCL/
> ADD > LIDOCAINE VISCOUS
AT ROXANE LABORATORIES 2%* N 88802

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

LIDOCAINE HYDROCHLORIDE (PAGE 3-115)

SOLUTION; TOPICAL
LIDOCAINE HCL

AT	ROXANE LABORATORIES	4%¤	N 88803

LINDANE (PAGE 3-116)

LOTION; TOPICAL
LINDANE

AT	BAY LABORATORIES	1%¤	N 88190

SHAMPOO; TOPICAL
LINDANE

AT	BAY LABORATORIES	1%¤	N 88191

LOXAPINE HYDROCHLORIDE (PAGE 3-118)

CONCENTRATE; ORAL
> DLT > /LOXITANE/
> ADD > LOXITANE C

INJECTABLE; INJECTION
> DLT > /LOXITANE/
> ADD > LOXITANE IM

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE (PAGE 3-119)

SOLUTION; IRRIGATION
PHYSIOLYTE IN PLASTIC CONTAINER

AP	ABBOTT LABORATORIES	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N 19024

SYNOVALYTE IN PLASTIC CONTAINER

AP	TRAVENOL LABS	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML¤	N 19326

MEDRYSONE (PAGE 3-122)

SUSPENSION; OPHTHALMIC
HMS

	ALLERGAN PHARMS	1%	N 16624

MENOTROPINS (PAGE 3-122)

INJECTABLE; INJECTION
PERGONAL

	SERONO LABS	150 IU/AMP	N 17646
> ADD >		300 IU/AMP¤	N 17646

MEPERIDINE HYDROCHLORIDE (PAGE 3-122)

INJECTABLE; INJECTION
MEPERIDINE HCL

AP	ABBOTT LABORATORIES	10MG/ML¤	N 88432
AP	INTL MEDICATION SYS	10MG/ML	N 86332

SYRUP; ORAL
DEMEROL

AA	WINTHROP LABS/STERL	50MG/5ML	N 05010

MEPERIDINE HCL

AA	ROXANE LABORATORIES	50MG/5ML¤	N 88744

TABLET; ORAL
MEPERIDINE HCL

AA	BARR LABORATORIES	100MG¤	N 88640

MEPHENTERMINE SULFATE (PAGE 3-123)

INJECTABLE; INJECTION
WYAMINE SULFATE

	/WYETH LABS/AMHO/	/15MG/ML/	/N 08248/
		/30MG/ML/	/N 08248/
	WYETH LABS/AMHO	EQ 15MG BASE/ML	N 08248
		EQ 30MG BASE/ML	N 08248

MEPIVACAINE HYDROCHLORIDE (PAGE 3-123)

INJECTABLE; INJECTION
CARBOCAINE

AP	BREON LABS/STERLING	2%	N 12250

MEPIVACAINE HCL

AP	CARTER-GLOGAU LABS	1%¤	N 88769
AP		2%¤	N 88770

POLOCAINE

AP	ASTRA PHARM PRODS	3%¤	N 88653

SCANDONEST PLAIN

AP	DEPROCO	3%¤	N 88387

MEPROBAMATE (PAGE 3-123)

TABLET; ORAL
MEPROBAMATE

/AA/	/MM MAST/	/200MG/	/N 86229/
/AA/		/400MG/	/N 86229/

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

METHICILLIN SODIUM (PAGE 3-127)

INJECTABLE; INJECTION
CELBENIN
AP BEECHAM LABS/BEECHAM EQ 900MG BASE/VIAL N 61493
AP EQ 3.6GM BASE/VIAL N 61493
AP EQ 5.4GM BASE/VIAL N 61493
EQ 1.8GM BASE/VIAL N 61493
EQ 9GM BASE/VIAL N 61493

METHOTREXATE SODIUM (PAGE 3-128)

INJECTABLE; INJECTION
MEXATE
BRISTOL LABS/B-M EQ 250MG BASE/VIAL* N 86358
MEXATE-AQ
AP BRISTOL CARIB/B-M/PR EQ 25MG BASE/ML* N 88760

METHYCLOTHIAZIDE (PAGE 3-129)

TABLET; ORAL
METHYCLOTHIAZIDE
AB CHELSEA LABORATORIES 2.5MG* N 88750
AB 5MG* N 88724
AB COLMED LABORATORIES 5MG* N 88745

METHYLDOPA (PAGE 3-130)

TABLET; ORAL
ALDOMET
> ADD > AB MS&D/MERCK 125MG N 13400
METHYLDOPA
> ADD > AB CHELSEA LABORATORIES 125MG* N 70260
> ADD > AB 250MG* N 70261
> ADD > AB 500MG* N 70262
AB MYLAN PHARMS 250MG* N 70075
AB 500MG* N 70076

METHYLPREDNISOLONE SODIUM SUCCINATE (PAGE 3-131)

INJECTABLE; INJECTION
SOLU-MEDROL
UPJOHN EQ 2GM BASE/VIAL* N 11856

METRONIDAZOLE (PAGE 3-133)

INJECTABLE; INJECTION
METRONIDAZOLE
AP INTL MEDICATION SYS 500MG/100ML* N 70004
AP LYPHOMED 500MG/100ML* N 70071
METRYL IV
AP LEMMON 500MG/100ML* N 70042

METRONIDAZOLE (PAGE 3-133)

TABLET; ORAL
METRONIDAZOLE
AB HALSEY DRUG 250MG* N 70021
AB PAR PHARMACEUTICAL 250MG* N 70040
AB 500MG* N 70039
AB SIDMAK LABORATORIES 250MG* N 70027
AB 500MG* N 70033
AB SUPERPHARM 250MG* N 70008
AB 500MG* N 70009
METRYL
AB LEMMON 250MG* N 70035
METRYL 500
AB LEMMON 500MG* N 70044
SATRIC
AB SAVAGE LABS/ALTANA 250MG* N 70029

MICONAZOLE NITRATE (PAGE 3-134)

SUPPOSITORY; VAGINAL
MONISTAT 3
ORTHO PHARMACEUTICAL 200MG* N 18888

MOLINDONE HYDROCHLORIDE (PAGE 3-135)

CAPSULE; ORAL
MOBAN
> ADD > ∂ DUPONT PHARMS/DUPONT 5MG N 17111
> ADD > ∂ 10MG N 17111
> ADD > ∂ 25MG N 17111

MORPHINE SULFATE (PAGE 3-135)

INJECTABLE; INJECTION
DURAMORPH PF
ELKINS-SINN/AHROBINS 0.5MG/ML* N 18565
1MG/ML* N 18565

NAFCILLIN SODIUM (PAGE 3-135)

INJECTABLE; INJECTION
NAFCIL
AP BRISTOL LABS/B-M EQ 10GM BASE/VIAL* N 62527
NALLPEN
AP BEECHAM LABS/BEECHAM EQ 10GM BASE/VIAL N 61999

NALBUPHINE HYDROCHLORIDE (PAGE 3-136)

INJECTABLE; INJECTION
NUBAIN
DUPONT PHARMS/DUPONT 20MG/ML* N 18024

Generated for Shearrer, Cynthia D. (University of Missouri-Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

NALTREXONE HYDROCHLORIDE (PAGE 3-136)

TABLET; ORAL
TREXAN
DUPONT PHARMS/DUPONT 50MG* N 18932

NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-137)

SOLUTION/DROPS; OPHTHALMIC
STATROL
ALCON LABORATORIES EQ 3.5MG BASE/ML; 16,250 UNITS/ML* N 62339

NOMIFENSINE MALEATE (PAGE 3-140)

CAPSULE; ORAL
MERITAL
HOECHST-ROUSSEL 25MG* N 18224
50MG* N 18224

NOREPINEPHRINE BITARTRATE (PAGE 3-140)

INJECTABLE; INJECTION
LEVOPHED
/BREON LABS/STERLING//EQ 1MG BASE/ML/ /N 07513/
WINTHROP-BREON/STERL EQ 1MG BASE/ML N 07513

NYSTATIN (PAGE 3-141)

SUSPENSION; ORAL
NYSTATIN
AA BAY LABORATORIES 100,000 UNITS/ML* N 62512
AA PHARMAFAIR 100,000 UNITS/ML* N 62541

TABLET; ORAL
NYSTATIN
AA QUANTUM PHARMICS 500,000 UNITS* N 62525

NYSTATIN; TRIAMCINOLONE ACETONIDE (PAGE 3-141)

CREAM; TOPICAL
MYCOLOG-II
AT ER SQUIBB AND SONS 100,000 UNITS/GM;0.1%* N 60576
AT 100,000 UNITS/GM;0.1%* N 62606
MYKACET
AT NMC LABORATORIES 100,000 UNITS/GM;0.1%* N 62367
> ADD > NYSTATIN AND TRIAMCINOLONE ACETONIDE
> ADD > AT CLAY-PARK LABS 100,000 UNITS/GM;0.1%* N 62186

> ADD > OINTMENT; TOPICAL
> ADD > MYCOLOG-II
> ADD > ER SQUIBB AND SONS 100,000 UNITS/GM;0.1%* N 60572

OXACILLIN SODIUM (PAGE 3-142)

INJECTABLE; INJECTION
BACTOCILL
BEECHAM LABS/BEECHAM EQ 10GM BASE/VIAL* N 61334

OXTRIPHYLLINE (PAGE 3-143)

ELIXIR; ORAL
CHOLEDYL
AA PARKE-DAVIS/W-L 100MG/5ML* N 09268
OXTRIPHYLLINE
AA BAY LABORATORIES 100MG/5ML N 88243

OXYPHENBUTAZONE (PAGE 3-143)

TABLET; ORAL
OXYPHENBUTAZONE
AB BOLAR PHARMACEUTICAL 100MG* N 88399
TANDEARIL
AB GEIGY/CIBA-GEIGY 100MG N 12542

/PENETATE CALCIUM TRISODIUM, YB-169 (PAGE 3-145)/

/INJECTABLE; INJECTION/
/YTTERBIUM YB 169 DTPA/
/DIAGNOSTIC PRODS/3M//2MCI/ML/ /N 17518/

PENTAMIDINE ISETHIONATE (PAGE 3-148)

INJECTABLE; INJECTION
PENTAM 300
LYPHOMED 300MG/VIAL* N 19264

PENTETATE CALCIUM TRISODIUM, YB-169 (PAGE 3-148)

INJECTABLE; INJECTION
YTTERBIUM YB 169 DTPA
MEDICAL PRODUCTS/3M 2MCI/ML N 17518

PENTOBARBITAL SODIUM (PAGE 3-149)

CAPSULE; ORAL
PENTOBARBITAL SODIUM
AA ∂ VITARINE/PHOENIX 100MG N 83284

TABLET; ORAL
PENTOBARBITAL SODIUM
AA ∂ VITARINE/PHOENIX 100MG N 83285

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

PENTOXIFYLLINE (PAGE 3-149)

TABLET, CONTROLLED RELEASE; ORAL
TRENTAL

	HOECHST-ROUSSEL	400MG*	N 18631

PHENDIMETRAZINE TARTRATE (PAGE 3-149)

CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE

AA	∂ DRUMMER/PHOENIX	35MG	N 86403
AA	∂	35MG	N 86408
AA	∂	35MG	N 86410
> ADD > AA	∂	35MG	N 87424
AA	∂ VITARINE/PHOENIX	35MG	N 85634
AA	∂	35MG	N 85645
AA	∂	35MG	N 85670

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	∂ DRUMMER/PHOENIX	35MG	N 86106
AA	∂ VITARINE/PHOENIX	35MG	N 85519
AA	∂	35MG	N 86005

PHENTERMINE HYDROCHLORIDE (PAGE 3-151)

CAPSULE; ORAL
PHENTERMINE HCL

AA	CHELSEA LABORATORIES	30MG*	N 86740
> ADD > AA	∂ DRUMMER/PHOENIX	30MG	N 87202
> ADD > AA	∂	30MG	N 87235
AA	PHARM BASICS	30MG*	N 88797

TABLET; ORAL
PHENTERMINE HCL

AA	∂ DRUMMER/PHOENIX	8MG	N 86453
AA	∂	8MG	N 86456

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-153)

SYRUP; ORAL
PHENERGAN VC

AA	WYETH LABS/AMHO	5MG/5ML;6.25MG/5ML	N 08604

PROMETH VC PLAIN

AA	NATL PHARM MFG/BARRE	5MG/5ML;6.25MG/5ML*	N 88761

PROMETHAZINE VC PLAIN

AA	BAY LABORATORIES	5MG/5ML;6.25MG/5ML*	N 88897

PHENYTOIN SODIUM (PAGE 3-153)

INJECTABLE; INJECTION
PHENYTOIN SODIUM

AP	INVENEX LABS/LIFE	50MG/ML*	N 89003
AP	SOLOPAK LABORATORIES	50MG/ML*	N 88519
AP		50MG/ML*	N 88520
AP		50MG/ML*	N 88521

PHENYTOIN SODIUM, EXTENDED (PAGE 3-153)

CAPSULE; ORAL
DILANTIN

AB	PARKE-DAVIS/W-L	100MG	N 84349

EXTENDED PHENYTOIN SODIUM

AB	BOLAR PHARMACEUTICAL	100MG*	N 88711

PILOCARPINE HYDROCHLORIDE (PAGE 3-154)

GEL; OPHTHALMIC
PILOPINE HS

	ALCON LABORATORIES	4%	N 18796

PINDOLOL (PAGE 3-154)

TABLET; ORAL
VISKEN

	SANDOZ PHARMS/SANDOZ	15MG	N 18285

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE (PAGE 3-155)

POWDER FOR RECONSTITUTION; ORAL
COLYTE

	EDLAW PREPARATIONS	120GM/PACKET;1.49GM/PACKET; 3.36GM/PACKET;2.92GM/PACKET; 11.36GM/PACKET*	N 18983
		227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET;*	N 18983
		360GM/PACKET;4.47GM/PACKET; 10.08GM/PACKET;8.76GM/PACKET; 34.08GM/PACKET*	N 18983

POTASSIUM CHLORIDE (PAGE 3-156)

INJECTABLE; INJECTION
POTASSIUM CHLORIDE IN PLASTIC CONTAINER

AP	INVENEX LABS/LIFE	2MEQ/ML*	N 88901
AP		2MEQ/ML*	N 88908

Generated for Shearrer, Cynthia D. (University of Missouri-Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

POTASSIUM CLAVULANATE; TICARCILLIN DISODIUM (PAGE 3-158)

INJECTABLE; INJECTION
TIMENTIN
BEECHAM LABS/BEECHAM EQ 100MG ACID/VIAL; EQ 3GM BASE/VIAL¤ N 50590
EQ 200MG ACID/VIAL; EQ 3GM BASE/VIAL¤ N 50590

PREDNISOLONE (PAGE 3-159)

TABLET; ORAL
PREDNISOLONE
BX SUPERPHARM 5MG¤ N 88892

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM (PAGE 3-160)

OINTMENT; OPHTHALMIC
PREDSULFAIR
AT PHARMAFAIR 0.5%;10% N 88032
VASOCIDIN
AT COOPERVISION PHARMS 0.5%;10%¤ N 88791

PREDNISONE (PAGE 3-161)

SOLUTION; ORAL
PREDNISONE
ROXANE LABORATORIES 5MG/5ML¤ N 88703
PREDNISONE INTENSOL
ROXANE LABORATORIES 5MG/ML¤ N 88810

TABLET; ORAL
PREDNISONE
BX SUPERPHARM 5MG¤ N 88865
BX 10MG¤ N 88866
BX 20MG¤ N 88867

PRILOCAINE HYDROCHLORIDE (PAGE 3-162)

INJECTABLE; INJECTION
CITANEST
∂ ASTRA PHARM PRODS 1% N 14763
∂ 2% N 14763
∂ 3% N 14763
/4%/ /N 14763/
CITANEST PLAIN
ASTRA PHARM PRODS 4% N 14763

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-163)

CAPSULE; ORAL
PROCAINAMIDE HCL
AB ROXANE LABORATORIES 250MG¤ N 88989
AB 500MG¤ N 88990

INJECTABLE; INJECTION
PROCAINAMIDE HCL
AP SOLOPAK LABORATORIES 100MG/ML¤ N 88530
AP 500MG/ML¤ N 88531
AP 500MG/ML¤ N 88532

TABLET, CONTROLLED RELEASE; ORAL
PROCAINAMIDE HCL
AB BOLAR PHARMACEUTICAL 250MG¤ N 88533
AB 500MG¤ N 88534
AB 750MG¤ N 88535
PROCAN SR
AB 250MG N 86468
AB 500MG N 86065
AB 750MG N 87510
/BC/ PARKE-DAVIS/W-L /500MG/ /N 86065/
1GM¤ N 88489

PROCHLORPERAZINE EDISYLATE (PAGE 3-164)

CONCENTRATE; ORAL
PROCHLORPERAZINE EDISYLATE
AA BAY LABORATORIES EQ 10MG BASE/ML¤ N 88598

SYRUP; ORAL
PROCHLORPERAZINE EDISYLATE
AA BAY LABORATORIES EQ 5MG BASE/5ML¤ N 88597

PROCHLORPERAZINE MALEATE (PAGE 3-164)

CAPSULE, CONTROLLED RELEASE; ORAL
COMPAZINE
∂ SK&F LABORATORIES EQ 75MG BASE N 11000

PROMETHAZINE HYDROCHLORIDE (PAGE 3-165)

SYRUP; ORAL
/BAYMETHAZINE/
PROMETHAZINE PLAIN

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-167)

CAPSULE; ORAL
PROPOXYPHENE HCL
AA LEMMON 65MG¤ N 88615

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

PROTAMINE SULFATE (PAGE 3-168)

INJECTABLE; INJECTION
PROTAMINE SULFATE
UPJOHN 250MG/VIAL* N 07413

PROTEIN HYDROLYSATE (PAGE 3-168)

INJECTABLE; INJECTION
AMINOSOL 5%
ABBOTT LABORATORIES 5%* N 05932

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-169)

SYRUP; ORAL
TRILITRON
NEWTRON PHARMS 30MG/5ML;1.25MG/5ML* N 88474
/TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL/
/AA/ /PHARMAFAIR/ /30MG/5ML;1.25MG/5ML*/ /N 88541/

TABLET; ORAL
ALLERFED
AA PRIVATE FORMULATIONS 60MG;2.5MG* N 88860
CORPHED
AA CORD LABORATORIES 60MG;2.5MG* N 88602
TRILITRON
AA NEWTRON PHARMS 60MG;2.5MG* N 88515
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
AA SUPERPHARM 60MG;2.5MG* N 88578
AA ZENITH LABORATORIES 60MG;2.5MG* N 85273

QUINIDINE GLUCONATE (PAGE 3-170)

TABLET, CONTROLLED RELEASE; ORAL
QUINIDINE GLUCONATE
> ADD > AB ASCOT HOSP PHARMS 324MG* N 88582

QUINIDINE SULFATE (PAGE 3-170)

TABLET; ORAL
CIN-QUIN
/AB/ ROWELL LABORATORIES /200MG/ /N 87255/
QUINIDINE SULFATE
AB SUPERPHARM 200MG* N 88973

RANITIDINE HYDROCHLORIDE (PAGE 3-171)

INJECTABLE; INJECTION
ZANTAC
GLAXO EQ 25MG BASE/ML* N 19090

RAUWOLFIA SERPENTINA (PAGE 3-171)

TABLET; ORAL
RAUVERID
BP FOREST LABORATORIES 50MG N 09225
/BP/ /ONEAL JONES-FELDMAN//50MG/ /N 09255/
WOLFINA
BP FOREST LABORATORIES 50MG N 09255
BP 100MG N 09255
/BP/ /ONEAL JONES-FELDMAN//50MG/ /N 09255/
/BP/ /100MG/ /N 09255/

RESERPINE (PAGE 3-172)

TABLET; ORAL
RESERPINE
BP LEMMON 0.1MG* N 89020
BP 0.25MG* N 89019

RITODRINE HYDROCHLORIDE (PAGE 3-173)

INJECTABLE; INJECTION
/RITODRINE HCL/
/AP/ /DUPHAR LABS/ /10MG/ML/ /N 18280/
YUTOPAR
/AP/ ASTRA PHARM PRODS 10MG/ML N 18580
15MG/ML* N 18580

TABLET; ORAL
/RITODRINE HCL/
/AB/ /DUPHAR LABS/ /10MG/ /N 18280/
YUTOPAR
/AB/ ASTRA PHARM PRODS 10MG N 18555

SAFFLOWER OIL; SOYBEAN OIL (PAGE 3-174)

INJECTABLE; INJECTION
LIPOSYN II 10%
ABBOTT LABORATORIES 5%;5%* N 18997
LIPOSYN II 20%
ABBOTT LABORATORIES 10%;10%* N 18991

SCOPOLAMINE (PAGE 3-174)

FILM, CONTROLLED RELEASE; PERCUTANEOUS
/TRANSDERM-V/
/ALZA/ /1.5MG/ /N 17874/
TRANSDERM-SCOP
CIBA/CIBA-GEIGY 1.5MG N 17874

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

SECOBARBITAL SODIUM (PAGE 3-174)

CAPSULE; ORAL
SECOBARBITAL SODIUM

AA	∂ DRUMMER/PHOENIX	100MG	N 85898
AA	∂ VITARINE/PHOENIX	100MG	N 86273

SODIUM CHLORIDE (PAGE 3-176)

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABORATORIES	9MG/ML	N 18800
AP	INVENEX LABS/LIFE	9MG/ML*	N 88909
AP		9MG/ML*	N 88911

SODIUM CHLORIDE IN PLASTIC CONTAINER

/AP/	/AM MCGAW/AM HOSP/	/900MG/100ML/	/N 17464/

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	AM MCGAW/AM HOSP	900MG/100ML	N 17464
AP	INVENEX LABS/LIFE	9MG/ML*	N 88912

SLUSH; IRRIGATION
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

	TRAVENOL LABS	900MG/100ML*	N 19319

SODIUM IODIDE, I-131 (PAGE 3-178)

SOLUTION; ORAL
SODIUM IODIDE I 131

> DLT >	/SYNCOR INTL/	/10 UCI-50MCI/ML/	/N 17315/
> ADD >	SYNCOR INTL	50MCI/ML	N 17315

SODIUM LACTATE (PAGE 3-178)

INJECTABLE; INJECTION
SODIUM LACTATE IN PLASTIC CONTAINER

	ABBOTT LABORATORIES	5MEQ/ML*	N 18947

SODIUM NITROPRUSSIDE (PAGE 3-178)

INJECTABLE; INJECTION
SODIUM NITROPRUSSIDE

AP	LYPHOMED	50MG/VIAL*	N 70031

SODIUM POLYSTYRENE SULFONATE (PAGE 3-179)

POWDER; ORAL, RECTAL
KAYEXALATE

AA	BREON LABS/STERLING	453.6GM/BOT	N 11287

SODIUM POLYSTYRENE SULFONATE

AA	BAY LABORATORIES	453.6GM/BOT*	N 88786

SODIUM POLYSTYRENE SULFONATE (PAGE 3-179)

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

AA	BAY LABORATORIES	15GM/60ML*	N 88717

SOYBEAN OIL (PAGE 3-180)

INJECTABLE; INJECTION
LIPOSYN III 10%

AP	ABBOTT LABORATORIES	10%*	N 18969

LIPOSYN III 20%

AP	ABBOTT LABORATORIES	20%*	N 18970

SPIRONOLACTONE (PAGE 3-180)

TABLET; ORAL
SPIRONOLACTONE

> ADD > AB	∂ PUREPAC/KALIPHARMA	25MG	N 88053

SUCCINYLCHOLINE CHLORIDE (PAGE 3-181)

INJECTABLE; INJECTION
ANECTINE

> ADD > AP	∂ BURROUGHS WELLCOME	50MG/ML	N 08453

SUCCINYLCHOLINE CHLORIDE

/AP/	/TRAVENOL LABS/	/500MG/VIAL/	/N 80263/
/AP/		/1GM/VIAL/	/N 80263/

SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE (PAGE 3-181)

TABLET; VAGINAL
SULTRIN

AT	ORTHO PHARMACEUTICAL	184MG;143.75MG;172.5MG	N 05794

TRIPLE SULFA

AT	E FOUGERA/ALTANA	184MG;143.75MG;172.5MG*	N 88463
AT	PHARMADERM/ALTANA	184MG;143.75MG;172.5MG*	N 88462

SULFACETAMIDE SODIUM (PAGE 3-181)

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

AT	PHARMAFAIR	10%*	N 88947
/AT/	/PHARMAFAIR/	/10%*/	/N 87949/

SULFAIR 10

AT	PHARMAFAIR	10%*	N 87949

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

SULFAMETHOXAZOLE (PAGE 3-182)

TALBET; ORAL
SULFAMETHOXAZOLE
/AB/ /HEATHER DRUG/ /500MG/ /N 86435/
AB HEATHER DRUG 500MG N 86163

SULFAMETHOXAZOLE; TRIMETHOPRIM (PAGE 3-183)

TABLET; ORAL
COTRIM
AB LEMMON 400MG;80MG* N 70034
COTRIM D.S.
AB LEMMON 800MG;160MG* N 70048
SULFAMETHOPRIM
AB PAR PHARMACEUTICAL 400MG;80MG* N 70022
SULFAMETHOPRIM-DS
AB PAR PHARMACEUTICAL 800MG;160MG* N 70032
SULFAMETHOXAZOLE & TRIMETHOPRIM
AB HEATHER DRUG 400MG;80MG* N 18946
AB 800MG;160MG* N 18946
SULFAMETHOXAZOLE AND TRIMETHOPRIM
AB BARR LABORATORIES 400MG;80MG* N 70006
AB CHELSEA LABORATORIES 400MG;80MG* N 70002
AB 800MG;160MG* N 70000
> ADD > SULFATRIM-DS
> ADD > AB SUPERPHARM 800MG;160MG* N 70066
> ADD > SULFATRIM-SS
> ADD > AB SUPERPHARM 400MG;80MG* N 70065
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
AB BARR LABORATORIES 800MG;160MG* N 70007
/TRIMETH/SULFA D/S/
/AB/ /CHELSEA LABORATORIES/800MG;160MG*/ /N 70000/
/TRIMETH/SULFA S/S/
/AB/ /CHELSEA LABORATORIES/400MG;80MG*/ /N 70002/

SULFISOXAZOLE (PAGE 3-184)

TABLET; ORAL
SULFISOXAZOLE
> ADD > BP ● DRUMMER/PHOENIX 500MG N 87332

TECHNETIUM, TC-99M, ALBUMIN AGGREGATED KIT (PAGE 3-185)

INJECTABLE; INJECTION
ALBUMIN MICROSPHERES (HUMAN) INSTANT MICROSPHERES
/BS/ /DIAGNOSTIC PRODS/3M//N/A/ /N 17832/
BS MEDICAL PRODUCTS/3M N/A N 17832
> DLT > /CINTICHEM TECHNETIUM 99M MAA/
> DLT > /BS/ /CINTICHEM/ /N/A/ /N 17773/
> ADD > TECHNETIUM TC 99M MAA
> ADD > BS MEDI-PHYSICS N/A N 17773

TECHNETIUM, TC-99M, ALBUMIN KIT (PAGE 3-185)

INJECTABLE; INJECTION
/CINTICHEM TECHNETIUM 99M HSA/
/CINTICHEM/ /N/A/ /N 17775/
TECHNETIUM TC 99M HSA
MEDI-PHYSICS N/A N 17775

TECHNETIUM, TC-99M, MEDRONATE KIT (PAGE 3-186)

INJECTABLE; INJECTION
/MDP KIT/
TECHNETIUM TC 99M MPI MDP

TECHNETIUM, TC-99M, PENTETATE KIT (PAGE 3-186)

INJECTABLE; INJECTION
> DLT > /DTPA (SN) KIT (CHELATE)/
> DLT > /AP/ /MEDI-PHYSICS/ /N/A/ /N 17255/
/KIDNEY/BRAIN SCANNING KIT/
/AP/ /GENERAL RADIOISOTOPE/N/A/ /N 17626/
> ADD > MPI DTPA KIT - CHELATE
> ADD > AP MEDI-PHYSICS N/A N 17255

TECHNETIUM, TC-99M, SULFUR COLLOID KIT (PAGE 3-187)

INJECTABLE; INJECTION
/CINTICHEM TECHNETIUM 99M TSC/
/AP/ /CINTICHEM/ /N/A/ /N 17784/
TECHNETIUM TC 99M TSC
AP MEDI-PHYSICS N/A N 17784

TERBUTALINE SULFATE (PAGE 3-187)

AEROSOL; INHALATION
BRETHAIRE
BN GEIGY/CIBA-GEIGY 0.2MG/INH* N 18762
BRICANYL
BN MERRELL DOW/DOW CHEM 0.2MG/INH* N 18000

INJECTABLE; INJECTION
BRICANYL
/AP/ /ASTRA PHARM PRODS/ /1MG/ML/ /N 17466/
AP MERRELL DOW/DOW CHEM 1MG/ML N 17466

TERFENADINE (PAGE 3-187)

TABLET; ORAL
SELDANE
MERRELL DOW/DOW CHEM 60MG* N 18949

Generated for Shearrer, Cynthia D. (University of Missouri-Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TETRACYCLINE HYDROCHLORIDE (PAGE 3-188)

CAPSULE; ORAL

	BRISTACYCLINE		
/AB/	BRISTOL LABS/B-M	/500MG/	/N 60211/
	TETRACYCLINE HCL		
AB	SUPERPHARM	250MG*	N 62540
AB		500MG*	N 62540

THEOPHYLLINE (PAGE 3-190)

CAPSULE; ORAL

	SOMOPHYLLIN-T		
BP	FISONS	100MG*	N 87155
BP		200MG*	N 87155
		250MG*	N 87155

CAPSULE, CONTROLLED RELEASE; ORAL

	ELIXOPHYLLIN SR		
BC	BERLEX/SCHERING	125MG*	N 86826
BC		250MG*	N 86826
	SLO-BID		
BC	WILLIAM H RORER	50MG*	N 88269
BC		100MG*	N 87892
BC		200MG*	N 87893
BC		300MG*	N 87894
	SLO-PHYLLIN		
BC	WILLIAM H RORER	125MG	N 85203
	SOMOPHYLLIN-CRT		
BC	FISONS	50MG*	N 87763
BC		200MG*	N 88382
BC		300MG*	N 88383
	THEO-24		
BC	SEARLE/SEARLE PHARMS	200MG	N 87943
BC		300MG	N 87944
	THEOBID		
BC	GLAXO	260MG*	N 85983
	THEOBID JR.		
BC	GLAXO	130MG*	N 87854
	THEOCLEAR L.A.-130		
BC	CENTRAL PHARMS	130MG	N 86569
	THEOPHYL-SR		
BC	MCNEIL PHARM	125MG*	N 86480
BC		250MG*	N 86471
	THEOPHYLLINE		
BC	CENTRAL PHARMS	125MG*	N 88654
BC		250MG*	N 88689
	THEOVENT		
BC	SCHERING	125MG*	N 87010
BC		250MG*	N 87910

TABLET, CONTROLLED RELEASE; ORAL

	THEOCHRON		
BC	FOREST LABORATORIES	100MG*	N 88320
BC		200MG*	N 88321

THEOPHYLLINE (PAGE 3-190)

TABLET, CONTROLLED RELEASE; ORAL

	THEOPHYLLINE		
BC	FOREST LABORATORIES	100MG*	N 88503
BC		200MG*	N 88504
AB		300MG*	N 88505

THIORIDAZINE HYDROCHLORIDE (PAGE 3-192)

TABLET; ORAL

	THIORIDAZINE HCL		
AB	BARR LABORATORIES	150MG*	N 88737
AB		200MG*	N 88738
AB	BIOCRAFT LABS	10MG*	N 88493
AB		100MG*	N 88456
AB	CORD LABORATORIES	100MG*	N 88135
> ADD > AB	DANBURY PHARMACAL	150MG*	N 88869
AB		200MG*	N 88872
AB	ROXANE LABORATORIES	100MG*	N 89048

TOBRAMYCIN (PAGE 3-194)

SOLUTION/DROPS; OPHTHALMIC

	TOBREX		
	ALCON LABORATORIES	0.3%*	N 62535

TOCAINIDE HYDROCHLORIDE (PAGE 3-194)

TABLET; ORAL

	TONOCARD		
	MS&D/MERCK	400MG*	N 18257
		600MG*	N 18257

TOLAZAMIDE (PAGE 3-194)

TABLET; ORAL

	TOLAZAMIDE		
AB	ZENITH LABORATORIES	100MG*	N 18894
AB		250MG*	N 18894
AB		500MG*	N 18894
	TOLINASE		
AB	UPJOHN	100MG	N 15500
AB		250MG	N 15500
AB		500MG	N 15500

TOLAZOLINE HYDROCHLORIDE (PAGE 3-194)

INJECTABLE; INJECTION

	PRISCOLINE		
	CIBA/CIBA-GEIGY	25MG/ML*	N 06403

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TOLBUTAMIDE (PAGE 3-194)

TABLET; ORAL
TOLBUTAMIDE

>_ADD_>	AB	PUREPAC/KALIPHARMA	500MG*	N 88950
	AB	SUPERPHARM	500MG*	N 88893

TOLMETIN SODIUM (PAGE 3-194)

CAPSULE; ORAL
TOLECTIN DS

	/MCNEIL LABORATORIES/	/EQ 400MG BASE/	/N 18084/
	MCNEIL PHARM	EQ 400MG BASE	N 18084

TABLET; ORAL
TOLECTIN

	/MCNEIL LABORATORIES/	/EQ 200MG BASE/	/N 17628/
	MCNEIL PHARM	EQ 200MG BASE	N 17628

TRAZODONE HYDROCHLORIDE (PAGE 3-194)

TABLET; ORAL
DESYREL

	MEAD JOHNSON/B-M	150MG*	N 18207

TRIAMCINOLONE ACETONIDE (PAGE 3-195)

CREAM; TOPICAL
ARISTOCORT A

AT	LEDERLE LABS/AM CYAN	0.025%*	N 88818
AT		0.1%*	N 88819
AT		0.5%*	N 88820

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	BAY LABORATORIES	0.025%*	N 88450
AT		0.1%*	N 88451

OINTMENT; TOPICAL
ARISTOCORT A

AT	LEDERLE LABS/AM CYAN	0.1%*	N 88780
AT		0.5%*	N 88781

TRIAMCINOLONE ACETONIDE

AT	PHARMADERM/BYK-GLDN	0.025%*	N 88692
AT		0.1%*	N 88690

TRYMEX

AT	SAVAGE LABS/BYK-GLDN	0.025%*	N 88693
AT		0.1%*	N 88691

TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-198)

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	DURAMED PHARMS	EQ 1MG BASE*	N 88967
AB		EQ 2MG BASE*	N 88968
AB		EQ 5MG BASE*	N 88969
AB		EQ 10MG BASE*	N 88970

TRIAZOLAM (PAGE 3-197)

TABLET; ORAL
HALCION

	UPJOHN	0.125MG*	N 17892

TRILOSTANE (PAGE 3-199)

CAPSULE; ORAL
MODRASTANE

	WINTHROP LABS/STERL	30MG*	N 18719
		60MG*	N 18719

TRIMEPRAZINE TARTRATE (PAGE 3-199)

SYRUP; ORAL
TRIMEPRAZINE TARTRATE

AA	BAY LABORATORIES	EQ 2.5MG BASE/5ML*	N 88285

TRIMETHOPRIM (PAGE 3-199)

TABLET; ORAL
TRIMETHOPRIM

>_ADD_> AB	DANBURY PHARMACAL	100MG*	N 70049

TRIPROLIDINE HYDROCHLORIDE (PAGE 3-200)

SYRUP; ORAL
TRIPROLIDINE HCL

AA	HALSEY DRUG	1.25MG/5ML*	N 88735

TRISULFAPYRIMIDINES (PAGE 3-200)

SUSPENSION; ORAL
/TRIPLE SULFOID/

/AB/	/VALE CHEMICAL/	/500MG/5ML/	/N 80167/

VECURONIUM BROMIDE (PAGE 3-202)

INJECTABLE; INJECTION
/NORCURON (NC-45)/
NORCURON

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

VERAPAMIL HYDROCHLORIDE (PAGE 3-202)

TABLET; ORAL

	CALAN		
AB	SEARLE/SEARLE PHARMS	80MG*	N 18817
AB		120MG*	N 18817
	ISOPTIN		
AB	KNOLL PHARMACEUTICAL	80MG	N 18593
AB		120MG	N 18593

VINCRISTINE SULFATE (PAGE 3-202)

INJECTABLE; INJECTION

	ONCOVIN		
	/ELI LILLY/	/1MG/AMP/	/N 14103/
		/5MG/AMP/	/N 14103/
	ELI LILLY	1MG/ML	N 14103

WARFARIN SODIUM (PAGE 3-203)

TABLET; ORAL

	WARFARIN SODIUM		
> ADD > AB	COLMED LABORATORIES	2MG*	N 88719

WATER FOR INJECTION, STERILE (PAGE 3-204)

LIQUID; N/A

	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER		
AP	TRAVENOL LABS	100%	N 18632
	STERILE WATER IN PLASTIC CONTAINER		
/AP/	/TRAVENOL LABS/	/100%/	/N 18632/

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

ADDENDUM
DESI PENDING LIST - 'EXEMPT' (COURT ORDER) CATEGORY
CUMULATIVE SUPPLEMENT NUMBER 10 / AUGUST '84 - JUNE '85

/ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;/
/ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE;/
/PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM;/
/THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E/(PAGE AD2)

/INJECTABLE; INJECTION/
/M.V.I. PEDIATRIC/
/USV PHARMACEUTICAL/ /80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;/
/5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;/
/17MG/VIAL;0.2MG/VIAL;/
/EQ 1MG BASE/VIAL;1.4MG/VIAL;/
/EQ 1.2MG BASE/VIAL;0.7MG/VIAL;/
/7MG/VIAL/ /N 18920/

/ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;/
/ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE/
/HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE/
/HYDROCHLORIDE; VITAMIN A; VITAMIN E/(PAGE AD2)
(SEE SPECIAL NOTE B.)

/INJECTABLE; INJECTION/
/M.V.I.-12/
/USV PHARMACEUTICAL/ /100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;/
/15MG/VIAL;0.005MG/VIAL;0.4MG/VIAL;/
/40MG/VIAL;4MG/VIAL;3.6MG/VIAL;/
/3MG/VIAL;1MG/VIAL;/
/10 IU/VIAL/ /N 18933/

/ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;/
/ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE/
/HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN/
/A/(PAGE AD2)
(SEE SPECIAL NOTE B.)

/INJECTABLE; INJECTION/
/MVC PLUS/
/ASCOT HOSP PHARMS/ /10MG/ML;0.006MG/ML;0.5 UGM/ML;/
/1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/
/0.4MG/ML;0.36MG/ML;0.3MG/ML;/
/330 IU/ML/ /N 18439/

/ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC/
/ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN;/
/THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN D; VITAMIN E/
(PAGE AD2)
(SEE SPECIAL NOTE B.)

/INJECTABLE; INJECTION/
/M.V.C. 9+3/
/LYPHOMED/ /20MG/ML;0.012MG/ML;0.001MG/ML;
/3MG/ML;0.06MG/ML;8MG/ML;0.8MG/ML;/
/0.72MG/ML;0.6MG/ML;660 IU/ML;/
/40 IU/ML;2 IU/ML/ /N 18440/

/ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; FOLIC ACID;/
/NIACINAMIDE; PANTHENOL; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN;/
/THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN D; VITAMIN E/
(PAGE AD2)
(SEE SPECIAL NOTE B.)

/INJECTABLE; INJECTION/
/MULTIVITAMIN ADDITIVE/
/ABBOTT LABORATORIES/ /100MG/5ML;0.06MG/5ML;0.005MG/5ML;
/0.4MG/5ML;20MG/5ML;15MG/5ML;/
/4.86MG/5ML;4.93MG/5ML;3.35MG/5ML;/
/3300 IU/5ML;200 IU/5ML;/
/10 IU/5ML/ /N 18223/

/ASCORBIC ACID; BIOTIN; DEXPANTHENOL; NIACINAMIDE; PYRIDOXINE/
/HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE/(PAGE AD2)
(SEE SPECIAL NOTE B.)

/INJECTABLE; INJECTION/
/BEROCCA C/
/HOFFMAN-LA ROCHE/ /50MG/ML;0.1MG/ML;10MG/ML;40MG/ML;/
/10MG/ML;5MG/ML;5MG/ML/ /N 06071/

/BEROCCA C 500/
/HOFFMAN-LA ROCHE/ /125MG/ML;1MG/ML;10MG/ML;40MG/ML/
/10MG/ML;5MG/ML;5MG/ML/ /N 06071/

/ASCORBIC ACID; DEXPANTHENOL; NIACINAMIDE; PYRIDOXINE/
/HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A;/
/VITAMIN D; VITAMIN E/(PAGE AD3)
(SEE SPECIAL NOTE B.)

/INJECTABLE; INJECTION/
/M.V.I./
/USV PHARMACEUTICAL/ /50MG/ML;2.5MG/ML;10MG/ML;1.5MG/ML;
/1MG/ML;5MG/ML;1,000 IU/ML;100 IU/ML;/
/0.5MG/ML/ /N 08809/
/100MG/ML;5MG/ML;20MG/ML;3MG/ML;/
/2MG/ML;10MG/ML;2,000 IU/ML;/
/200 IU/ML;1MG/ML/ /N 08809/

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

DIPYRIDAMOLE (PAGE AD4)

TABLET; ORAL
DIPYRIDAMOLE

DANBURY PHARMACAL	25MG	N 88945
	50MG	N 88800
	75MG	N 87432
PHARM BASICS	50MG	N 88822
SIDMAK LABORATORIES	25MG	N 88683
	50MG	N 88684
	75MG	N 88685

/ISOSORBIDE DINITRATE/(PAGE AD5)
(ALL PRODUCTS - SEE SPECIAL NOTE B.)

/TABLET; ORAL/
/ISOSORBIDE DINITRATE/
/BARR LABORATORIES/ /30MG/ /N 87564/

/TABLET; SUBLINGUAL/
/ISOSORBIDE DINITRATE/
/BARR LABORATORIES/ /10MG/ /N 87545/

/TABLET, CONTROLLED RELEASE; ORAL/
/ISOCHRON/
/FOREST LABORATORIES//20MG/ /N 88428/

NITROGLYCERIN (PAGE AD7)

/CAPSULE, CONTROLLED RELEASE; ORAL/
(ALL PRODUCTS - SEE SPECIAL NOTE B.)

/TABLET, CONTROLLED RELEASE; ORAL/
(ALL PRODUCTS - SEE SPECIAL NOTE B.)

PENTAERYTHRITOL TETRANITRATE (PAGE AD8)

CAPSULE, CONTROLLED RELEASE; ORAL
PENTAERYTHRITOL TETRANITRATE

∂ VITARINE/PHOENIX	80MG	N 86305
∂	80MG	N 87529
∂	80MG	N 87531

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

CURRENT STATUS - INEFFECTIVE

/BENTYL W/ PHENOBARBITAL/ /MERRELL DOW/DOW CHEM/
/DICYCLOMINE HYDROCHLORIDE; PHENOBARBITAL/

BEROCCA C HOFFMANN-LA ROCHE
ASCORBIC ACID; BIOTIN; DEXPANTHENOL; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE

BEROCCA C 500 HOFFMANN-LA ROCHE
ASCORBIC ACID; BIOTIN; DEXPANTHENOL; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE

> DLT > /CORTISPORIN/ /BURROUGHS WELLCOME/
> DLT > /GRAMICIDIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE;/
> DLT > /POLYMYXIN B SULFATE/

DIMETAPP AH ROBINS
BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE

/CETACORT/ /OWEN LABS/DERM PRODS/
/HYDROCORTISONE/

ELIXIR DIMETAPP AH ROBINS
BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE

/HC (HYDROCORTISONE)/ /C AND M PHARMACAL/
/HYDROCORTISONE/

/HYDROCORTISONE/ /TOWNE PAULSEN/
/HYDROCORTISONE/

/ILOTYCIN/ /ELI LILLY/
/ERYTHROMYCIN/

/MYCOLOG/ /BR SQUIBB AND SONS/
/GRAMICIDIN; NEOMYCIN SULFATE; NYSTATIN;/
/TRIAMCINOLONE ACETONIDE/

/NEOSPORIN G/ /BURROUGHS WELLCOME/
/GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE/

CURRENT STATUS - INEFFECTIVE

> DLT > /NYSTATIN; NEOMYCIN SULFATE; GRAMICIDIN; TRIAMCINOLONE/
> DLT > /ACETONIDE/ /CLAY-PARK LABS/
> DLT > /GRAMICIDIN; NEOMYCIN SULFATE; NYSTATIN;/
> DLT > /TRIAMCINOLONE ACETONIDE/

/TERRA-CORTRIL/ /PFIZER LABS/PFIZER/
/HYDROCORTISONE; OXYTETRACYCLINE HCL/

/NUTRACORT/ /OWEN LABS/DERM PRODS/
/HYDROCORTISONE/

/PRISCOLINE/ /CIBA/CIBA-GEIGY/
/TOLAZOLINE HYDROCHLORIDE/

TUSS-ORNADE SK&F LABORATORIES
CARAMIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE; ISOPROPAMIDE IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CURRENT STATUS - EFFECTIVENESS TO BE DETERMINED

M.V.I. PEDIATRIC USV PHARMACEUTICAL
ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

ADDENDUM D: DRUG PRICE COMPETITION AND PATENT TERM RESTORATION

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984. The Act amends section 505 of the Federal Food, Drug and Cosmetic Act, authorizing the Agency to accept abbreviated new drug applications for most previously approved drug products. This new legislation also provides for extending the term of a patent which claims a product, use, or method of manufacture that was subject to a regulatory review period in accordance with the Act.

The statute requires that FDA make publicly available a list of approved drug products containing the following information:

1) an alphabetical list of all drugs by official and proprietary name approved for safety and effectiveness, with monthly updates;

2) the application number and approval date for each drug product approved from January 1, 1982; and

3) whether *in vitro* and/or *in vivo* bioequivalence studies are required for ANDA approval.

The *Approved Prescription Drug Products with Therapeutic Equivalence Evaluations*, 5th Edition, (APDP) and its monthly supplements will be used to satisfy this new requirement.

In addition, the APDP will identify drugs which qualify under the new statute for periods of exclusivity (during which ANDAs and paper NDAs for those drugs may not be submitted or made effective as identified below) and will provide information on the current patent status of the listed drugs. Exclusivity prevents the filing and/or approval of ANDAs or paper NDAs. It does not prevent the filing or approval of a second full NDA. Applications qualifying for periods of exclusivity are:

(1) A new drug application approved between January 1, 1982, and September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other application. Approval of an ANDA or paper NDA for the same drug may not be made effective for a period of ten years from the date of the approval of the original application.

Original from UNIVERSITY OF MICHIGAN
Digitized by Google

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google

(2) A new drug application approved after September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other new drug application. Generally, no subsequent ANDA or paper NDA for the same drug may be submitted for a period of five years from the date of approval of the original application, except that such an application may be submitted after four years if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.

(3) A new drug application approved after September 24, 1984, for a drug product involving an active ingredient (or any ester or salt of that active ingredient) that has been approved in an earlier new drug application and which includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant or for which the applicant had a right of reference, and the investigations must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or paper NDA may not be made effective for the same drug before the expiration of three years from the date of approval of the original application.

(4) A supplement to a new drug application approved after September 24, 1984, which contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant or to which the applicant had a right of reference. The approval of a subsequent application for a change approved in the supplement may not be made effective for three years from the date of approval of the original supplement.

(5) A new drug application (or supplement to a new drug application) approved during the period from January 1, 1982, to September 24, 1984, which includes an active ingredient (including any ester or salt of the active ingredient) that has been approved in another application. The approval of a subsequent application for the drug or a significant change made in a supplement may not be made effective for two years from September 24, 1984.

Original from UNIVERSITY OF MICHIGAN

The Act required approved new drug applications to be supplemented with the required patent information by October 24, 1984. Patent information must now be filed with all newly submitted drug applications, and no NDA may be approved after September 24, 1984, without the pertinent patent information. The patent numbers and the expiration dates of any appropriate product or use patent on a marketed drug that is the subject of an approved NDA will be published in the APDP. Patent information on unapproved applications or on patents beyond the scope (i.e., process or manufacturing) of the Act will not be published.

The following explains how the APDP implements this.

Antibiotics, Insulin and Biologicals

Title I of the Act has been interpreted by the Agency not to include products approved under sections 506 or 507 of the Federal Food, Drug and Cosmetic Act (antibiotic and insulin products). Because of this, (1) antibiotic and insulin products are not considered eligible for exclusivity protection, (2) holders of approved applications for insulin and antibiotic products need not submit the patent information as required of NDA application holders, and (3) Antibiotic Form 6 sponsors are not required to provide the patent certification statement which must be included in ANDAs.

However, Title II, the patent term restoration portion of the Act, specifically addresses antibiotic, non-antibiotic, and human biological products (as those terms are used in the Federal Food, Drug and Cosmetic and Public Health Service Acts) in its provisions.

Bioavailability/Bioequivalence Requirements

The therapeutic equivalence evaluation codes in the APDP will enable firms to determine whether *in vitro* and/or *in vivo* bioavailability/bioequivalence study data must be included with their ANDA submissions.

Currently, drugs approved prior to 1962 fall into three major biopharmaceutic classes: (1) those which pose an actual or potential bioequivalence problem, and for which demonstration of bioequivalence through *in vivo* testing and acceptable dissolution performance is necessary; (2) those which pose an actual or potential bioequivalence problem but for which an *in vivo* study may be waived if acceptable dissolution performance is demonstrated (the list of such drugs is provided under TABLE I); and (3) those which pose no actual or potential bioequivalence problem and for which the only biopharmaceutic requirement is demonstration of acceptable dissolution for solid oral dosage forms.

All firms submitting an abbreviated new drug application for a single source drug product or a drug product which was first approved after 1962 will be required to demonstrate *in vivo* bioequivalence or else submit information sufficient to permit the Agency to waive demonstration of *in vivo* bioequivalence. Manufacturers of drug products formulated in dosage forms which do not present bioequivalence problems, such as an intravenous solution, may request that the *in vivo* bioequivalence requirement be waived.

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Sheerer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google

Before the passage of the Drug Price Competition and Patent Term Restoration Act, the Agency approved various drugs with bioavailability/bioequivalence problems and deferred the in vivo testing requirement for a number of reasons. The new law requires information to show that the proposed ANDA drug product is bioequivalent to the listed drug. Therefore, new applications for drugs such as amitriptyline hydrochloride which formerly may have been approved without an in vivo study now require an in vivo study as a condition for approval under the new Act.

Topicals

In the absence of contrary data, FDA regarded all pharmaceutically equivalent topical products of pre-1962 (DESI) drugs to be therapeutically equivalent. However, the Agency required that applicants for topical drug products initially approved after 1962, including "paper NDAs," either demonstrate the safety and efficacy of their products through clinical trials or through a bioequivalence study in order to be approved and evaluated as therapeutically equivalent.

The new Act requires applicants to demonstrate the bioequivalence of their topical drug product to the listed drug as one of the requirements for ANDA approval. This is the same policy that is presently being used in the "paper NDA" approval process. The Agency is now reviewing the therapeutic equivalence evaluation policy that has been made on the pre-1962 topical products to determine whether a change in this policy is warranted. In the meantime, an in vivo demonstration of bioequivalence will be required for approval of all topical products unless a waiver or in vitro alternatives can be justified by the applicant.

OTC Drug Products Eligible for Abbreviated New Drug Applications

Previous editions of the APDP excluded OTC drug products, because the main purpose of that publication was to provide information to states regarding FDAs recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. With the passage of the Drug Price Competition and Patent Term Restoration Act of 1984, the Agency now has the responsibility to publish an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required. There are some drugs for which there are both approved and unapproved OTC drug products in the market place. This situation occurs as a result of the Agency's current OTC compliance policy which allows the marketing of various unapproved OTC drug products pending the effective date of the applicable final OTC monograph. The OTC products included in APDP cumulative supplement TABLE II are limited to those for which approved applications are currently required as a condition of marketing. Appropriate patent numbers, exclusivity information, and expiration dates are also included.

Original from UNIVERSITY OF MICHIGAN

NDA's Approved by the Office of Biological Research and Review Not Previously Published in the APDP

All products accepted and approved under Section 505 of the Act as NDAs by the Office of Biological Research and Review (OBRR) will now be published in the APDP (see TABLE III). The application holder should have submitted relevant patent and exclusivity information as for other NDA drug products. These products will be listed drugs and ANDA applications may be submitted for marketing of drugs from this group. Appropriate patent numbers, exclusivity information, and expiration dates are also included.

Patent and Exclusivity Information

It was originally planned that TABLE IV of Cumulative Supplement 2 to the APDP would contain patent and exclusivity information. Because some firms submitted patent information in excess of that covered by the statute, FDA has reviewed all of the patent information to assure that only appropriate patents are listed. The patents that FDA regards as covered by the statutory provisions for submission of patent information are those that claim the active ingredient or ingredients or the drug product (excluding process patents), or use patents for a particular indication or method of using the product. The Agency has concluded that formulation/composition patents should be added to the List.

A patent that claims a drug (as contrasted with one that claims a use) must refer to an approved drug product. To ensure that only appropriate patents are published, the Agency has an obligation to carefully screen the patent information that is submitted by the NDA holder. Therefore the Agency is asking all holders of approved applications and applicants with pending applications, whether or not they previously submitted information on composition or formulation patents, to submit such information with the following certification: "The undersigned certifies that the drug or formulation or composition of such drug claimed by the following patents is currently approved under section 505 of the Federal Food, Drug and Cosmetic Act." The certification must be signed by the patent holder or by the person responsible for the NDA submission. The Agency intends to publish this additional patent information in its next supplement to the List after the information with the above described certification is received. The Agency will continue its policy of not publishing process or chemical intermediate patents.

The Agency is required by the law to publish all use patents, even if the use has not been approved by the Agency. Therefore, the publication of a use patent in TABLE IV in no way confers Agency approval on or implies that the indication has been approved. TABLE IV contains patent numbers and expiration dates and, for drug products approved after 1981, the date of approval and application number as required by the Act.

Original from UNIVERSITY OF MICHIGAN
Digitized by Google
Generated for Sheerer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google

Firms submitting ANDAs after September 24, 1984, that certified that no patent information had been filed should amend their applications, if patent information now appears in this list.

TABLES II-IV now identify all drugs which qualify under the new statute for periods of exclusivity. (See pages A-1 & A-2 of the Addendum for an explanation of exclusivity).

FDA has finished reviewing all patent and exclusivity information received initially from interested parties. The Agency believes TABLES II-IV now contain all appropriate patent and exclusivity information that the Agency regards as being covered by the new statute. This table will be updated monthly to include appropriate patent and exclusivity information. The exclusivity information column in TABLES II-IV designates the date on which the exclusivity ends and the basis for the exclusivity through the use of codes as explained on pages A-7 and A-8.

FDA invites comments from all interested parties on whether it has excluded any patent or exclusivity information that should have been included, or included patent or exclusivity information that should have been excluded. Any revisions to the list will be published in subsequent supplements.

Original from
UNIVERSITY OF MICHIGAN

DO TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMNS OF TABLES I-IV THE FOLLOWING ABBREVIATIONS HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THIS PAGE FOR AN EXPLANATION OF THE EXCLUSIVITY ABBREVIATIONS FOUND IN THE TABLES.

ABBREVIATIONS

NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NR	NEW ROUTE
PP	PARENTERAL IN PLASTIC CONTAINER
RTO	PRESCRIPTION TO OTC STATUS CHANGE
NS	NEW STRENGTH
D	NEW DOSING SCHEDULE (SEE REFERENCE, BELOW)
I	NEW INDICATION (SEE REFERENCE, BELOW)

REFERENCES

NEW DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google
Digitized by Google
Original from UNIVERSITY OF MICHIGAN

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

INDICATIONS

I-1	SEVERE HYPERTENSION IN PEDIATRICS AND NON-MALIGNANT HYPERTENSION
I-2	DYSMENORRHEA
I-3	TREATMENT OF TINEA VERSICOLOR
I-4	SYMPTOMATIC GASTROESOPHAGEAL REFLUX
I-5	NEPHROTOMOGRAPHY
I-6	CONTRAST ENHANCEMENT IN CRANIAL COMPUTED TOMOGRAPHY
I-7	VENOGRAPHY OF LOWER EXTREMITIES
I-8	WHOLE-BODY COMPUTED TOMOGRAPHY
I-9	GATED CARDIAC POOL IMAGING
I-10	POST-MYOCARDIAL INFARCTION
I-11	COLORECTAL SURGERY
I-12	NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
I-13	CISPLATIN INDUCED EMESIS
I-14	DIABETIC GASTROPARESIS
I-15	POST-MYOCARDIAL INFARCTION
I-16	ACROMEGALY
I-17	PITUITARY TUMORS
I-18	POSTMENOPAUSAL OSTEOPOROSIS
I-19	ANTIDOTE FOR ACETAMINOPHEN OVERDOSAGE
I-20	CONGESTIVE HEART FAILURE BID DOSAGE SCHEDULE
I-21	ACUTE OTITIS MEDIA
I-22	EXERCISE INDUCED BRONCHOSPASMS
I-23	MI OR STROKE
I-24	COMBINED USE WITH NICOTINIC ACID TO LOWER CHOLESTEROL LEVEL
I-25	BLASTOMYCOSES DERMATITIDES
I-26	PEDIATRIC SUBARACHNOID VASCULAR
I-27	PETRIELLIDIUM BOYDII INFECTION
I-28	HEREDITARY ANGIOEDEMA
I-29	INTRACORONARY USE
I-30	PEDIATRIC USE
I-31	DIRECT ISOTOPIC CYSTOGRAPHY
I-32	POSTPARTUM HEMORRHAGE
I-33	USE IN METHODONE INDUCED RESPIRATORY DEPRESSION
I-34	PROLACTIN SECRETING ADENOMAS
I-35	SHORT TERM TREATMENT OF GASTRIC ULCER DISEASE

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE I. LIST OF DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN; ASPIRIN; BUTALBITAL;
CAPSULE OR TABLET; ORAL
160-165MG; 160-165MG; 50MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 325MG; 50MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG; 160-165MG; 50MG; 40MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 325MG; 50MG; 40MG

ACETAMINOPHEN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325; 50MG
650; 50MG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 50MG; 40MG
650MG; 50MG; 40MG

AMINOPHYLLINE
TABLET; ORAL
100MG
200MG

ASPIRIN; BUTALBITAL;
CAPSULE OR TABLET; ORAL
325; 50MG
650; 50MG

ASPIRIN; BUTALBITAL, CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 50MG; 40MG;
650MG; 50MG; 40MG;

ASPIRIN; CAFFEINE; CARISOPRODOL
TABLET; ORAL
160MG; 32MG; 200MG

ASPIRIN; CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE
TABLET; ORAL
160MG; 32MG; 200MG; 16MG

ASPIRIN; CARISOPRODOL
TABLET; ORAL
325MG; 200MG

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
325MG; 200MG; 10MG

ASPIRIN; MEPROBAMATE
TABLET; ORAL
325MG; 200MG

ASPIRIN; METHOCARBAMOL
TABLET; ORAL
325MG; 200MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

ESTROGENS, CONJUGATED; MEPROBAMATE
TABLET; ORAL
0.4MG; 200MG
0.4MG; 400MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG
25MG
50MG
100MG

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google
Digitized by Google
Original from UNIVERSITY OF MICHIGAN

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google
Digitized by Google
Original from
UNIVERSITY OF MICHIGAN

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ACETAMINOPHEN 120MG	NEOPAP (SUPPOSITORY; RECTAL)	WEBCON PHARMS/ALCON	16-401 11-07-68		
ACETAMINOPHEN 650MG	TYLENOL (SUPPOSITORY; RECTAL)	MCNEIL LABORATORIES	17-756 05-26-76		
ACETAMINOPHEN 120MG	TYLENOL (SUPPOSITORY; RECTAL)	MCNEIL LABORATORIES	17-756 05-26-76		
ACETAMINOPHEN 120MG	ACEPHEN (SUPPOSITORY; RECTAL)	G AND W LABORATORIES	18-060 02-09-78		
ACETAMINOPHEN 650MG	ACEPHEN (SUPPOSITORY; RECTAL)	G AND W LABORATORIES	18-060 02-09-78		
ACETAMINOPHEN 650MG	ACETAMINOPHEN (SUPPOSITORY; RECTAL)	UPSHER-SMITH LABS	18-337 04-22-80		
ACETAMINOPHEN 120MG	ACETAMINOPHEN (SUPPOSITORY; RECTAL)	UPSHER-SMITH LABS	18-337 09-12-83		
ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE 80MG; 20MG	GAVISCON (TABLET, CHEWABLE; ORAL)	MARION LABORATORIES	18-685 12-09-83		NP 09-24-86
ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE 160MG; 40MG	GAVISCON-2 (TABLET, CHEWABLE; ORAL)	MARION LABORATORIES	18-685 12-09-83		NP 09-24-86
BROMPHENIRAMINE MALEATE 8MG	DIMETANE (TABLET, CONTROLLED RELEASE; ORAL)	AH ROBINS	10-799 06-10-83		RTO 09-24-86
BROMPHENIRAMINE MALEATE 12MG	DIMETANE (TABLET, CONTROLLED RELEASE; ORAL)	AH ROBINS	10-799 06-10-83		RTO 09-24-86
BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 12MG; 75MG	DIMETAPP (TABLET, CONTROLLED RELEASE; ORAL)	AH ROBINS	12-436 04-02-84		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CHLORHEXIDINE GLUCONATE 0.5%	HIBITANE (TINCTURE; TOPICAL)	ICI AMERICAS	18-049 12-18-78		
CHLORHEXIDINE GLUCONATE 0.5%	HIBISTAT (SOLUTION; TOPICAL)	ICI AMERICAS	18-300 05-23-80		
CHLORHEXIDINE GLUCONATE 4%	EXIDINE (SOLUTION; TOPICAL)	XTTRIUM LABS	19-125 12-24-84		
CHLORHEXIDINE GLUCONATE 4%	EXIDINE (AEROSOL; TOPICAL)	XTTRIUM LABS	19-127 12-24-84		
CHLORHEXIDINE GLUCONATE 4%	HIBICLENS (SOLUTION; TOPICAL)	ICI AMERICAS	17-768 09-17-76		
CHLORHEXIDINE GLUCONATE 4%	HIBICLENS (SPONGE; TOPICAL)	ICI AMERICAS	18-423 08-27-81		
CHLORPHENIRAMINE MALEATE 8MG	TELDRIN (CAPSULE, CONTROLLED RELEASE; ORAL)	MENLEY & JAMES/SKF	17-369 05-11-78		
CHLORPHENIRAMINE MALEATE 12MG	TELDRIN (CAPSULE, CONTROLLED RELEASE; ORAL)	MENLEY & JAMES/SKF	17-369 05-11-78		
CHLORPHENIRAMINE MALEATE 8MG	CHLOR-TRIMETON (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	07-638 10-18-78		
CHLORPHENIRAMINE MALEATE 12MG	CHLOR-TRIMETON (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	07-638 10-18-78		
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 4MG; 25MG	DEMAZIN (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	18-556 05-14-84		NS 09-24-86
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 8MG; 75MG	CONTAC (CAPSULE, CONTROLLED RELEASE; ORAL)	MENLEY & JAMES/SKF	18-099 02-04-80		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 8MG; 75MG	COLD CAPSULE V (CAPSULE, CONTROLLED RELEASE; ORAL)	DM GRAHAM LABS	18-794 04-23-85		
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 8MG; 75MG	PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE (CAPSULE, CONTROLLED RELEASE; ORAL)	CENTRAL PHARMS	18-809 05-07-84		
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 12MG; 75MG	TRIAMINIC-12 (TABLET, CONTROLLED RELEASE; ORAL)	DORSEY LABS/SANDOZ	18-115 07-23-81		
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 12MG; 75MG	COLD CAPSULE IV (CAPSULE, CONTROLLED RELEASE; ORAL)	DM GRAHAM LABS	18-793 04-25-85		
CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE 8MG; 120MG	CHLOR-TRIMETON (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	18-397 03-31-81		
CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE 8MG; 120MG	PSEUDOEPHEDRINE HCL/ CHLORPHENIRAMINE MALEATE (CAPSULE, CONTROLLED RELEASE; ORAL)	DM GRAHAM LABS	18-844 03-20-85		
CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE 12MG; 120MG	PSEUDOEPHEDRINE HCL/ CHLORPHENIRAMINE MALEATE (CAPSULE, CONTROLLED RELEASE; ORAL)	DM GRAHAM LABS	18-843 03-18-85		
CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE 12MG; 120MG	CODIMAL-L.A. 12 (CAPSULE, CONTROLLED RELEASE; ORAL)	CENTRAL PHARMS	18-935 04-15-85		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX EQ 4MG MALEATE/5ML; EQ 37.5MG HCL/5ML	CORSYM (SYRUP; ORAL)	PENNWALT PHARM	18-050 01-04-84	4221778 09-09-97	NDF 09-24-86
DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE 2MG; 60MG	DISOPHROL (TABLET; ORAL)	SCHERING	12-394 06-03-60		RTO 09-24-86
DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE 6MG; 120MG	DRIXORAL (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	13-483 09-13-82		RTO 09-24-86
DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE 6MG; 120MG	DISOPHROL (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	13-483 09-13-82		RTO 09-24-86
DEXTROMETHORPHAN RESIN COMPLEX EQ 30MG HBR/5ML	DELSYM (SUSPENSION, CONTROLLED RELEASE; ORAL)	PENNWALT PHARM	18-658 10-08-82	4221778 09-09-97	NDF 09-24-86
DIPHENHYDRAMINE HYDROCHLORIDE 12.5MG/5ML	BENYLIN (SYRUP; ORAL)	PARKE-DAVIS/W-L	06-514 08-07-81		
DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE 12.5MG/5ML; 30MG/5ML	BENYLIN (SOLUTION; ORAL)	PARKE-DAVIS/W-L	19-014 06-11-85		
DOXYLAMINE SUCCINATE 25MG	UNISOM (TABLET; ORAL)	PFIZER	18-066 10-06-78		
IBUPROFEN 200MG	ADVIL (TABLET; ORAL)	WHITEHALL LABS/AMHO	18-989 05-18-84		NS 09-24-86
IBUPROFEN 200MG	NUPRIN (TABLET; ORAL)	UPJOHN MANUFACTURING	19-012 05-18-84		NS 09-24-86
INSULIN SUSPENSION, ISOPHANE, BEEF 40 UNITS/ML	SEMILENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-929 02-08-77		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
INSULIN SUSPENSION, ISOPHANE, BEEF 100 UNITS/ML	SEMILENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-929 02-08-77		
INSULIN SUSPENSION, ISOPHANE, BIOSYNTHETIC HUMAN 100 UNITS/ML	HUMULIN N (INJECTABLE; INJECTION)	ELI LILLY	18-781 10-28-82		
INSULIN SUSPENSION, ISOPHANE, MIXED BEEF AND PORK 40 UNITS/ML	NPH ILETIN I (BEEF-PORK) (INJECTABLE; INJECTION)	LILLY RES LABS DIV	17-936 02-08-77		
INSULIN SUSPENSION, ISOPHANE, MIXED BEEF AND PORK 100 UNITS/ML	NPH ILETIN I (BEEF-PORK) (INJECTABLE; INJECTION)	LILLY RES LABS DIV	17-936 02-08-77		
INSULIN SUSPENSION, ISOPHANE, PURIFIED BEEF 100 UNITS/ML	NPH ILETIN II (INJECTABLE; INJECTION)	ELI LILLY	18-479 06-12-80		
INSULIN SUSPENSION, ISOPHANE, PURIFIED PORK 100 UNITS/ML	INSULIN INSULATARD NPH NORDISK (INJECTABLE; INJECTION)	NORDISK	18-194 01-16-80		
INSULIN SUSPENSION, ISOPHANE, PURIFIED PORK 100 UNITS/ML	NPH ILETIN II (PORK) (INJECTABLE; INJECTION)	ELI LILLY	18-345 12-05-79		
INSULIN SUSPENSION, ISOPHANE, PURIFIED PORK 100 UNITS/ML	NPH PURIFIED PORK ISOPHANE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-623 07-30-81		
INSULIN SUSPENSION, ISOPHANE, PURIFIED PORK; INSULIN, PURIFIED PORK 100 UNITS/ML	INSULIN NORDISK MIXTARD (PORK) (INJECTABLE; INJECTION)	NORDISK	18-195 01-16-80		
INSULIN SUSPENSION, PROTAMINE ZINC, MIXED BEEF AND PORK; 40 UNITS/ML	PROTAMINE, ZINC & ILETIN I (BEEF-PORK) (INJECTABLE; INJECTION)	ELI LILLY	17-932 02-08-77		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
INSULIN SUSPENSION, PROTAMINE ZINC, MIXED BEEF AND PORK 100 UNITS/ML	PROTAMINE, ZINC & ILETIN I (BEEF-PORK) (INJECTABLE; INJECTION)	ELI LILLY	17-932 02-08-77		
INSULIN SUSPENSION, PROTAMINE ZINC, PURIFIED BEEF 40 UNITS/ML	PROTAMINE ZINC INSULIN (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-928 02-08-77		
INSULIN SUSPENSION, PROTAMINE ZINC, PURIFIED BEEF 100 UNITS/ML	PROTAMINE ZINC INSULIN (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-928 02-08-77		
INSULIN SUSPENSION, PROTAMINE ZINC, PURIFIED BEEF; INSULIN, PURIFIED BEEF 100 UNITS/ML	PROTAMINE ZINC AND ILETIN II (INJECTABLE; INJECTION)	ELI LILLY	18-476 06-12-80		
INSULIN SUSPENSION, PROTAMINE ZINC, PURIFIED PORK; INSULIN, PURIFIED PORK 100 UNITS/ML	PROTAMINE ZINC AND ILETIN II(PORK) (INJECTABLE; INJECTION)	ELI LILLY	18-346 12-05-79		
INSULIN ZINC SUSPENSION, BEEF 40 UNITS/ML	LENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-998 02-08-77		
INSULIN ZINC SUSPENSION, BEEF 100 UNITS/ML	LENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-998 02-08-77		
INSULIN ZINC SUSPENSION, SEMISYNTHETIC PURIFIED HUMAN 100 UNITS/ML	NOVOLIN L (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-777 08-30-83		
INSULIN ZINC SUSPENSION, EXTENDED, PURIFIED BEEF 100 UNITS/ML	ULTRALENTE (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-385 03-17-80		
INSULIN ZINC SUSPENSION, EXTENDED, BEEF 100 UNITS/ML	ULTRALENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-997 02-08-77		
INSULIN ZINC SUSPENSION, PROMPT, BEEF 100 UNITS/ML	SEMILENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-996 02-08-77		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
INSULIN ZINC SUSPENSION, PROMPT, PURIFIED PORK 100 UNITS/ML	SEMILENTE (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-382 03-17-80		
INSULIN ZINC SUSPENSION, PURIFIED BEEF 100 UNITS/ML	LENTE ILETIN II (INJECTABLE; INJECTION)	ELI LILLY	18-477 06-12-80		
INSULIN ZINC SUSPENSION, PURIFIED BEEF AND PORK 100 UNITS/ML	LENTARD (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-384 03-17-80		
INSULIN ZINC SUSPENSION, PURIFIED PORK 100 UNITS/ML	LENTE ILETIN II (PORK) (INJECTABLE; INJECTION)	ELI LILLY	18-347 12-05-79		
INSULIN ZINC SUSPENSION, PURIFIED PORK 100 UNITS/ML	LENTE (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-383 03-17-80		
INSULIN, SEMISYNTHETIC PURIFIED HUMAN 100 UNITS/ML	NOVOLIN R (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-778 08-30-83		
INSULIN, BIOSYNTHETIC HUMAN 100 UNITS/ML	HUMULIN R (INJECTABLE; INJECTION)	ELI LILLY	18-780 10-28-82		
INSULIN, PORK 40 UNITS/ML	INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-926 02-08-77		
INSULIN, PORK 100 UNITS/ML	INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-926 02-08-77		
INSULIN, PURIFIED BEEF 100 UNITS/ML	REGULAR ILETIN II (INJECTABLE; INJECTION)	ELI LILLY	18-478 06-12-80		
INSULIN, PURIFIED PORK 100 UNITS/ML	INSULIN NORDISK QUICK (PORK) (INJECTABLE;INJECTION)	NORDISK INSULIN LABS	18-193 01-16-80		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
INSULIN, PURIFIED PORK 100 UNITS/ML	REGULAR ILETIN II (PORK) (INJECTABLE; INJECTION)	ELI LILLY	18-344 12-05-79		
INSULIN, PURIFIED PORK 100 UNITS/ML	REGULAR PURIFIED PORK INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-381 03-17-80		
INSULIN SUSPENSION, ISOPHANE, SEMISYNTHETIC, PURIFIED HUMAN 100 UNITS/ML	NOVOLIN N (INJECTABLE; INJECTION)	SQUIBB-NOVO	19-065 01-23-85		
NONOXYNOL-9 1GM	TODAY (SPONGE; VAGINAL)	VLI CORPORATION	18-683 04-01-83		NDF 09-24-86
POTASSIUM IODIDE 130MG	THYRO-BLOCK (TABLET; ORAL)	WALLACE LABS/C-W	18-307 11-09-79		
POTASSIUM IODIDE 1GM/ML	POTASSIUM IODIDE (SOLUTION; ORAL)	ROXANE LABORATORIES	18-551 02-19-82		NDF 09-24-86
POTASSIUM IODIDE 130MG	IOSAT (TABLET; ORAL)	ANBEX	18-664 10-14-82		
PSEUDOEPHEDRINE HYDROCHLORIDE 120MG	SUDAFED S.A. (CAPSULE, CONTROLLED RELEASE; ORAL)	BURROUGHS WELLCOME	17-941 01-15-79		
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 30MG/5ML; 1.25MG/5ML	ACTIFED (SYRUP; ORAL)	BURROUGHS WELLCOME	11-935 11-26-82		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	ACTIFED (TABLET; ORAL)	BURROUGHS WELLCOME	11-936 11-26-82		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	ACTIFED (CAPSULE; ORAL)	BURROUGHS WELLCOME	19-208 01-15-85		RTO 09-24-86

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 30MG/5ML; 1.25MG/5ML	ALLERBAN PLUS (SYRUP; ORAL)	BAY LABORATORIES	88-116 03-04-83		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	TRI-SUDO (TABLET; ORAL)	MD PHARMACEUTICAL	85-024 01-10-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	TRIPODRINE (TABLET; ORAL)	DANBURY PHARMACAL	88-112 01-20-83		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 30MG/5ML; 1.25MG/5ML	TRIOFED (SYRUP; ORAL)	NATL PHARM MFG/BARRE	88-115 03-04-83		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 30MG/5ML; 1.25MG/5ML	TRIPOSED (SYRUP; ORAL)	HALSEY DRUG	88-213 03-30-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL (TABLET; ORAL)	CHELSEA LABORATORIES	88-118 01-26-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	TRIPOSED (TABLET; ORAL)	HALSEY DRUG	88-192 05-01-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	TRIPROLIDINE AND PSEUDOEPHEDRINE (TABLET; ORAL)	BOLAR PHARMACEUTICAL	88-318 01-13-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 30MG/5ML; 1.25MG/5ML	TRIPOSED (SYRUP; ORAL)	HALSEY DRUG	88-213 05-01-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 120MG; 5MG	ACTIFED (CAPSULE, CONTROLLED RELEASE; ORAL)	BURROUGHS WELLCOME	18-996 06-17-85		
PSEUDOEPHEDRINE SULFATE 120MG	AFRINOL (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	18-191 10-30-80		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
TIOCONAZOLE 1%	TROSYD (CREAM; TOPICAL)	PFIZER CEN RES/PFIZR	18-682 02-18-83	4062966 12-13-94	NCE 02-18-93
TRIPROLIDINE HYDROCHLORIDE 2.5MG	ACTIDIL (TABLET; ORAL)	BURROUGHS WELLCOME	11-110 04-14-58		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 2.5MG	TRIPROLIDINE HCL (TABLET; ORAL)	BOLAR PHARMACEUTICAL	84-453 02-06-76		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 2.5MG	TRIPROLIDINE HCL (TABLET; ORAL)	DANBURY PHARMACAL	85-094 02-07-77		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 2.5MG	TRIPROLIDINE HCL (TABLET; ORAL)	DRUMMER/PHOENIX	85-610 03-21-78		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 1.25MG/5ML	ACTIDIL (SYRUP; ORAL)	BURROUGHS WELLCOME	11-496 07-24-58		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 1.25MG/5ML	BAYIDYL (SYRUP; ORAL)	BAY LABORATORIES	87-963 01-18-83		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 1.25MG/5ML	TRIPROLIDINE HCL (SYRUP; ORAL)	NATL PHARM MFG/BARRE	85-940 07-13-79		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 1.25MG/5ML	TRIPROLIDINE HCL (SYRUP; ORAL)	PHARMS ASSOC/BEACH	87-514 02-10-82		RTO 09-24-86

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	10-102 12-14-61		
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	DELMED	11-912 9-2-59		
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	10-855 06-11-59		
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	16-918 3-17-78		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	80-77 11-6-80		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION	NONE (INJECTABLE; INJECTION)	DELMED	78-519 4-23-80		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION	NONE (INJECTABLE; INJECTION)	TERUMO AMERICA	82-528 11-3-82		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	77-420 5-12-78		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	16-527 6-22-70		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	80-222 8-23-82		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	DELMED	16-907 5-15-73		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TERUMO AMERICA	78-1211 6-10-81		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	17-401 12-6-77		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	81-1012 6-28-83		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google
Digitized by Google
Original from UNIVERSITY OF MICHIGAN

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP 2.2GM/100ML, SODIUM CHLORIDE USP 0.9GM/100ML, MANNITOL USP 0.75GM/100ML, ADENINE 0.27GM/100ML	ADSOL[R] RED CELL PRESERVATION SOLUTION (INJECTABLE; INJECTION)	TRAVENOL LABS	81-1104 5-16-83		
ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP 0.42GM/100ML, DIBASIC SODIUM PHOSPHATE USP 0.285GM/100ML, SODIUM CHLORIDE USP 0.718 GM/100ML, ADENINE 0.017GM/100ML, DEXTROSE USP 0.396GM/100ML, SODIUM CITRATE USP 0.588GM/100ML	AS-2 NUTRICEL ADITIVE SYSTEM (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	82-915 9-22-83		
ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP 0.042 GM/100ML, MONOBASIC SODIUM PHOSPHATE USP 0.276GM/100ML, SODIUM CHLORIDE USP 0.410 GM/100ML, ADENINE 0.30 GM/100ML, DEXTROSE USP 1.10 GM/100ML, SODIUM CITRATE USP 0.588GM/100ML	AS-3 NUTRICEL ADDITIVE SYSTEM (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	82-915 10-19-84		
ANTICOAGULANT HEPARIN SOLUTION USP	NONE (INJECTABLE; INJECTION)	DELMED	77-822 5-17-78		
ANTICOAGULANT HEPARIN SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	81-1217 5-16-83		
ANTICOAGULANT SODIUM CITRATE SOLUTION USP	NONE (INJECTABLE; INJECTION)	ALPHA THERAPEUTIC	81-416 10-12-83		
ANTICOAGULANT SODIUM CITRATE SOLUTION USP	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	76-305 6-30-78		
ANTICOAGULANT SODIUM CITRATE SOLUTION USP	NONE (INJECTABLE; INJECTION)	DELMED	16-702 12-28-70		
ANTICOAGULANT SODIUM CITRATE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TERUMO AMERICA	78-1214 2-8-80		
ANTICOAGULANT SODIUM CITRATE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	77-923 1-20-78		

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	NONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	16-375 7-25-67		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	16-375 7-25-67		
DEXTRAN 75, 6% 6GM/100ML IN DEXTROSE 5% 5GM/100ML	NONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	8-819 3-31-53		
DEXTRAN 75, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	8-819 3-31-53		
DEXTRAN 75, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-253 2-4-83		
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	NONE (INJECTABLE; INJECTION)	AMERICAN MCGAW	16-767 4-6-70		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	AMERICAN MCGAW	16-767 4-6-70		
DEXTRAN 70, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	AMERICAN MCGAW	9-024 8-18-69		
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	16-653 9-23-69		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	16-653 9-23-69		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTRAN 70, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	8-716 8-11-69		
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	NONE (INJECTABLE; INJECTION)	PHARMACHEM	16-836 11-14-70		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	PHARMACHEM	16-836 11-14-70		
DEXTRAN 75, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	PHARMACHEM	8-564 9-19-52		
DEXTRAN 75, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	PHARMACHEM	16-759 8-19-70		
DEXTRAN 1 150MG/ML IN SODIUM CHLORIDE 0.6% 6MG/ML	PROMIT (INJECTABLE;INJECTION)	PHARMACIA LABS	83-715 10-30-84		
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	RHEOMACRODEX[R] (INJECTABLE; INJECTION)	PHARMACIA LABS	14-716 1-18-67		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	RHEOMACRODEX[R] (INJECTABLE; INJECTION)	PHARMACIA LABS	14-716 1-18-67		
DEXTRAN 70, 6% 6GM/100ML IN DEXTROSE 5% 5GM/100ML	MACRODEX[R] (INJECTABLE; INJECTION)	PHARMACIA LABS	6-826 6-8-54		
DEXTRAN 70, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	MACRODEX[R] (INJECTABLE; INJECTION)	PHARMACIA LABS	6-826 6-8-54		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	GENTRAN[R] 40 (INJECTABLE; INJECTION)	TRAVENOL LABS	16-628 11-4-68		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	GENTRAN[R] 40 (INJECTABLE; INJECTION)	TRAVENOL LABS	16-628 11-4-68		
DEXTRAN 40, 10% 10GM/100ML DEXTROSE 5% 5GM/100ML	GENTRAN[R] 40 (INJECTABLE; INJECTION)	TRAVENOL LABS	84-619 2-22-85		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	GENTRAN[R] 40 (INJECTABLE; INJECTION)	TRAVENOL LABS	84-620 2-22-85		
DEXTRAN 75, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	GENTRAN[R] 75 (INJECTABLE; INJECTION)	TRAVENOL LABS	16-607 1-26-70		
DEXTRAN 75, 6% INVERTED SUGAR 10% 6GM/100ML;10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	6% GENTRAN[R] 75 AND 10% TRAVERT[R] (INJECTABLE; INJECTION)	TRAVENOL LABS	8-788 2-9-53		
HETASTARCH, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	HESPAN[R] (INJECTABLE; INJECTION)	AM CRITICAL CARE	16-889 7-17-72	3523938 8-11-87	
PROPIOLACTONE 99% 99GM/100ML	BETAPRONE (SOLUTION; CHEMICAL STERILIZING AGENT)	ONEAL JONES&FELDMAN	11-657 9-11-59		
UROKINASE 5000 IU/VIAL	ABBOKINASE OPEN-CATHETER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	76-1021 12-15-83		NS 09-24-86
UROKINASE 250,000 IU/VIAL	ABBOKINASE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	76-1021 7-31-78		I-29 09-24-86
UROKINASE 250,000 IU/VIAL	BREOKINASE (INJECTABLE; INJECTION)	STERLING DRUG	17-873 8-28-79		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ACEBUTOLOL HYDROCHLORIDE EQ 200MG BASE	SECTRAL (CAPSULE; ORAL)	IVES LABS/AMHO	18-917 12-28-84	3726919 04-10-90 3857952 12-31-91	NCE 12-28-89
ACEBUTOLOL HYDROCHLORIDE EQ 400MG BASE	SECTRAL (CAPSULE; ORAL)	IVES LABS/AMHO	18-917 12-28-84	3726919 04-10-90 3857952 12-31-91	NCE 12-28-89
ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE 650MG; EQ 25MG BASE	TALACEN (TABLET; ORAL)	STERLING DRUG	18-458 09-23-82	4105659 08-08-95	NC 09-24-86
ACETIC ACID, GLACIAL 250MG/100ML	ACETIC ACID 0.25% IN PLASTIC CONTAINER (SOLUTION; URETHRAL)	TRAVENOL LABS	18-523 02-19-82		
ACETOHYDROXAMIC ACID 250MG	LITHOSTAT (TABLET; ORAL)	URO-RESEARCH	18-749 05-31-83		NCE 05-31-93
ACYCLOVIR 5%	ZOVIRAX (OINTMENT; TOPICAL)	BURROUGHS WELLCOME	18-604 03-29-82	4199574 04-22-97	NCE 03-29-92
ACYCLOVIR 200MG	ZOVIRAX (CAPSULE; ORAL)	BURROUGHS WELLCOME	18-828 01-25-85	4199574 04-22-97	NCE 03-29-92
ACYCLOVIR SODIUM EQ 500MG BASE/VIAL	ZOVIRAX (INJECTABLE; INJECTION)	BURROUGHS WELLCOME	18-603 10-22-82	4199574 04-22-97	NCE 03-29-92
ALBUTEROL 0.09MG/INH	PROVENTIL (AEROSOL; INHALATION)	SCHERING	17-559 05-01-81	3644353 02-22-89 3705233 12-05-89	I-22 09-24-86
ALBUTEROL 0.09MG/INH	VENTOLIN (AEROSOL; INHALATION)	GLAXO	18-473 05-01-81	3644353 02-22-89 3705233 12-05-89	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ALBUTEROL SULFATE EQ 2MG BASE	PROVENTIL (TABLET; ORAL)	SCHERING	17-853 05-07-82	3644353 02-22-89 3705233 12-05-89	NE 09-24-86
ALBUTEROL SULFATE EQ 4MG BASE	PROVENTIL (TABLET; ORAL)	SCHERING	17-853 05-07-82	3644353 02-22-89 3705233 12-05-89	NE 09-24-86
ALBUTEROL SULFATE EQ 2MG BASE/5ML	PROVENTIL (SYRUP; ORAL)	SCHERING	18-062 01-19-83	3644353 02-22-89 3705233 12-05-89 4499108 02-12-02	
ALCLOMETASONE DIPROPIONATE 0.05%	VADERM (OINTMENT; TOPICAL)	SCHERING	18-702 12-14-82	4124707 11-07-95	NCE 12-14-92
ALCLOMETASONE DIPROPIONATE 0.05%	VADERM (CREAM; TOPICAL)	SCHERING	18-707 12-14-82	4124707 11-07-95	NCE 12-14-92
ALLOPURINOL 100MG	ALLOPURINOL (TABLET; ORAL)	BOLAR PHARMACEUTICAL	18-241 11-16-84		
ALLOPURINOL 300MG	ALLOPURINOL (TABLET; ORAL)	BOLAR PHARMACEUTICAL	18-241 11-16-84		
ALLOPURINOL 100MG	ALLOPURINOL (TABLET; ORAL)	CHELSEA LABORATORIES	18-785 09-28-84		
ALLOPURINOL 300MG	ALLOPURINOL (TABLET; ORAL)	CHELSEA LABORATORIES	18-785 09-28-84		
ALLOPURINOL 100MG	ALLOPURINOL (TABLET; ORAL)	DANBURY PHARMACAL	18-832 09-28-84		
ALLOPURINOL 300MG	ALLOPURINOL (TABLET; ORAL)	DANBURY PHARMACAL	18-877 09-28-84		

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ALLOPURINOL 100MG	ZYLOPRIM (TABLET; ORAL)	BURROUGHS WELLCOME	16-084 08-19-66	3624205 11-30-88	
ALLOPURINOL 300MG	ZYLOPRIM (TABLET; ORAL)	BURROUGHS WELLCOME	16-084 01-14-74	3624205 11-30-88	
ALLOPURINOL 100MG	LOPURIN (TABLET; ORAL)	BOOTS PHARMACEUTICAL	18-297 06-10-80	3624205 11-30-88	
ALLOPURINOL 300MG	LOPURIN (TABLET; ORAL)	BOOTS PHARMACEUTICAL	18-297 06-10-80	3624205 11-30-88	
ALPRAZOLAM 0.25MG	XANAX (TABLET; ORAL)	UPJOHN	18-276 10-16-81	3987052 10-19-93 3980789 09-14-93	
ALPRAZOLAM 0.5MG	XANAX (TABLET; ORAL)	UPJOHN	18-276 10-16-81	3987052 10-19-93 3980789 09-14-93	
ALPRAZOLAM 1MG	XANAX (TABLET; ORAL)	UPJOHN	18-276 10-16-81	3987052 10-19-93 3980789 09-14-93	
AMCINONIDE 0.1%	CYCLOCORT (CREAM; TOPICAL)	LEDERLE LABS/AM CYAN	18-116 10-18-71	4158055 06-12-96	
AMCINONIDE 0.1%	CYCLOCORT (OINTMENT; TOPICAL)	LEDERLE LABS/AM CYAN	18-498 11-13-81	4158055 06-12-96	
AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE 5MG; 50MG	MODURETIC 5/50 (TABLET; ORAL)	MS&D/MERCK	18-201 10-05-81	3781430 12-25-90	
AMINO ACIDS 6.9%	FREAMINE HBC 6.9% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	16-822 05-17-83		NS 09-24-86

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
AMINO ACIDS 6.5%	RENAMIN W/O ELECTROLYTES (INJECTABLE; INJECTION)	TRAVENOL LABS	17-493 10-15-82		NS 09-24-86
AMINO ACIDS 8.5%	NOVAMINE 8.5% (INJECTABLE; INJECTION)	CUTTER LABS/MILES	17-957 08-09-82		
AMINO ACIDS 11.4%	NOVAMINE 11.4% (INJECTABLE; INJECTION)	CUTTER LABS/MILES	17-957 08-09-82		
AMINO ACIDS 8%	HEPATAMINE 8% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-676 08-03-82	3950529 04-13-93	NS 09-24-86
AMINO ACIDS 4%	BRANCHAMIN 4% (INJECTABLE; INJECTION)	TRAVENOL LABS	18-678 09-28-84	4438144 03-20-01	NS 09-28-87
AMINO ACIDS 4%	BRANCHAMIN 4% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-684 09-28-84	4438144 03-20-01	NS 09-28-87
AMINO ACIDS 6.5%	NEOPHAM 6.5% (INJECTABLE; INJECTION)	CUTTER-VITRUM	18-792 01-17-84		NS 09-24-86
AMINO ACIDS 3.5%	AMINOSYN 3.5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-804 05-15-84		NS 09-24-86
AMINO ACIDS 3.5%	AMINOSYN 3.5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-875 08-08-84		NS 09-24-86
AMINO ACIDS 5.2%	AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE (INJECTABLE; INJECTION)	CUTTER-VITRUM	18-901 04-06-84		
AMINO ACIDS 5.5%	TRAVASOL 5.5% W/O ELECTROLYTES IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-931 08-23-84		NS 09-24-86

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
AMINO ACIDS 8.5%	TRAVASOL 8.5% W/O ELECTROLYTES IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-931 08-23-84		
AMINO ACIDS 10%	TRAVASOL 10% W/O ELECTROLYTES IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-931 08-23-84		
AMINO ACIDS 6%	TROPHAMINE 6% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-018 07-20-84		NS 09-24-86
AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 3%; 26MG/100ML; 3GM/100ML; 54MG/100ML; 41MG/100ML; 149MG/100ML; 204MG/100ML; 117MG/100ML	PERIPHRAMINE (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-582 05-08-82		NC 09-24-86
AMINO ACIDS; DEXTROSE 3.5%; 5%	AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-120 10-11-84		
AMINO ACIDS; DEXTROSE 3.5%; 25%	AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-118 10-11-84		
AMINO ACIDS; DEXTROSE 4.25%; 25%	AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-119 10-11-84		
AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE 3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	AMINOSYN 3.5% M IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-804 05-15-84		NC 09-24-86

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE 3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	AMINOSYN 3.5% M IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-875 08-08-84		NC 09-24-86
AMINOACETIC ACID 1.5GM/100ML	AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-522 02-19-82		
AMINOCAPROIC ACID 250MG/ML	AMINOCAPROIC ACID (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-590 10-29-82		
AMINOGLUTETHIMIDE 250MG	CYTADREN (TABLET; ORAL)	CIBA/CIBA-GEIGY	18-202 10-29-80	3595960 07-27-88 3944671 03-16-93	
AMINOPHYLLINE 300MG/5ML	SOMOPHYLLIN (ENEMA; RECTAL)	FISONS	18-232 04-02-82		NR 09-24-86
AMINOPHYLLINE; SODIUM CHLORIDE 100MG/100ML; 450MG/100ML	AMINOPHYLLINE W/ SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-924 12-12-84		
AMINOPHYLLINE; SODIUM CHLORIDE 200MG/100ML; 450MG/100ML	AMINOPHYLLINE W/ SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-924 12-12-84		
AMINOPHYLLINE; SODIUM CHLORIDE 400MG/100ML; 450MG/100ML	AMINOPHYLLINE W/ SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-924 12-12-84		
AMINOPHYLLINE; SODIUM CHLORIDE 500MG/100ML; 450MG/100ML	AMINOPHYLLINE W/ SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-924 12-12-84		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
AMITRIPTYLINE HYDROCHLORIDE 10MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 04-07-61	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 25MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 07-05-74	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 50MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 04-07-61	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 75MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 10-28-76	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 100MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 10-28-76	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 150MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 09-17-76	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 10MG/ML	ELAVIL (INJECTABLE; INJECTION)	MS&D/MERCK	12-704 04-11-61	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE 12.5MG; 5MG	LIMBITROL (TABLET; ORAL)	HOFFMANN-LA ROCHE	16-949 12-23-77	4316897 02-23-99	
AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE 25MG; 10MG	LIMBITROL (TABLET; ORAL)	HOFFMANN-LA ROCHE	16-949 12-23-77	4316897 02-23-99	
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 10MG; 4MG	ETRAFON A (TABLET; ORAL)	SCHERING	14-713 12-30-65	3428735 02-18-86	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 25MG; 2MG	ETRAFON 2-25 (TABLET; ORAL)	SCHERING	14-713 12-30-65	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 25MG; 4MG	ETRAFON-FORTE (TABLET; ORAL)	SCHERING	14-713 12-30-65	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 10MG; 2MG	ETRAFON 2-10 (TABLET; ORAL)	SCHERING	14-713 12-30-65	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 10MG; 4MG	TRIAVIL 4-10 (TABLET; ORAL)	MS&D/MERCK	14-715 12-30-65	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 25MG; 2MG	TRIAVIL 2-25 (TABLET; ORAL)	MS&D/MERCK	14-715 08-23-65	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 10MG; 2MG	TRIAVIL 2-10 (TABLET; ORAL)	MS&D/MERCK	14-715 04-04-67	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 25MG; 4MG	TRIAVIL 4-25 (TABLET; ORAL)	MS&D/MERCK	14-715 08-25-65	3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 50MG; 4MG	TRIAVIL 4-50 (TABLET; ORAL)	MS&D/MERCK	14-715 03-15-78	3428735 02-18-86	
AMMONIUM LACTATE EQ 12% ACID	LAC-HYDRIN (LOTION; TOPICAL)	BRISTOL-MYERS	19-155 04-24-85		NE 04-24-88
AMOXAPINE 25MG	ASENDIN (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-021 09-22-80	3546226 12-08-87 3663696 05-16-89 3681357 08-01-89	

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
AMOXAPINE 50MG	ASENDIN (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-021 09-22-80	3546226 12-08-87 3663696 05-16-89 3681357 08-01-89	
AMOXAPINE 100MG	ASENDIN (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-021 09-22-80	3546226 12-08-87 3663696 05-16-89 3681357 08-01-89	
AMOXAPINE 150MG	ASENDIN (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-021 09-22-80	3546226 12-08-87 3663696 05-16-89 3681357 08-01-89	
AMRINONE LACTATE EQ 5MG BASE/ML	INOCOR (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	18-700 07-31-84	4072746 02-07-95	NCE 07-31-94
ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE 356.4MG; 30MG; 16MG	SYNALGOS-DC (CAPSULE; ORAL)	IVES LABS/AMHO	11-483 09-06-83		
ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE 385MG; 30MG; 25MG	NORGESIC (TABLET; ORAL)	RIKER LABS/3M	13-416 10-27-82		
ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE 770MG; 60MG; 50MG	NORGESIC FORTE (TABLET; ORAL)	RIKER LABS/3M	13-416 10-27-82		
ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE 389MG; 32.4MG; 32MG	DARVON COMPOUND (CAPSULE; ORAL)	ELI LILLY INDSTRS/PR	10-996 03-08-83		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE 389MG; 32.4MG; 65MG	DARVON COMPOUND-65 (CAPSULE; ORAL)	ELI LILLY INDSTRS/PR	10-996 03-08-83		
ASPIRIN; CARISOPRODOL 325MG; 200MG	SOMA COMPOUND (TABLET; ORAL)	WALLACE PHARMS/C-W	12-365 07-11-83		
ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE 325MG; 200MG; 16MG	SOMA COMPOUND W/ CODEINE (TABLET; ORAL)	WALLACE PHARMS/C-W	12-366 07-11-83		
ASPIRIN; MEPROBAMATE 325MG; 200MG	EQUAGESIC (TABLET; ORAL)	WYETH LABS/AMHO	11-702 12-29-83		
ASPIRIN; PENTAZOCINE HYDROCHLORIDE 325MG; EQ 12.5MG BASE	TALWIN COMPOUND (TABLET; ORAL)	WINTHROP LABS/STERL	16-891 11-12-75	4105659 08-08-95	
ATENOLOL 50MG	TENORMIN (TABLET; ORAL)	STUART PHARMS/ICI AM	18-240 08-19-81	3663607 05-16-89 3934032 01-20-93 3836671 09-17-91	
ATENOLOL 100MG	TENORMIN (TABLET; ORAL)	STUART PHARMS/ICI AM	18-240 08-19-81	3663607 05-16-89 3934032 01-20-93 3836671 09-17-91	
ATENOLOL; CHLORTHALIDONE 100MG; 25MG	TENORETIC 100 (TABLET; ORAL)	STUART PHARMS/ICI AM	18-760 06-08-84	3663607 05-16-89 3934032 01-20-93 3836671 09-17-91	NC 09-24-86

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ATENOLOL; CHLORTHALIDONE 50MG; 25MG	TENORETIC 50 (TABLET; ORAL)	STUART PHARMS/ICI AM	18-760 06-08-84	3663607 05-16-89 3934032 01-20-93 3836671 09-17-91	NC 09-24-86
ATRACURIUM BESYLATE 10MG/ML	TRACRIUM (INJECTABLE; INJECTION)	BURROUGHS WELLCOME	18-831 11-23-83	4179507 12-18-96	NCE 11-23-93
ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE 0.025MG; 0.5MG	MOTOFEN HALF-STRENGTH (TABLET; ORAL)	MCNEIL LABORATORIES	17-744 07-14-78	3646207 02-28-89	
AURANOFIN 3MG	RIDAURA (CAPSULE; ORAL)	SK&F LABORATORIES	18-689 05-24-85	3635945 01-18-89 3708579 01-02-90	NCE 05-24-90
ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE 0.025MG; 1MG	MOTOFEN (TABLET; ORAL)	MCNEIL LABORATORIES	17-744 07-14-78	3646207 02-28-89	
AZATADINE MALEATE 1MG	OPTIMINE (TABLET; ORAL)	SCHERING	17-601 03-29-77	3419565 12-31-85 3717647 02-20-90	
AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE 1MG; 120MG	TRINALIN (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	18-506 03-23-82	3419565 12-31-85 3717647 02-20-90	NC 09-24-86
BACLOFEN 10MG	LIORESAL (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-851 11-22-77	3471548 10-07-86	
BACLOFEN 20MG	LIORESAL DS (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-851 01-20-82	3471548 10-07-86	NS 09-24-86
BECLOMETHANSONE DIPROPIONATE 0.042MG/INH	BECLOVENT (AEROSOL; INHALATION)	GLAXO	18-153 06-24-80	4414209 08-23-94 4364923 12-21-99	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
BECLOMETHANSONE DIPROPIONATE 0.042MG/INH	VANCERIL (AEROSOL; INHALATION)	SCHERING	17-573 05-12-76	4414209 08-23-94 4364923 10-29-99	
BECLOMETHANSONE DIPROPIONATE 0.042MG/INH	BECONASE (AEROSOL; INHALATION/NASAL)	GLAXO	18-584 09-30-81	4414209 08-23-94 4364923 12-21-99	
BECLOMETHANSONE DIPROPIONATE 0.042MG/INH	VANCENASE (AEROSOL; INHALATION/NASAL)	SCHERING	18-521 09-24-81	4414209 08-23-94 4364923 10-29-99	
BENDROFLUMETHIAZIDE 2.5MG	NATURETIN-2.5 (TABLET; ORAL)	ER SQUIBB AND SONS	12-164 12-07-59	3392168 07-09-85	
BENDROFLUMETHIAZIDE 5MG	NATURETIN-5 (TABLET; ORAL)	ER SQUIBB AND SONS	12-164 12-07-59	3392168 07-09-85	
BENDROFLUMETHIAZIDE 10MG	NATURETIN-10 (TABLET; ORAL)	ER SQUIBB AND SONS	12-164 03-29-77	3392168 07-09-85	
BENDROFLUMETHIAZIDE; NADOLOL 5MG; 40MG	CORZIDE (TABLET; ORAL)	ER SQUIBB AND SONS	18-647 05-25-83	3982021 09-21-93 3935267 01-27-93	NC 09-24-86
BENDROFLUMETHIAZIDE; NADOLOL 5MG; 80MG	CORZIDE (TABLET; ORAL)	ER SQUIBB AND SONS	18-647 05-25-83	3982021 09-21-93 3935267 01-27-93	NC 09-24-86
BENTIROMIDE 500MG/7.5ML	CHYMEX (SOLUTION; ORAL)	ADRIA LABORATORIES	18-366 12-29-83	3801562 04-02-91 3745212 07-10-90	NCE 12-29-93
BETAMETHASONE 0.6MG	CELESTONE (TABLET; ORAL)	SCHERING	12-657 04-17-61	3485854 12-23-86	

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
BETAMETHASONE 0.6MG/5ML	CELESTONE (SYRUP; ORAL)	SCHERING	14-215 04-18-64	3485854 12-23-86	
BETAMETHASONE 0.2%	CELESTONE (CREAM; TOPICAL)	SCHERING	14-762 04-10-64	3485854 12-23-86	
BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE 3MG/ML; EQ 3MG BASE/ML	CELESTONE SOLUSPAN (INJECTABLE; INJECTION)	SCHERING	14-602 03-03-65	3485854 12-23-86	
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	DIPROLENE (OINTMENT; TOPICAL)	SCHERING	18-741 07-27-83		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	BETAMETHASONE DIPROPIONATE (CREAM; TOPICAL)	PHARMADERM/BYK-GLDN	19-136 06-26-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	BETAMETHASONE DIPROPIONATE (CREAM; TOPICAL)	E FOUGERA/BYK-GLDN	19-137 06-26-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	ALPHATREX (CREAM; TOPICAL)	SAVAGE LABS/BYK-GLDN	19-138 06-26-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	BETAMETHASONE DIPROPIONATE (OINTMENT; TOPICAL)	PHARMADERM/BYK-GLDN	19-140 09-04-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	BETAMETHASONE DIPROPIONATE (OINTMENT; TOPICAL)	E FOUGERA/BYK-GLDN	19-141 09-04-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	ALPHATREX (OINTMENT; TOPICAL)	SAVAGE LABS/BYK-GLDN	19-143 09-04-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	DIPROSONE (CREAM; TOPICAL)	SCHERING	17-536 01-29-75		D-1 09-24-86
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	DIPROSONE (OINTMENT; TOPICAL)	SCHERING	17-691 04-15-76		D-1 09-24-86
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	DIPROSONE (LOTION; TOPICAL)	SCHERING	17-781 02-01-77		D-1 09-24-86
BETAMETHASONE DIPROPIONATE EQ 0.1% BASE	DIPROSONE (AEROSOL; TOPICAL)	SCHERING	17-829 05-24-77		D-1 09-24-86

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE EQ 0.05% BASE; 1%	LOTRISONE (CREAM; TOPICAL)	SCHERING	18-827 07-10-84	3660577 05-02-89 3705172 12-05-89 4298604 11-03-98 3839573 10-01-91	NC 09-24-86
BETAMETHASONE VALERATE EQ 0.1% BASE	BETA-VAL (CREAM; TOPICAL)	LEMMON	18-642 03-24-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETADERM (CREAM; TOPICAL)	TJ ROACO	18-839 06-30-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (CREAM; TOPICAL)	PHARMADERM/BYK-GLDN	18-860 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (CREAM; TOPICAL)	E FOUGERA/BYK-GLDN	18-861 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETATREX (CREAM; TOPICAL)	SAVAGE LABS/BYK-GLDN	18-862 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETATREX (OINTMENT; TOPICAL)	SAVAGE LABS/BYK-GLDN	18-863 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (OINTMENT; TOPICAL)	PHARMADERM/BYK-GLDN	18-864 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (OINTMENT; TOPICAL)	E FOUGERA/BYK-GLDN	18-865 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (LOTION; TOPICAL)	E FOUGERA/BYK-GLDN	18-866 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETATREX (LOTION; TOPICAL)	SAVAGE LABS/BYK-GLDN	18-867 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (LOTION; TOPICAL)	PHARMADERM/BYK-GLDN	18-870 08-31-83		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
BETHANIDINE SULFATE 10MG	TENATHAN (TABLET; ORAL)	AH ROBINS	17-675 05-29-81	3495013 02-10-87	
BETHANIDINE SULFATE 25MG	TENATHAN (TABLET; ORAL)	AH ROBINS	17-675 05-29-81	3495013 02-10-87	
BITOLTEROL MESYLATE 0.8%	TORNALATE (AEROSOL; INHALATION)	WINTHROP-BREON/STERL	18-770 12-28-84	4138581 02-06-96	NCE 12-28-89
BRETYLIUM TOSYLATE 50MG/ML	BRETYLOL (INJECTABLE; INJECTION)	AM CRITICAL CARE/AHS	17-954 07-18-78	RE29618 04-29-86	
BROMOCRIPTINE MESYLATE EQ 2.5MG BASE	PARLODEL (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	17-962 06-28-78	3752888 08-14-90 3752814 08-14-90	I-16 12-14-87 I-34 06-28-88
BROMOCRIPTINE MESYLATE EQ 5MG BASE	PARLODEL (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	17-962 03-01-82	3752888 08-14-90 3752814 08-14-90	I-16 12-14-87 I-34 06-28-88
BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE 12.5MG/5ML; 10MG/5ML	AMBENYL (SYRUP; ORAL)	MARION LABORATORIES	09-319 01-10-84		
BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 2MG/5ML; 10MG/5ML; 12.5MG/5ML	DIMETANE-DC (SYRUP; ORAL)	AH ROBINS	11-694 03-29-84		
BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE 2MG/5ML; 10MG/5ML; 30MG/5ML	DIMETANE-DX (SYRUP; ORAL)	AH ROBINS	11-694 03-29-84		
BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE 2MG/5ML; 10MG/5ML; 30MG/5ML	DIMETANE-DX (SYRUP; ORAL)	AH ROBINS	19-279 08-24-84		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 4MG/5ML; 25MG/5ML	ELIXIR DIMETAPP (ELIXIR; ORAL)	AH ROBINS	13-087 03-29-84		
BUMETANIDE 1MG	BUMEX (TABLET; ORAL)	HOFFMANN-LA ROCHE	18-225 02-28-83	3634583 01-11-89 3806534 04-23-91	NCE 02-28-93
BUMETANIDE 2MG	BUMEX (TABLET; ORAL)	HOFFMANN-LA ROCHE	18-225 06-14-85	3634583 01-11-89 3806534 04-23-91	NCE 02-28-93
BUMETANIDE 0.5MG	BUMEX (TABLET; ORAL)	HOFFMANN-LA ROCHE	18-225 02-28-83	3634583 01-11-89 3806534 04-23-91	NCE 02-28-93
BUMETANIDE 0.25MG/ML	BUMEX (INJECTABLE; INJECTION)	HOFFMANN-LA ROCHE	18-226 02-28-83	3634583 01-11-89 3806534 04-23-91	NCE 02-28-93
BUMETANIDE 2MG	BUMEX (TABLET; ORAL	HOFFMANN-LA ROCHE	18-225 06-14-85		
BUPIVACAINE HYDROCHLORIDE; DEXTROSE 0.75%; 8.25%	MARCAINE SPINAL (INJECTABLE; INJECTION)	BREON LABS/STERLING	18-692 05-04-84		NC 09-24-86
BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE 0.5%; 0.0091MG/ML	SENSORCAINE (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	18-304 09-02-83		
BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE 0.75%; 0.0091MG/ML	SENSORCAINE (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	18-304 09-02-83		
BUTORPHANOL TARTRATE 1MG/ML	STADOL (INJECTABLE; INJECTION)	BRISTOL LABS/B-M	17-857 08-22-78	3819635 06-25-91	
BUTORPHANOL TARTRATE 2MG/ML	STADOL (INJECTABLE; INJECTION)	BRISTOL LABS/B-M	17-857 08-22-78	3819635 06-25-91	
CALCEFEDIOL, ANHYDROUS 0.02MG	CALDEROL (CAPSULE; ORAL)	UPJOHN	18-312 08-05-80	3833622 09-03-91 3565924 03-23-86	

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CALCEFEDIOL, ANHYDROUS 0.05MG	CALDEROL (CAPSULE; ORAL)	UPJOHN	18-312 08-05-80	3833622 09-03-91 3565924 03-23-86	
CALCITONIN 200 IU/VIAL	CALCIMAR (INJECTABLE; INJECTION)	ARMOUR PHARM	17-769 12-21-84		I-18 12-21-87
CALCITONIN 400 IU/VIAL	CALCIMAR (INJECTABLE; INJECTION)	ARMOUR PHARM	17-497 12-21-84		I-18 12-21-87
CALCITRIOL 0.25 UGM	ROCALTROL (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	18-044 08-17-78	3697559 10-10-89 4391802 07-05-00 4341774 07-27-99 4225596 09-30-97	
CALCITRIOL 0.5 UGM	ROCALTROL (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	18-044 08-17-78	3697559 10-10-89 4391802 07-05-00 4341774 07-27-99 4225596 09-30-97	
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE 34MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-269 01-17-83		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	AM MCGAW/AM HOSP	18-807 08-26-83		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	AM MCGAW/AM HOSP	18-807 08-26-83		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	AM MCGAW/AM HOSP	18-807 08-26-83		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	AM MCGAW/AM HOSP	18-807 08-26-83		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	INPERSOL-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	ABBOTT LABORATORIES	18-379 07-07-82		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	ABBOTT LABORATORIES	18-379 07-07-82		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	INPERSOL-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	ABBOTT LABORATORIES	18-379 07-07-82		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 26MG/100ML; 2.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	DIALYTE W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	AM MCGAW/AM HOSP	18-460 11-02-83		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-635 02-07-83		
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML	TPN ELECTROLYTES IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-895 07-20-84		NC 09-24-86
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE 35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	ISOLYTE E IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-899 10-31-83		
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML	PLEGISOL IN PLASTIC CONTAINER (SOLUTION; PERFUSION, CARDIAC)	ABBOTT LABORATORIES	18-608 02-26-82		NC 09-24-86
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	ACETATED RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-725 11-29-82		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 33MG/100ML; 30MG/100ML; 860MG/100ML	RINGER'S IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-495 02-19-82		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 33MG/100ML; 30MG/100ML; 860MG/100ML	RINGERS INJECTION IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-648 02-07-83		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 33MG/100ML; 30MG/100ML; 860MG/100ML	RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-721 11-09-82		

Generated for Shearrer, Cynthia D. (University of Missouri-Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SODIUM LACTATE 20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-367 04-05-85		
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SODIUM LACTATE 20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-367 04-05-85		
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SODIUM LACTATE 20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-367 04-05-85		
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SODIUM LACTATE 20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-367 04-05-85		
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SODIUM LACTATE 20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-367 04-05-85		
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SODIUM LACTATE 20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-367 04-05-85		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SODIUM LACTATE 20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-367 04-05-85		
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SODIUM LACTATE 20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-367 04-05-85		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	LACTATED RINGER'S IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-494 02-19-82		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	LACTATED RINGER'S IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	AM MCGAW/AM HOSP	18-681 12-27-82		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	LACTATED RINGER'S IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-921 04-03-84		
CALCIUM METRIZOATE; MAGNESIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE SODIUM 0.78MG/ML; 0.15MG/ML; 75.9MG/ML; 16.6MG/ML	ISOPAQUE 440 (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	16-847 11-17-73	3476802 11-04-86	
CALCIUM; MEGLUMINE; METRIZOIC ACID 0.35MG/ML; 140.1MG/ML; 461.8MG/ML	ISOPAQUE 280 (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	17-506 04-30-74	3476802 11-04-86	
CAPTOPRIL 12.5MG	CAPOTEN (TABLET; ORAL)	ER SQUIBB AND SONS	18-343 01-17-85	4105776 08-08-95	I-20 09-24-86 D-7 10-12-87

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CAPTOPRIL 25MG	CAPOTEN (TABLET; ORAL)	ER SQUIBB AND SONS	18-343 04-06-81	4105776 08-08-95	I-20 09-24-86 D-7 10-12-87
CAPTOPRIL 50MG	CAPOTEN (TABLET; ORAL)	ER SQUIBB AND SONS	18-343 04-06-81	4105776 08-08-95	I-20 09-24-86 D-7 10-12-87
CAPTOPRIL 100MG	CAPOTEN (TABLET; ORAL)	ER SQUIBB AND SONS	18-343 04-06-81	4105776 08-08-95	I-20 09-24-86 D-7- 10-12-87
CAPTOPRIL; HYDROCHLOROTHIAZIDE 25MG; 15MG	CAPOZIDE 25/15 (TABLET; ORAL)	ER SQUIBB AND SONS	18-709 10-12-84	4105776 08-08-95 4217347 08-12-97	NC 10-12-87
CAPTOPRIL; HYDROCHLOROTHIAZIDE 25MG; 25MG	CAPOZIDE 25/25 (TABLET; ORAL)	ER SQUIBB AND SONS	18-709 10-12-84	4105776 08-08-95 4217347 08-12-97	NC 10-12-87
CAPTOPRIL; HYDROCHLOROTHIAZIDE 50MG; 15MG	CAPOZIDE 50/15 (TABLET; ORAL)	ER SQUIBB AND SONS	18-709 10-12-84	4105776 08-08-95 4217347 08-12-97	NC 10-12-87
CAPTOPRIL; HYDROCHLOROTHIAZIDE 50MG; 25MG	CAPOZIDE 50/25 (TABLET; ORAL)	ER SQUIBB AND SONS	18-709 10-12-84	4105776 08-08-95 4217347 08-12-97	NC 10-12-87
CARBAMAZEPINE 200MG	TEGRETOL (TABLET; ORAL)	GEIGY/CIBA-GEIGY	16-608 03-11-68	4409212 10-11-00	
CARBAMAZEPINE 100MG	TEGRETOL (TABLET, CHEWABLE; ORAL)	GEIGY/CIBA-GEIGY	18-281 12-14-81	4409212 10-11-00	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CARBIDOPA 25MG	LODOSYN (TABLET; ORAL)	MS&D/MERCK	17-830 04-25-77	3462536 08-19-86 3830827 08-20-91 3781415 12-25-90	
CARBIDOPA; LEVODOPA 10MG; 100MG	SINEMET (TABLET; ORAL)	MS&D/MERCK	17-555 05-02-75	3462536 08-19-86 3769424 10-30-90 3781415 12-25-90 3830827 08-20-91 RE29892 10-30-90	
CARBIDOPA; LEVODOPA 25MG; 250MG	SINEMET (TABLET; ORAL)	MS&D/MERCK	17-555 05-02-75	3462536 08-19-86 3769424 10-30-90 3781415 12-25-90 3830827 08-20-91 RE29892 10-30-90	
CARBIDOPA; LEVODOPA 25MG; 100MG	SINEMET (TABLET; ORAL)	MS&D/MERCK	17-555 05-02-75	3462536 08-19-86 3769424 10-30-90 3781415 12-25-90 3830827 08-20-91 RE29892 10-30-90	
CARBOPROST TROMETHAMINE EQ 0.25MG BASE/ML	PROSTIN/15M (INJECTABLE; INJECTION)	UPJOHN	17-989 01-09-79	3728382 04-17-90	I-32 03-21-88
CELLULOSE SODIUM PHOSPHATE 2.5GM/PACKET	CALCIBIND (POWDER; ORAL)	MISSION PHARMACAL	18-757 12-28-82		NCE 12-28-92
CERULETIDE DIETHYLAMINE 0.02MG/ML	TYMTRAN (INJECTABLE; INJECTION)	ADRIA LABORATORIES	18-296 12-24-81	3472832 10-14-86	

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CHENODIOL 250MG	CHENIX (TABLET; ORAL)	ROWELL LABORATORIES	18-513 07-28-83		NCE 07-28-93
CHLORDIAZEPOXIDE 25MG	LIBRITABS (TABLET; ORAL)	ROCHE PRODUCTS	13-071 10-31-66	4316897 02-23-99	
CHLORDIAZEPOXIDE 5MG	LIBRITABS (TABLET; ORAL)	ROCHE PRODUCTS	13-071 10-31-66	4316897 02-23-99	
CHLORDIAZEPOXIDE 10MG	LIBRITABS (TABLET; ORAL)	ROCHE PRODUCTS	13-071 10-31-66	4316897 02-23-99	
CHLORDIAZEPOXIDE 30MG	LIBRELEASE (CAPSULE, CONTROLLED RELEASE; ORAL)	HOFFMANN-LA ROCHE	17-813 09-12-83	4316897 02-23-99	NDF 09-24-86
CHLORDIAZEPOXIDE HYDROCHLORIDE 5MG	LIBRIUM (CAPSULE; ORAL)	ROCHE PRODUCTS	12-249 02-24-60	4316897 02-23-99	
CHLORDIAZEPOXIDE HYDROCHLORIDE 10MG	LIBRIUM (CAPSULE; ORAL)	ROCHE PRODUCTS	12-249 02-24-60	4316897 02-23-99	
CHLORDIAZEPOXIDE HYDROCHLORIDE 25MG	LIBRIUM (CAPSULE; ORAL)	ROCHE PRODUCTS	12-249 02-24-60	4316897 02-23-99	
CHLORDIAZEPOXIDE HYDROCHLORIDE 100MG/AMP	LIBRIUM (INJECTABLE; INJECTION)	HOFFMANN-LA ROCHE	12-301 07-21-61	4316897 02-23-99	
CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE 5MG; 2.5MG	LIBRAX (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	12-750 05-02-61	4316897 02-23-99	
CHLORDIAZEPOXIDE; ESTROGENS, CONJUGATED 5MG; 0.2MG	MENRIUM 5-2 (TABLET; ORAL)	HOFFMANN-LA ROCHE	14-740 10-27-69	4316897 02-23-99	
CHLORDIAZEPOXIDE; ESTROGENS, CONJUGATED 5MG; 0.4MG	MENRIUM 5-4 (TABLET; ORAL)	HOFFMANN-LA ROCHE	14-740 10-27-69	4316897 02-23-99	
CHLORDIAZEPOXIDE; ESTROGENS, CONJUGATED 10MG; 0.4MG	MENRIUM 10-4 (TABLET; ORAL)	HOFFMANN-LA ROCHE	14-740 10-27-69	4316897 02-23-99	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CHLOROXINE 2%	CAPITROL (SHAMPOO; TOPICAL)	WESTWOOD PHARMS	17-594 10-19-76	3886277 05-27-92	
CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE 15MG; 0.1MG	COMBIPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-503 08-22-74	3454701 07-08-86	
CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE 15MG; 0.2MG	COMBIPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-503 08-22-74	3454701 07-08-86	
CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE 15MG; 0.3MG	COMBIPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-503 04-10-84	3454701 07-08-86	
CHOLESTYRAMINE EQ 4GM RESIN/PACKET	QUESTRAN (POWDER; ORAL)	MEAD JOHNSON/B-M	16-019 12-06-66		I-23 09-24-86
CHOLESTYRAMINE EQ 4GM RESIN/PACKET	QUESTRAN (POWDER; ORAL)	MEAD JOHNSON/B-M	16-640 08-03-73		I-23 09-24-86
CHYMOPAPAIN 12,500 UNITS/VIAL	DISCASE (INJECTABLE; INJECTION)	TRAVENOL LABS	18-625 01-18-84		NCE 11-10-92
CHYMOPAPAIN 10,000 UNITS/VIAL	CHYMODIACTIN (INJECTABLE; INJECTION)	SMITH LABORATORIES	18-663 11-10-82	4439423 03-26-01	NCE 11-10-92
CHYMOPAPAIN 4,000 UNITS/VIAL	CHYMODIACTIN (INJECTABLE; INJECTION)	SMITH LABORATORIES	18-663 08-21-84	4439423 03-26-01	NCE 11-10-92
CICLOPIROX OLAMINE 1%	LOPROX (CREAM; TOPICAL)	HOECHST-ROUSSEL	18-748 12-30-82	3883545 05-13-92	NCE 12-30-92
CIMETIDINE 200MG	TAGAMET (TABLET; ORAL)	SK&F LAB	17-920 08-16-77	3950333 04-13-93 4024271 05-17-94	
CIMETIDINE 300MG	TAGAMET (TABLET; ORAL)	SK&F LAB	17-920 08-16-77	3950333 04-13-93 4024271 05-17-94	

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CIMETIDINE 400MG	TAGAMET (TABLET; ORAL)	SK&F LAB	17-920 12-14-83	3950333 04-13-93 4024271 05-17-94	NS 09-24-86
CIMETIDINE HYDROCHLORIDE EQ 300MG BASE/5ML	TAGAMET (SOLUTION; ORAL)	SK&F LAB	17-924 08-16-77	3950333 04-13-93 4024271 05-17-94	
CIMETIDINE HYDROCHLORIDE EQ 150MG BASE/ML	TAGAMET (INJECTABLE; INJECTION)	SK&F LAB	17-939 08-16-77	3950333 04-13-93 4024271 05-17-94	
CINOXACIN 250MG	CINOBAC (CAPSULE; ORAL)	ELI LILLY	18-067 06-13-80	3669965 06-13-89	
CINOXACIN 500MG	CINOBAC (CAPSULE; ORAL)	ELI LILLY	18-067 06-13-80	3669965 06-13-89	
CISPLATIN 0.5MG/ML	PLATINOL-AQ (INJECTABLE; INJECTION)	BRISTOL LABS/B-M	18-057 07-18-84	4177263 12-04-96 4310515 01-12-99	NDF 09-24-86
CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE 3.24GM/100ML; 380MG/100ML; 430MG/100ML	IRRIGATING SOLUTION G IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-519 06-22-82		NC 09-24-86
CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE 3.24GM/100ML; 380MG/100ML; 430MG/100ML	UROLOGIC G IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	ABBOTT LABORATORIES	18-904 05-27-83		NC 09-24-86
CLEMASTINE FUMARATE EQ 0.5MG BASE/5ML	TAVIST (SYRUP; ORAL)	DORSEY LABS/SANDOZ	18-675 06-28-85		NDF 06-28-88
CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE EQ 1MG BASE; 75MG	TAVIST D (TABLET, CONTROLLED RELEASE; ORAL)	DORSEY LABS/SANDOZ	18-298 12-15-82	3933999 01-20-93	NDF 09-24-86
CLOMIPHENE CITRATE 50MG	CLOMIPHENE CITRATE (TABLET; ORAL)	PLANTEX/IKAPHARM	18-361 03-22-82		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CLONAZEPAM 0.5MG	CLONOPIN (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-533 06-04-75	4316897 02-23-99	
CLONAZEPAM 1MG	CLONOPIN (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-533 06-04-75	4316897 02-23-99	
CLONAZEPAM 2MG	CLONOPIN (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-533 06-04-75	4316897 02-23-99	
CLONIDINE 2.5MG	CATAPRES-TTS-1 (FILM, CONTROLLED RELEASE; PERCUTANEOUS)	BOEHRINGER INGELHEIM	18-891 10-10-84	3454701 07-08-86	NR 10-10-87
CLONIDINE 5MG	CATAPRES-TTS-2 (FILM, CONTROLLED RELEASE; PERCUTANEOUS)	BOEHRINGER INGELHEIM	18-891 10-10-84	3454701 07-08-86	NR 10-10-87
CLONIDINE 7.5MG	CATAPRES-TTS-3 (FILM, CONTROLLED RELEASE; PERCUTANEOUS)	BOEHRINGER INGELHEIM	18-891 10-10-84	3454701 07-08-86	NR 10-10-87
CLONIDINE HYDROCHLORIDE 0.1MG	CATAPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-407 09-03-74	3454701 07-08-86	
CLONIDINE HYDROCHLORIDE 0.2MG	CATAPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-407 09-03-74	3454701 07-08-86	
CLONIDINE HYDROCHLORIDE 0.3MG	CATAPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-407 09-20-79	3454701 07-08-86	
CLORAZEPATE DIPOTASSIUM 3.75MG	TRANXENE (CAPSULE; ORAL)	ABBOTT LABORATORIES	17-105 06-23-72	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 7.5MG	TRANXENE (CAPSULE; ORAL)	ABBOTT LABORATORIES	17-105 06-23-72	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 15MG	TRANXENE (CAPSULE; ORAL)	ABBOTT LABORATORIES	17-105 06-23-72	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 22.5MG	TRANXENE SD (TABLET; ORAL)	ABBOTT LABORATORIES	17-105 03-31-75	RE28315 06-23-87	

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CLORAZEPATE DIPOTASSIUM 11.25MG	TRANXENE SD (TABLET; ORAL)	ABBOTT LABORATORIES	17-105 08-04-76	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 3.75MG	TRANXENE (TABLET; ORAL)	ABBOTT LABORATORIES	17-105 03-10-80	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 7.5MG	TRANXENE (TABLET; ORAL)	ABBOTT LABORATORIES	17-105 03-10-80	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 15MG	TRANXENE (TABLET; ORAL)	ABBOTT LABORATORIES	17-105 03-10-80	RE28315 06-23-87	
CLOTRIMAZOLE 1%	LOTRIMIN (SOLUTION; TOPICAL)	SCHERING	17-613 02-03-75	3660577 05-02-89 3705172 12-05-89 3839573 10-01-91	
CLOTRIMAZOLE 1%	LOTRIMIN (CREAM; TOPICAL)	SCHERING	17-619 03-18-75	3660577 05-02-89 3705172 12-05-89 3839573 10-01-91	
CLOTRIMAZOLE 1%	GYNE-LOTRIMIN (CREAM; VAGINAL)	SCHERING	18-052 11-08-78	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CLOTRIMAZOLE 100MG	GYNE-LOTRIMIN (TABLET; VAGINAL)	SCHERING	17-717 03-24-76	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CLOTRIMAZOLE 1%	MYCELEX (SOLUTION; TOPICAL)	MILES PHARMS/MILES	18-181 01-15-79	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CLOTRIMAZOLE 100MG	MYCELEX-G (TABLET; VAGINAL)	MILES PHARMS/MILES	18-182 02-27-79	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CLOTRIMAZOLE 500MG	MYCELEX-G (TABLET; VAGINAL)	MILES PHARMS/MILES	19-069 04-19-85	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	NS 04-19-88
CLOTRIMAZOLE 1%	MYCELEX (CREAM; TOPICAL)	MILES PHARMS/MILES	18-183 01-15-79	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CLOTRIMAZOLE 1%	MYCELEX-G (CREAM; VAGINAL)	MILES PHARMS/MILES	18-230 02-16-79	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CLOTRIMAZOLE 10MG	MYCELEX (TROCHE/LOZENGE; ORAL)	MILES PHARMS/MILES	18-713 06-17-83	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	NDF 09-24-86

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CLOTRIMAZOLE 1%	LOTRIMIN (LOTION; TOPICAL)	SCHERING	18-813 02-17-84	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE 10MG/5ML; 5MG/5ML; 6.25MG/5ML	PHENERGAN VC W/ CODEINE (SYRUP; ORAL)	WYETH LABS/AMHO	08-306 04-02-84		
CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE 10MG/5ML; 6.25MG/5ML	PHENERGAN W/ CODEINE (SYRUP; ORAL)	WYETH LABS/AMHO	08-306 04-02-84		
CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 10MG/5ML; 30MG/5ML; 1.25MG/5ML	ACTIFED W/ CODEINE (SYRUP; ORAL)	BURROUGHS WELLCOME	12-575 04-04-84		
COLESTIPOL HYDROCHLORIDE 5GM/PACKET	COLESTID (GRANULE; ORAL)	UPJOHN	17-563 04-04-77	3692895 09-19-89	I-24 09-24-86
COLESTIPOL HYDROCHLORIDE 500GM/BOT	COLESTID (GRANULE; ORAL)	UPJOHN	17-563 04-04-77	3692895 09-19-89	I-24 09-24-86
COPPER 89MG	CU-7 (INTRAUTERINE DEVICE; INTRAUTERINE)	SEARLE PHARMS	17-408 02-25-74	3563235 02-16-88 4040417 08-09-94 3783861 01-08-91 3803308 12-01-87 RE28399 04-29-92	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
COPPER 120MG	TATUM-T (INTRAUTERINE DEVICE; INTRAUTERINE)	SEARLE PHARMS	18-205 08-16-79	3563235 02-16-88 4040417 08-09-94 3783861 01-08-91 3803308 12-01-87 RE28399 04-29-92	
CROMOLYN SODIUM 20MG	INTAL (CAPSULE; INHALATION)	FISONS	16-990 06-20-73	3686412 08-22-89 3777033 08-22-89 3419578 12-31-85 3957965 05-18-93	I-22 09-24-86
CROMOLYN SODIUM 4%	NASALCROM (SOLUTION; NASAL)	FISONS	18-306 03-18-83	3686412 08-22-89 3777033 08-22-89 3419578 12-31-85 3975536 08-17-93 4053628 10-11-94	NDF 09-24-86
CROMOLYN SODIUM 4%	OPTICROM (SOLUTION; OPHTHALMIC)	FISONS	18-155 10-03-84	3686412 08-22-89 3777033 08-22-89 3419578 12-31-85 3975536 08-17-93 4053628 10-11-94	NDF 10-03-87

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CROMOLYN SODIUM 10MG/ML	INTAL (SOLUTION; INHALATION)	FISONS	18-596 05-28-82	3686412 08-22-89 3777033 08-22-89 3419578 12-31-85 3975536 08-17-93	I-22 01-19-88
CYCLOBENZAPRINE HYDROCHLORIDE 5MG	FLEXERIL (TABLET; ORAL)	MS&D/MERCK	17-821 08-26-77	3454643 07-08-86 3882246 05-06-92	
CYCLOBENZAPRINE HYDROCHLORIDE 10MG	FLEXERIL (TABLET; ORAL)	MS&D/MERCK	17-821 08-26-77	3454643 07-08-86 3882246 05-06-92	
CYCLOPHOSPHAMIDE 1GM/VIAL	CYTOXAN (INJECTABLE; INJECTION)	MEAD JOHNSON/B-M	12-142 08-30-82		NS 09-24-86
CYCLOPHOSPHAMIDE 1GM/VIAL	NEOSAR (INJECTABLE; INJECTION)	ADRIA LABORATORIES	87-442 07-08-83		NS 09-24-86
CYCLOPHOSPHAMIDE 2GM/VIAL	CYTOXAN (INJECTABLE; INJECTION)	MEAD JOHNSON/B-M	12-142 08-30-82		NS 09-24-86
CYTARABINE 100MG/VIAL	CYTOSAR-U (INJECTABLE; INJECTION)	UPJOHN	16-793 06-17-69	3444294 05-13-86	
CYTARABINE 500MG/VIAL	CYTOSAR-U (INJECTABLE; INJECTION)	UPJOHN	16-793 06-17-69	3444294 05-13-86	
DANTROLENE SODIUM 25MG	DANTRIUM (CAPSULE; ORAL)	NORWICH EATON/P&G	17-443 01-15-74	3415821 12-10-85	
DANTROLENE SODIUM 100MG	DANTRIUM (CAPSULE; ORAL)	NORWICH EATON/P&G	17-443 01-15-74	3415821 12-10-85	
DANTROLENE SODIUM 50MG	DANTRIUM (CAPSULE; ORAL)	NORWICH EATON/P&G	17-443 10-10-75	3415821 12-10-85	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DANTROLENE SODIUM 20MG/VIAL	DANTRIUM (INJECTABLE; INJECTION)	NORWICH EATON/P&G	18-264 09-18-79	3415821 12-10-85	
DEFEROXAMINE MESYLATE 500MG/VIAL	DESFERAL MESYLATE (INJECTABLE; INJECTION)	CIBA/CIBA-GEIGY	16-267 04-01-68	3471476 10-07-86	
DESIPRAMINE HYDROCHLORIDE 25MG	PERTOFRANE (CAPSULE; ORAL)	USV LABORATORIES	13-621 12-18-64	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 50MG	PERTOFRANE (CAPSULE; ORAL)	USV LABORATORIES	13-621 04-10-68	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 25MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 11-20-64	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 50MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 01-09-67	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 75MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 03-01-77	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 100MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 03-01-77	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 150MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 03-01-77	3454698 07-08-86 3454554 07-08-86	

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DESIPRAMINE HYDROCHLORIDE 10MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 02-11-82	3454698 07-08-86 3454554 07-08-86	NS 09-24-86
DESMOPRESSIN ACETATE 0.01%	DDAVP (SOLUTION; NASAL)	ARMOUR PHARM	17-922 02-21-78	3497491 02-24-87	
DESMOPRESSIN ACETATE 0.004MG/ML	DDAVP (INJECTABLE; INJECTION)	ARMOUR PHARM	18-938 03-30-84	3497491 02-24-87	NDF 09-24-86
DESONIDE 0.05%	DESOWEN (CREAM; TOPICAL)	OWEN LABS/DERM PRODS	19-048 12-14-84		
DESOXIMETASONE 0.05%	TOPICORT (GEL; TOPICAL)	HOECHST-ROUSSEL	18-586 03-29-82		NDF 09-24-86
DESOXIMETASONE 0.05%	TOPICORT (OINTMENT; TOPICAL)	HOECHST-ROUSSEL	18-594 01-17-85		NDF 09-24-86
DESOXIMETASONE 0.25%	TOPICORT (OINTMENT; TOPICAL)	HOECHST-ROUSSEL	18-763 09-30-83		NDF 09-24-86
DEXAMETHASONE 6MG	DECADRON (TABLET; ORAL)	MS&D/MERCK	11-664 07-30-82		NS 09-24-86
DEXAMETHASONE 6MG	DEXAMETHASONE (TABLET; ORAL)	PAR PHARMACEUTICAL	88-481 11-28-83		NS 09-24-86
DEXAMETHASONE 6MG	DEXAMETHASONE (TABLET; ORAL)	ROXANE LABORATORIES	88-316 09-15-83		NS 09-24-86
DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE 15MG/5ML; 6.25MG/5ML	PHENERGAN W/ DEXTROMETHORPHAN (SYRUP; ORAL)	WYETH LABS/AMHO	11-265 04-02-84		
DEXTROSE 60GM/100ML	DEXTROSE 60% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	17-521 03-26-82		
DEXTROSE 70GM/100ML	DEXTROSE 70% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	17-521 03-26-82		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE 60GM/100ML	DEXTROSE 60% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-346 01-25-85		
DEXTROSE 30GM/100ML	DEXTROSE 30% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-345 01-26-85		
DEXTROSE 60GM/100ML	DEXTROSE 60% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	17-995 04-27-78	3729568 04-24-90	
DEXTROSE 60GM/100ML	DEXTROSE 60% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	17-995 09-22-82	3729568 04-24-90	
DEXTROSE 70GM/100ML	DEXTROSE 70% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-561 03-23-82		
DEXTROSE 40GM/100ML	DEXTROSE 40% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-562 03-23-82		
DEXTROSE 50GM/100ML	DEXTROSE 50% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-563 03-23-82		
DEXTROSE 20GM/100ML	DEXTROSE 20% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-564 03-23-82		
DEXTROSE 38.5GM/100ML	DEXTROSE 38.5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-923 09-19-84		
DEXTROSE 50MG/ML	DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-222 07-13-84		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE; DOPAMINE HYDROCHLORIDE 5GM/100ML; 80MG/100ML	DOPAMINE HCL (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-132 02-04-82		NC 09-24-86
DEXTROSE; DOPAMINE HYDROCHLORIDE 5GM/100ML; 160MG/100ML	DOPAMINE HCL (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-132 02-04-82		NC 09-24-86
DEXTROSE; DOPAMINE HYDROCHLORIDE 5GM/100ML; 80MG/100ML	DOPAMINE HCL IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-826 09-30-83		NC 09-24-86
DEXTROSE; DOPAMINE HYDROCHLORIDE 5GM/100ML; 160MG/100ML	DOPAMINE HCL IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-826 09-30-83		NC 09-24-86
DEXTROSE; DOPAMINE HYDROCHLORIDE 5GM/100ML; 320MG/100ML	DOPAMINE HCL IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-826 09-30-83		NC 09-24-86
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 200 UNITS/100ML	HEPARIN SODIUM 1,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-130 12-31-83		NC 09-24-86
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 200 UNITS/100ML	HEPARIN SODIUM 2,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-130 12-31-83		NC 09-24-86
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 1,000 UNITS/100ML	HEPARIN SODIUM 5,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-130 12-31-83		NC 09-24-86
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 4,000 UNITS/100ML	HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-814 10-31-83		NC 09-24-86

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 5,000 UNITS/100ML	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 5,000 UNITS/100ML	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-339 03-27-85		
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 5,000 UNITS/100ML	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-339 03-27-85		
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 5,000 UNITS/100ML	HEPARIN SODIUM 25000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-134 03-29-85		
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 10,000 UNITS/100ML	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 10,000 UNITS/100ML	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-339 03-27-85		
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 10,000 UNITS/100ML	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 10,000 UNITS/100ML	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-339 03-27-85		
DEXTROSE; LIDOCAINE HYDROCHLORIDE 5GM/100ML; 800MG/100ML	LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-388 11-05-82		NS 09-24-86
DEXTROSE; LIDOCAINE HYDROCHLORIDE 5GM/100ML; 800MG/100ML	LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-461 02-22-82		NS 09-24-86
DEXTROSE; LIDOCAINE HYDROCHLORIDE 5GM/100ML; 200MG/100ML	LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-967 03-30-84		NS 09-24-86
DEXTROSE; LIDOCAINE HYDROCHLORIDE 5GM/100ML; 400MG/100ML	LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-967 03-30-84		NS 09-24-86
DEXTROSE; LIDOCAINE HYDROCHLORIDE 5GM/100ML; 800MG/100ML	LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-967 03-30-84		NS 09-24-86
DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE DIBASIC; SODIUM ACETATE 5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-025 12-27-84		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE; OXYTOCIN 5GM/100ML; 1 USP UNIT/100ML	OXYTOCIN 5 USP UNITS IN DEXTROSE 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-185 03-29-85		
DEXTROSE; OXYTOCIN 5GM/100ML; 1 USP UNIT/100ML	OXYTOCIN 10 USP UNITS IN DEXTROSE 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-185 03-29-85		
DEXTROSE; OXYTOCIN 5GM/100ML; 2 USP UNIT/100ML	OXYTOCIN 10 USP UNITS IN DEXTROSE 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-185 03-29-85		
DEXTROSE; OXYTOCIN 5GM/100ML; 2 USP UNIT/100ML	OXYTOCIN 20 USP UNITS IN DEXTROSE 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-185 03-29-85		
DEXTROSE; POTASSIUM CHLORIDE 5GM/100ML; 75MG/100ML	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-744 11-09-82		
DEXTROSE; POTASSIUM CHLORIDE 5GM/100ML; 150MG/100ML	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-744 11-09-82		
DEXTROSE; POTASSIUM CHLORIDE 5GM/100ML; 220MG/100ML	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-744 11-09-82		
DEXTROSE; POTASSIUM CHLORIDE 5GM/100ML; 300MG/100ML	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-744 11-09-82		
DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE 5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML	DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-840 06-29-83		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 900MG/100ML	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-308 04-05-85		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 75MG/100ML; 900MG/100ML	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-308 04-05-85		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 900MG/100ML	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-308 04-05-85		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 900MG/100ML	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-308 04-05-85		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 300MG/100ML; 900MG/100ML	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-308 04-05-85		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 900MG/100ML	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-308 04-05-85		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 300MG/100ML; 900MG/100ML	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-308 04-05-85		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 300MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 300MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 200MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-567 02-16-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 200MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-567 02-16-83		

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 200MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-567 02-16-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 200MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-567 02-16-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 75MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 75MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 300MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 300MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 40MG/100ML	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-211 12-14-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 40MG/100ML	THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-083 11-07-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 80MG/100ML	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-211 12-14-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 80MG/100ML	THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-083 11-07-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 160MG/100ML	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-211 12-14-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 160MG/100ML	THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-083 11-07-84		

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE; THEOPHYLLINE 5GM/100ML; 200MG/100ML	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-211 12-14-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 200MG/100ML	THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-212 11-07-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 400MG/100ML	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-211 12-14-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 400MG/100ML	THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-212 11-07-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 400MG/100ML	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-649 07-26-82		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 80MG/100ML	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-649 07-26-82		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 160MG/100ML	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-649 07-26-82		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 200MG/100ML	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-649 07-26-82		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 400MG/100ML	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-649 07-26-82		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DIATRIZOATE MEGLUMINE 30%	RENO-M-DIP (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	10-040 01-08-60		I-7; I-8 09-24-86
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM 52%; 8%	RENOGRAFIN-60 (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	10-040 08-29-74		I-8 09-24-86
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM 66%; 10%	RENOGRAFIN-76 (INJECTABLE; INJFCTION)	ER SQUIBB AND SONS	10-040 10-27-72		I-5 09-24-86
DIAZEPAM 2MG	VALIUM (TABLET; ORAL)	HOFFMANN-LA ROCHE	13-263 11-15-63	4316897 02-23-99	
DIAZEPAM 5MG	VALIUM (TABLET; ORAL)	HOFFMANN-LA ROCHE	13-263 11-15-63	4316897 02-23-99	
DIAZEPAM 10MG	VALIUM (TABLET; ORAL)	HOFFMANN-LA ROCHE	13-263 11-15-63	4316897 02-23-99	
DIAZEPAM 5MG/ML	VALIUM (INJECTABLE; INJECTION)	HOFFMANN-LA ROCHE	16-087 08-24-66	4316897 02-23-99	
DIAZEPAM 15MG	VALRELEASE (CAPSULE, CONTROLLED RELEASE; ORAL)	HOFFMANN-LA ROCHE	18-179 03-12-81	4316897 02-23-99	
DIAZOXIDE 15MG/ML	HYPERSTAT (INJECTABLE; INJECTION)	SCHERING	16-996 01-22-73		I-1 09-24-86
DICYCLOMINE HYDROCHLORIDE 10MG	BENTYL (CAPSULE; ORAL)	MERRELL DOW/DOW CHEM	07-409 10-15-84		
DICYCLOMINE HYDROCHLORIDE 20MG	BENTYL (CAPSULE; ORAL)	MERRELL DOW/DOW CHEM	07-409 10-15-84		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DICYCLOMINE HYDROCHLORIDE 10MG/ML	BENTYL (INJECTABLE; INJECTION)	MERRELL DOW/DOW CHEM	08-370 10-15-84		
DICYCLOMINE HYDROCHLORIDE 10MG/5ML	BENTYL (SYRUP; ORAL)	MERRELL DOW/DOW CHEM	07-961 10-15-84		
DIFLORASONE DIACETATE 0.05%	FLORONE (CREAM; TOPICAL)	UPJOHN	17-741 09-14-77	3980778 09-14-93	
DIFLORASONE DIACETATE 0.05%	FLORONE (OINTMENT; TOPICAL)	UPJOHN	17-994 03-01-78	3980778 09-14-93	
DIFLUNISAL 250MG	DOLOBID (TABLET; ORAL)	MS&D/MERCK	18-445 04-19-82	3714226 08-01-89 3674870 07-04-89	NCE 04-19-92
DIFLUNISAL 500MG	DOLOBID (TABLET; ORAL)	MS&D/MERCK	18-445 04-19-82	3714226 08-01-89 3674870 07-04-89	NCE 04-19-92
DIGOXIN 0.2MG	LANOXICAPS (CAPSULE; ORAL)	BURROUGHS WELLCOME	18-118 07-26-82	4088750 05-09-95	NDF 09-24-86
DIGOXIN 0.05MG	LANOXICAPS (CAPSULE; ORAL)	BURROUGHS WELLCOME	18-118 07-26-82	4088750 05-09-95	NDF 09-24-86
DIGOXIN 0.15MG	LANOXICAPS (CAPSULE; ORAL)	BURROUGHS WELLCOME	18-118 09-24-84	4088750 05-09-95	NS 09-24-86
DIGOXIN 0.1MG	LANOXICAPS (CAPSULE; ORAL)	BURROUGHS WELLCOME	18-118 07-26-82	4088750 05-09-95	NDF 09-24-86
DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE 0.5MG/0.5ML; 2500 UNITS/0.5ML; 5.33MG/0.5ML	EMBOLEX (INJECTABLE; INJECTION)	SANDOZ PHARMS/SANDOZ	18-885 11-30-84	4451458 05-29-01 4402949 09-06-00	NC 11-30-87

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE 0.5MG/0.7ML; 5000 UNITS/0.7ML; 7.46MG/0.7ML	EMBOLEX (INJECTABLE; INJECTION)	SANDOZ PHARMS/SANDOZ	18-885 11-30-84	4451458 05-29-01 4402949 09-06-00	NC 11-30-87
DILTIAZEM HYDROCHLORIDE 30MG	CARDIZEM (TABLET; ORAL)	MARION LABORATORIES	18-602 11-05-82	3562257 02-09-88	NCE 11-05-92
DILTIAZEM HYDROCHLORIDE 60MG	CARDIZEM (TABLET; ORAL)	MARION LABORATORIES	18-602 11-05-82	3562257 02-09-88	NCE 11-05-92
DIMETHYL SULFOXIDE 50%	RIMSO-50 (SOLUTION; URETHRAL)	RESEARCH INDUSTRIES	17-788 04-04-78	3549770 12-22-87	
DINOPROST TROMETHAMINE EQ 5MG BASE/ML	PROSTIN F2 ALPHA (INJECTABLE; INJECTION)	UPJOHN	17-434 11-26-73	3657327 04-18-87 3706789 12-19-89 3778506 12-11-90	
DINOPROSTONE 20MG	PROSTIN E2 (SUPPOSITORY; VAGINAL)	UPJOHN	17-810 08-23-77	3899587 08-12-92 3598858 08-10-88	
DIPIVEFRIN HYDROCHLORIDE 0.1%	PROPINE (SOLUTION; OPHTHALMIC)	ALLERGAN PHARMS	18-239 05-02-80	3839584 10-01-91 3809714 05-07-91	
DISOPYRAMIDE PHOSPHATE EQ 100MG BASE	NORPACE CR (CAPSULE, CONTROLLED RELEASE; ORAL)	SEARLE/SEARLE PHARMS	18-655 07-20-82		NDF 09-24-86
DISOPYRAMIDE PHOSPHATE EQ 150MG BASE	NORPACE CR (CAPSULE, CONTROLLED RELEASE; ORAL)	SEARLE/SEARLE PHARMS	18-655 07-20-82		NDF 09-24-86
DIVALPROEX SODIUM EQ 250MG BASE	DEPAKOTE (TABLET, ENTERIC COATED; ORAL)	ABBOTT LABORATORIES	18-723 03-10-83		NE 09-24-86

Generated for Shearrer, Cynthia D. (University of Missouri-Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DIVALPROEX SODIUM EQ 500MG BASE	DEPAKOTE (TABLET, ENTERIC COATED; ORAL)	ABBOTT LABORATORIES	18-723 03-10-83		NE 09-24-86
DOBUTAMINE HYDROCHLORIDE EQ 250MG BASE/VIAL	DOBUTREX (INJECTABLE; INJECTION)	ELI LILLY	17-820 07-18-78	3987200 10-19-93	
DOPAMINE HYDROCHLORIDE 80MG/ML	DOPAMINE HCL (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-132 07-09-82		
DOPAMINE HYDROCHLORIDE 80MG/ML	DOPAMINE (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-398 03-22-82		
DOPAMINE HYDROCHLORIDE 40MG/ML	DOPAMINE HCL (INJECTABLE; INJECTION)	BRISTOL LABS/B-M	18-549 03-11-83		
DOPAMINE HYDROCHLORIDE 40MG/ML	DOPAMINE (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	18-656 06-28-83		
DOXEPIN HYDROCHLORIDE EQ 25MG BASE	SINEQUAN (CAPSULE; ORAL)	PFIZER LABS/PFIZER	16-798 09-23-69	3420851 01-07-86	
DOXEPIN HYDROCHLORIDE EQ 50MG BASE	SINEQUAN (CAPSULE; ORAL)	PFIZER LABS/PFIZER	16-798 09-23-69	3420851 01-07-86	
DOXEPIN HYDROCHLORIDE EQ 10MG BASE	SINEQUAN (CAPSULE; ORAL)	PFIZER LABS/PFIZER	16-798 03-31-75	3420851 01-07-86	
DOXEPIN HYDROCHLORIDE EQ 100MG BASE	SINEQUAN (CAPSULE; ORAL)	PFIZER LABS/PFIZER	16-798 03-31-75	3420851 01-07-86	
DOXEPIN HYDROCHLORIDE EQ 75MG BASE	SINEQUAN (CAPSULE; ORAL)	PFIZER LABS/PFIZER	16-798 06-04-76	3420851 01-07-86	
DOXEPIN HYDROCHLORIDE EQ 150MG BASE	SINEQUAN (CAPSULE; ORAL)	PFIZER LABS/PFIZER	16-798 03-15-78	3420851 01-07-86	
DOXEPIN HYDROCHLORIDE EQ 10MG BASE	ADAPIN (CAPSULE; ORAL)	PENNWALT PHARM	16-987 01-31-72	3420851 01-07-86	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DOXEPIN HYDROCHLORIDE EQ 25MG BASE	ADAPIN (CAPSULE; ORAL)	PENNWALT PHARM	16-987 01-31-72	3420851 01-07-86	
DOXEPIN HYDROCHLORIDE EQ 50MG BASE	ADAPIN (CAPSULE; ORAL)	PENNWALT PHARM	16-987 01-31-72	3420851 01-07-86	
DOXEPIN HYDROCHLORIDE EQ 100MG BASE	ADAPIN (CAPSULE; ORAL)	PENNWALT PHARM	16-987 12-12-77	3420851 01-07-86	
DOXEPIN HYDROCHLORIDE EQ 75MG BASE	ADAPIN (CAPSULE; ORAL)	PENNWALT PHARM	16-987 04-15-80	3420851 01-07-86	
DOXEPIN HYDROCHLORIDE EQ 10MG BASE/ML	SINEQUAN (CONCENTRATE; ORAL)	PFIZER LABS/PFIZER	17-516 03-11-74	3420851 01-07-86	
DRONABINOL 2.5MG	MARINOL (CAPSULE; ORAL)	UNIMED	18-651 05-31-85		NCE 05-31-90
DRONABINOL 5MG	MARINOL (CAPSULE; ORAL)	UNIMED	18-651 05-31-85		NCE 05-31-90
DRONABINOL 10MG	MARINOL (CAPSULE; ORAL)	UNIMED	18-651 05-31-85		NCE 05-31-90
DRONABINOL 2.5MG	MARINOL (CAPSULE; ORAL)	UNIMED	18-651 05-31-85		
ECONAZOLE NITRATE 1%	SPECTAZOLE (CREAM; TOPICAL)	ORTHO PHARMACEUTICAL	18-751 12-23-82	3717655 02-20-90 3839574 10-01-91	NCE 12-23-92
ENFLURANE 99.9%	ETHRANE (LIQUID; INHALATION)	ANAQUEST/BOC	17-087 08-28-72	3469011 09-23-86 3527813 09-08-87	
EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE 0.005MG/ML; 0.5%	DURANEST (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	17-751 08-30-76	3862321 01-21-92 3812147 05-21-91	

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE 0.005MG/ML; 1%	DURANEST (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	17-751 08-30-76	3862321 01-21-92 3812147 05-21-91	
EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE 0.005MG/ML; 1.5%	DURANEST (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	17-751 08-30-76	3862321 01-21-92 3812147 05-21-91	
ERGOLOID MESYLATES 1MG	HYDERGINE LC (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	18-706 01-18-83	4366145 12-28-99	NDF 09-24-86
ERGOLOID MESYLATES 1MG	HYDERGINE (SOLUTION; ORAL)	SANDOZ PHARMS/SANDOZ	18-418 01-30-81	4138565 02-06-96	
ESTRADIOL 0.01%	ESTRACE (CREAM; VAGINAL)	MEAD JOHNSON/B-M	86-069 01-31-84	4436738 03-13-01	NDF 09-24-86
ESTROGENS, CONJUGATED 0.9MG	PREMARIN (TABLET; ORAL)	AYERST LABS/AMHO	04-782 01-26-84		NS 09-24-86
ETHINYL ESTRADIOL; LEVONORGESTREL 0.03MG; 0.15MG	NORDETTE-21 (TABLET; ORAL-21)	WYETH LABS/AMHO	18-668 05-10-82	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91	NC 09-24-86
ETHINYL ESTRADIOL; LEVONORGESTREL 0.03MG; 0.15MG	NORDETTE-28 (TABLET; ORAL-28)	WYETH LABS/AMHO	18-782 07-21-82	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91	NC 09-24-86
ETHINYL ESTRADIOL; LEVONORGESTREL 0.03MG; 0.05MG 0.04MG; 0.075MG 0.03MG; 0.125MG	TRIPHASIL-28 (TABLET; ORAL-28)	WYETH LABS/AMHO	19-190 11-01-84	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91 3957982 05-18-93	NS 11-01-87

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ETHINYL ESTRADIOL; LEVONORGESTREL 0.03MG; 0.05MG 0.04MG; 0.075MG 0.03MG; 0.125MG	TRIPHASIL-21 (TABLET; ORAL-21)	WYETH LABS/AMHO	19-192 11-01-84	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91 3957982 05-18-93	NS 11-01-87
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG	ORTHO-NOVUM 10/11-21 (TABLET; ORAL-21)	ORTHO PHARMACEUTICAL	18-354 01-11-82		D-5 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG	ORTHO-NOVUM 10/11-28 (TABLET; ORAL-28)	ORTHO PHARMACEUTICAL	18-354 01-11-82		D-5 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG	TRI-NORINYL 21-DAY (TABLET; ORAL-21)	SYNTEX (FP)	18-977 04-13-84	4390531 06-28-00	D-6 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG	TRI-NORINYL 28-DAY (TABLET; ORAL-28)	SYNTEX (FP)	18-977 04-13-84	4390531 06-28-00	D-6 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG, 0.75MG AND 1MG	ORTHO-NOVUM 7/7/7-21 (TABLET; ORAL-21)	ORTHO PHARMACEUTICAL	18-985 04-04-84		D-3 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG, 0.75MG AND 1MG	ORTHO-NOVUM 7/7/7-28 (TABLET; ORAL-28)	ORTHO PHARMACEUTICAL	18-985 04-04-84		D-3 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG	ORTHO-NOVUM 7/14-21 (TABLET; ORAL-21)	ORTHO PHARMACEUTICAL	19-004 04-04-84		D-4 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG	ORTHO-NOVUM 7/14-28 (TABLET; ORAL-28)	ORTHO PHARMACEUTICAL	19-004 04-04-84		D-4 09-24-86
ETHINYL ESTRADIOL; NORGESTREL 0.05MG; 0.5MG	OVRAL (TABLET; ORAL-21)	WYETH LABS/AMHO	16-672 04-16-68	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91	

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ETHINYL ESTRADIOL; NORGESTREL 0.05MG; 0.5MG	OVRAL-28 (TABLET; ORAL-28)	WYETH LABS/AMHO	16-806 11-26-68	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91	
ETHINYL ESTRADIOL; NORGESTREL 0.03MG; 0.3MG	LO/OVRAL (TABLET; ORAL-21)	WYETH LABS/AMHO	17-612 03-17-75	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91	
ETHINYL ESTRADIOL; NORGESTREL 0.03MG; 0.3MG	LO/OVRAL-28 (TABLET; ORAL-28)	WYETH LABS/AMHO	17-802 03-16-76	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91	
ETIDOCAINE HYDROCHLORIDE 0.5%	DURANEST (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	17-751 08-30-76	3862321 01-21-92 3812147 05-21-91	
ETIDOCAINE HYDROCHLORIDE 1%	DURANEST (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	17-751 08-30-76	3862321 01-21-92 3812147 05-21-91	
ETIDRONATE DISODIUM 200MG	DIDRONEL (TABLET; ORAL)	NORWICH EATON/P&G	17-831 09-01-77	4254114 03-03-98 4216211 08-05-97 4137309 01-30-96 3683080 08-08-89	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
ETIDRONATE DISODIUM 400MG	DIDRONEL (TABLET; ORAL)	NORWICH EATON/P&G	17-831 07-06-84	4254114 03-03-98 4216211 08-05-97 4137309 01-30-96 3683080 08-08-89	NS 09-24-86
ETOMIDATE 2MG/ML	AMIDATE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-227 09-07-82		NCE 09-07-92
ETOPOSIDE 20MG/ML	VEPESID (INJECTABLE; INJECTION)	BRISTOL LABS/B-M	18-768 11-10-83	3524844 08-18-87	NCE 11-10-93
FENFLURAMINE HYDROCHLORIDE 60MG	PONDIMIN (TABLET, CONTROLLED RELEASE; ORAL)	AH ROBINS	16-618 07-27-82		NDF 09-24-86
FENOPROFEN CALCIUM EQ 300MG BASE	NALFON (CAPSULE; ORAL)	DISTA PRODS/LILLY	17-604 03-16-76	3600437 08-17-88	
FENOPROFEN CALCIUM EQ 200MG BASE	NALFON 200 (CAPSULE; ORAL)	DISTA PRODS/LILLY	17-604 10-15-80	3600437 08-17-88	
FENOPROFEN CALCIUM EQ 600MG BASE	NALFON (TABLET; ORAL)	DISTA PRODS/LILLY	17-710 03-16-76	3600437 08-17-88	
FENTANYL CITRATE EQ 0.05MG BASE/ML	FENTANYL CITRATE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-115 01-12-85		
FENTANYL CITRATE EQ 0.05MG BASE/ML	FENTANYL (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	19-101 07-11-84		
FLUMETHASONE PIVALATE 0.03%	LOCORTEN (CREAM; TOPICAL)	CIBA/CIBA-GEIGY	16-379 09-16-69	3499016 03-03-87	
FLUNISOLIDE 0.025MG/INH	BRONALIDE (AEROSOL; INHALATION)	SYNTEX LABS/SYNTEX	18-340 08-17-84		NDF 09-24-86

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
FLUOCINONIDE 0.05%	LIDEX (SOLUTION; TOPICAL)	SYNTEX LABS/SYNTEX	18-849 04-06-84		NDF 09-24-86
FLUOCINONIDE 0.05%	LIDEX (CREAM; TOPICAL)	SYNTEX LABS/SYNTEX	16-908 06-30-71	3888995 07-13-88 3592930 07-13-88	
FLUOCINONIDE 0.05%	VASODERM (CREAM; TOPICAL)	K-LINE PHARMS	19-117 06-26-84		
FLUOCINONIDE 0.05%	LIDEX (OINTMENT; TOPICAL)	SYNTEX LABS/SYNTEX	16-909 09-22-71	4017615 04-12-94	
FLUPHENAZINE DECANOATE 25MG/ML	PROLIXIN DECANOATE (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	16-727 06-20-72	3394131 07-23-85	
FLUPHENAZINE ENANTHATE 25MG/ML	PROLIXIN ENANTHATE (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	16-110 03-15-67	3394131 07-23-85	
FLURANDRENOLIDE 0.004MG/SQ CM	CORDRAN (TAPE; TOPICAL)	DISTA PRODS/LILLY	16-455 07-29-69	3632740 01-04-89	
FLURAZEPAM HYDROCHLORIDE 15MG	DALMANE (CAPSULE; ORAL)	ROCHE PRODUCTS	16-721 04-07-70	4316897 02-23-99	
FLURAZEPAM HYDROCHLORIDE 30MG	DALMANE (CAPSULE; ORAL)	ROCHE PRODUCTS	16-721 04-07-70	4316897 02-23-99	
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	CHELSEA LABORATORIES	18-369 05-14-82		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	CHELSEA LABORATORIES	18-369 05-14-82		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	SUPERPHARM	18-370 02-10-83		
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	SUPERPHARM	18-370 06-26-84		
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	ZENITH LABORATORIES	18-413 11-30-83		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	ZENITH LABORATORIES	18-413 11-30-83		
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-415 07-27-82		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-415 07-27-82		
FUROSEMIDE 80MG	FUROSEMIDE (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-415 11-26-84		
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	PARKE-DAVIS/W-L	18-419 01-31-83		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	PARKE-DAVIS/W-L	18-419 01-31-83		
FUROSEMIDE 80MG	FUROSEMIDE (TABLET; ORAL)	PARKE-DAVIS/W-L	18-419 11-13-84		
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	PARKE-DAVIS/W-L	18-420 02-26-82		
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	LYPHOMED	18-507 07-30-82		
FUROSEMIDE 80MG	FUROSEMIDE (TABLET; ORAL)	CORD LABORATORIES	18-569 08-14-84		
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	NATCON	18-579 11-30-83		
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-667 05-28-82		
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	WYETH LABS/AMHO	18-670 07-20-82		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	DRUMMER/PHOENIX	18-750 07-30-84		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	INTL MEDICATION SYS	18-753 02-28-84		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	INTL MEDICATION SYS	18-753 02-28-84		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	BARR LABORATORIES	18-790 11-29-83		
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	ROXANE LABORATORIES	18-823 11-10-83		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	ROXANE LABORATORIES	18-823 11-10-83		
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	KALAPHARM	18-868 06-28-83		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	KALAPHARM	18-868 06-28-83		
FUROSEMIDE 20MG	LASIX (TABLET; ORAL)	HOECHST-ROUSSEL	16-273 05-07-74	4324779 04-13-99	
FUROSEMIDE 40MG	LASIX (TABLET; ORAL)	HOECHST-ROUSSEL	16-273 07-01-66	4324779 04-13-99	
FUROSEMIDE 80MG	LASIX (TABLET; ORAL)	HOECHST-ROUSSEL	16-273 04-24-78	4324779 04-13-99	
FUROSEMIDE 10MG/ML	LASIX (SOLUTION; ORAL)	HOECHST-ROUSSEL	17-688 03-08-77	4324779 04-13-99	
FUROSEMIDE 10MG/ML	LASIX (INJECTABLE; INJECTION)	HOECHST-ROUSSEL	16-363 03-20-68	4324779 04-13-99	
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	INVENEX LABS/LIFE	18-902 05-22-84		
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	INVENEX LABS/LIFE	19-036 08-13-84		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
GEMFIBROZIL 200MG	LOPID (CAPSULE; ORAL)	PARKE-DAVIS/W-L	18-422 12-21-81	3674836 07-04-89	
GEMFIBROZIL 300MG	LOPID (CAPSULE; ORAL)	PARKE-DAVIS/W-L	18-422 12-21-81	3674836 07-04-89	
GLIPIZIDE 5MG	GLUCOTROL (TABLET; ORAL)	ROERIG/PFIZER	17-783 05-08-84	3669966 04-21-92	NCE 05-08-94
GLIPIZIDE 10MG	GLUCOTROL (TABLET; ORAL)	ROERIG/PFIZER	17-783 05-08-84	3669966 04-21-92	NCE 05-08-94
GLYBURIDE 1.25MG	MICRONASE (TABLET; ORAL)	UPJOHN	17-498 05-01-84	3426067 04-21-92 3454635 04-21-92 3507954 04-21-92 3507961 04-21-92	NCE 05-01-94
GLYBURIDE 2.5MG	MICRONASE (TABLET; ORAL)	UPJOHN	17-498 05-01-84	3426067 04-21-92 3454635 04-21-92 3507954 04-21-92 3507961 04-21-92	NCE 05-01-94
GLYBURIDE 5MG	MICRONASE (TABLET; ORAL)	UPJOHN	17-498 05-01-84	3426067 04-21-92 3454635 04-21-92 3507954 04-21-92 3507961 04-21-92	NCE 05-01-94

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
GLYBURIDE 1.25MG	DIABETA (TABLET; ORAL)	HOECHST-ROUSSEL	17-532 05-01-84	3426067 04-21-92 3454635 04-21-92 3507961 04-21-92 3507954 04-21-92 4060634 09-07-93	NCE 05-01-94
GLYBURIDE 2.5MG	DIABETA (TABLET; ORAL)	HOECHST-ROUSSEL	17-532 05-01-84	3426067 04-21-92 3454635 04-21-92 3507961 04-21-92 3507954 04-21-92 4060634 09-07-93	NCE 05-01-94
GLYBURIDE 5MG	DIABETA (TABLET; ORAL)	HOECHST-ROUSSEL	17-532 05-01-84	3426067 04-21-92 3454635 04-21-92 3507961 04-21-92 3507954 04-21-92 4060634 09-07-93	NCE 05-01-94
GONADORELIN HYDROCHLORIDE EQ 0.1MG BASE/VIAL	FACTREL (INJECTABLE; INJECTION)	AYERST LABS/AMHO	18-123 09-30-82	3947569 03-30-93 4110438 08-29-95	NCE 09-30-92

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
GONADORELIN HYDROCHLORIDE EQ 0.2MG BASE/VIAL	FACTREL (INJECTABLE; INJECTION)	AYERST LABS/AMHO	18-123 09-30-82	3947569 03-30-93 4110438 08-29-95	NCE 09-30-92
GONADORELIN HYDROCHLORIDE EQ 0.5MG BASE/VIAL	FACTREL (INJECTABLE; INJECTION)	AYERST LABS/AMHO	18-123 09-30-82	3947569 03-30-93 4110438 08-29-95	NCE 09-30-92
GONADOTROPIN, CHORIONIC 2,000 UNITS/VIAL	CHORIONIC GONADOTROPIN (INJECTABLE; INJECTION)	CARTER-GLOGAU LABS	17-016 12-27-84		
GONADOTROPIN, CHORIONIC 15,000 UNITS/VIAL	CHORIONIC GONADOTROPIN (INJECTABLE; INJECTION)	CARTER-GLOGAU LABS	17-016 02-15-84		
GUANABENZ ACETATE EQ 4MG BASE	WYTENSIN (TABLET; ORAL)	WYETH LABS/AMHO	18-587 09-07-82	3658993 04-25-89	NCE 09-07-92
GUANABENZ ACETATE EQ 8MG BASE	WYTENSIN (TABLET; ORAL)	WYETH LABS/AMHO	18-587 09-07-82	3658993 04-25-89	NCE 09-07-92
GUANADREL SULFATE 10MG	HYLOREL (TABLET; ORAL)	UPJOHN	18-104 12-29-82	3547951 12-15-87	NCE 12-29-92
GUANADREL SULFATE 25MG	HYLOREL (TABLET; ORAL)	UPJOHN	18-104 12-29-82	3547951 12-15-87	NCE 12-29-92
HALAZEPAM 20MG	PAXIPAM (TABLET; ORAL)	SCHERING	17-736 09-24-81	3429874 02-25-86	
HALAZEPAM 40MG	PAXIPAM (TABLET; ORAL)	SCHERING	17-736 09-24-81	3429874 02-25-86	

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
HALOPERIDOL 0.5MG	HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 04-12-67	3438991 04-15-86	
HALOPERIDOL 1MG	HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 04-12-67	3438991 04-15-86	
HALOPERIDOL 2MG	HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 04-12-67	3438991 04-15-86	
HALOPERIDOL 5MG	HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 04-16-74	3438991 04-15-86	
HALOPERIDOL 10MG	HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 04-16-74	3438991 04-15-86	
HALOPERIDOL 20MG	HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 02-02-82	3438991 04-15-86	NS 09-24-86
HALOPERIDOL LACTATE EQ 2MG BASE/ML	HALDOL (CONCENTRATE; ORAL)	MCNEIL LABORATORIES	15-922 04-12-67	3438991 04-15-86	
HALOPERIDOL LACTATE EQ 5MG BASE/ML	HALDOL (INJECTABLE; INJECTION)	MCNEIL LABORATORIES	15-923 05-18-71	3438991 04-15-86	
HEPARIN SODIUM 10 UNITS/ML	HEPARIN LOCK FLUSH (INJECTABLE; INJECTION)	INVENEX LABS/LIFE	17-029 05-06-82		
HEPARIN SODIUM; SODIUM CHLORIDE 100 UNITS/ML; 4.5MG/ML	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
HEPARIN SODIUM; SODIUM CHLORIDE 100 UNITS/ML; 4.5MG/ML	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 450MG/100ML	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 450MG/100ML	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 10,000 UNITS/100ML; 450MG/100ML	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
HEPARIN SODIUM; SODIUM CHLORIDE 10,000 UNITS/100ML; 450MG/100ML	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 10,000 UNITS/100ML; 450MG/100ML	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 200 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 1000 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-042 03-29-85		
HEPARIN SODIUM; SODIUM CHLORIDE 200 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 1000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-609 04-28-82		
HEPARIN SODIUM; SODIUM CHLORIDE 200 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 2000 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-042 03-29-85		
HEPARIN SODIUM; SODIUM CHLORIDE 200 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 2000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-609 04-28-82		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
HEPARIN SODIUM; SODIUM CHLORIDE 500 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 5000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-609 04-28-82		
HEPARIN SODIUM; SODIUM CHLORIDE 1,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 1,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-042 03-29-85		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-135 03-29-85		
HEPARIN SODIUM; SODIUM CHLORIDE 10,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 10,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEXACHLOROPHENE 3%	TURGEX (SOLUTION; TOPICAL)	XTTRIUM LABS	19-055 11-30-84		
HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE 25MG; 50MG	LOPRESSOR HCT 50/25 (TABLET; ORAL)	GEIGY/CIBA-GEIGY	18-303 12-31-84	3876802 04-08-92 3998790 12-21-93	NC 12-31-87
HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE 25MG; 100MG	LOPRESSOR HCT 100/25 (TABLET; ORAL)	GEIGY/CIBA-GEIGY	18-303 12-31-84	3876802 04-08-92 3998790 12-21-93	NC 12-31-87
HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE 50MG; 100MG	LOPRESSOR HCT 100/50 (TABLET; ORAL)	GEIGY/CIBA-GEIGY	18-303 12-31-84	3876802 04-08-92 3998790 12-21-93	NC 12-31-87
HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE 25MG; 10MG	TIMOLIDE (TABLET; ORAL)	MS&D/MERCK	18-061 12-11-81	3655663 04-11-89 4238485 12-09-97	
HYDROCHLOROTHIAZIDE; TRIAMTERENE 50MG; 75MG	MAXZIDE (TABLET; ORAL)	MYLAN PHARMS	19-129 10-22-84	4444769 04-24-01	NS 10-22-87
HYDROCORTISONE ACETATE 10%	CORTIFOAM (AEROSOL; RECTAL)	REED&CARNRICK PHARMS	17-351 02-10-82		NDF 09-24-86
HYDROCORTISONE BUTYRATE 0.1%	LOCOID (CREAM; TOPICAL)	OWEN LABS/DERM PRODS	18-795 01-07-83		NP 09-24-86
HYDROCORTISONE BUTYRATE 0.1%	LOCOID (OINTMENT; TOPICAL)	OWEN LABS/DERM PRODS	19-106 07-03-84		NP 09-24-86
HYDROCORTISONE VALERATE 0.2%	WESTCORT (OINTMENT; TOPICAL)	WESTWOOD PHARMS	18-726 08-08-83		NDF 09-24-86

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
HYDROMORPHONE HYDROCHLORIDE 10MG/ML	DILAUDID-HP (INJECTABLE; INJECTION)	KNOLL PHARMACEUTICAL	19-034 01-11-84		NCE 01-11-94
HYDROXYUREA 500MG	HYDREA (CAPSULE; ORAL)	ER SQUIBB AND SONS	16-295 12-07-67	3968249 07-06-93	
IBUPROFEN 400MG	MOTRIN (TABLET; ORAL)	UPJOHN MANUFACTURING	17-463 09-19-74		I-2 09-24-86
IBUPROFEN 300MG	MOTRIN (TABLET; ORAL)	UPJOHN MANUFACTURING	17-463 09-19-74		I-2 09-24-86
IBUPROFEN 600MG	MOTRIN (TABLET; ORAL)	UPJOHN MANUFACTURING	17-463 03-09-79		I-2 09-24-86
IBUPROFEN 400MG	RUFEN (TABLET; ORAL)	BOOTS PHARMACEUTICAL	18-197 05-19-81		I-2 09-24-86
IBUPROFEN 600MG	RUFEN (TABLET; ORAL)	BOOTS PHARMACEUTICAL	18-197 03-05-84		I-2 09-24-86
INDAPAMIDE 2.5MG	LOZOL (TABLET; ORAL)	USV PHARMACEUTICAL	18-538 07-06-83	3565911 02-23-88	NCE 07-06-93
INDOMETHACIN 50MG	INDOCIN (SUPPOSITORY; RECTAL)	MS&D RES LABS/MERCK	17-814 08-13-84	3644630 02-22-89 3849549 11-19-91	NDF 09-24-86
INDOMETHACIN 75MG	INDOCIN SR (CAPSULE, CONTROLLED RELEASE; ORAL)	MS&D RES LABS/MERCK	18-185 02-23-82	4173626 11-06-96	NDF 09-24-86
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	CHELSEA LABORATORIES	18-690 07-31-84		
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	CHELSEA LABORATORIES	18-690 07-31-84		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	ZENITH LABORATORIES	18-730 05-04-84		
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	ZENITH LABORATORIES	18-730 05-04-84		
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	PAR PHARMACEUTICAL	18-829 08-06-84		
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	PAR PHARMACEUTICAL	18-829 08-06-84		
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	18-851 05-18-84		
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	18-851 05-18-84		
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	MYLAN PHARMS	18-858 04-20-84		
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	MYLAN PHARMS	18-858 04-20-84		
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	PARKE-DAVIS/W-L	18-806 11-23-84		
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	PARKE-DAVIS/W-L	18-806 11-23-84		
INDOMETHACIN SODIUM TRIHYDRATE EQ 1MG BASE/VIAL	INDOCIN I. V. (INJECTABLE; INJECTION)	MS&D/MERCK	18-878 01-30-85		
IODAMIDE MEGLUMINE 24%	RENOVUE-DIP (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-903 07-10-78		I-6 09-24-86
IODAMIDE MEGLUMINE 65%	RENOVUE-65 (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-902 07-24-78		I-6 09-24-86
IODOHIPPURATE SODIUM, I-123 1MCI/ML	NEPHROFLOW (INJECTABLE; INJECTION)	MEDI-PHYSICS	18-289 12-28-84		NCE 12-28-89

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
IODOXAMATE MEGLUMINE 9.9%	CHOLOVUE (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	18-076 08-14-81	3654272 04-04-89	
IODOXAMATE MEGLUMINE 40.3%	CHOLOVUE (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	18-077 08-14-81	3654272 04-04-89	
ISOFLURANE 99.9%	FORANE (GAS; INHALATION)	ANAQUEST/BOC	17-624 12-18-79	3535425 01-24-93 3535388 01-24-93	
ISOTRETINOIN 10MG	ACCUTANE (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	18-662 05-07-82	4200647 04-29-97 4322438 03-30-99 4464394 08-07-01	NCE 05-07-92
ISOTRETINOIN 20MG	ACCUTANE (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	18-662 03-28-83	4200647 04-29-97 4322438 03-30-99 4464394 08-07-01	NCE 05-07-92
ISOTRETINOIN 40MG	ACCUTANE (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	18-662 05-07-82	4200647 04-29-97 4322438 03-30-99 4464394 08-07-01	NCE 05-07-92
KETOCONAZOLE 200MG	NIZORAL (TABLET; ORAL)	JANSSEN PHARMA	18-533 06-12-81	4335125 06-15-99	I-25 09-24-86
LABETALOL HYDROCHLORIDE 200MG	NORMODYNE (TABLET; ORAL)	SCHERING	18-687 08-01-84	4012444 03-15-94 4066755 01-03-95	NCE 08-01-94

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
LABETALOL HYDROCHLORIDE 300MG	NORMODYNE (TABLET; ORAL)	SCHERING	18-687 08-01-84	4012444 03-15-94 4066755 01-03-95	NCE 08-01-94
LABETALOL HYDROCHLORIDE 400MG	NORMODYNE (TABLET; ORAL)	SCHERING	18-687 08-01-84	4012444 03-15-94 4066755 01-03-95	NCE 08-01-94
LABETALOL HYDROCHLORIDE 5MG/ML	NORMODYNE (INJECTABLE; INJECTION)	SCHERING	18-686 08-01-84	4012444 03-15-94 4066755 01-03-95 4328213 05-04-99	NCE 08-01-94
LABETALOL HYDROCHLORIDE 100MG	TRANDATE (TABLET; ORAL)	GLAXO	18-716 05-24-85	4012444 03-15-94 4066755 01-03-95	NCE 08-01-94
LABETALOL HYDROCHLORIDE 200MG	TRANDATE (TABLET; ORAL)	GLAXO	18-716 08-01-84	4012444 03-15-94 4066755 01-03-95	NCE 08-01-94
LABETALOL HYDROCHLORIDE 300MG	TRANDATE (TABLET; ORAL)	GLAXO	18-716 08-01-84	4012444 03-15-94 4066755 01-03-95	NCE 08-01-94
LABETALOL HYDROCHLORIDE 400MG	TRANDATE (TABLET; ORAL)	GLAXO	18-716 08-01-84	4012444 03-15-94 4066755 01-03-95	NCE 08-01-94

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
LACTULOSE 10GM/15ML	CEPHULAC (SYRUP; ORAL)	MERRELL DOW/DOW CHEM	17-657 03-25-76	3461204 08-12-86 3867524 02-18-92 3860708 01-14-92 3860707 01-14-92 3562388 02-09-88 3558774 01-26-88	
LEUCOVORIN CALCIUM EQ 5MG BASE	WELLCOVORIN (TABLET; ORAL)	BURROUGHS WELLCOME	18-342 07-08-83		NDF 09-24-86
LEUCOVORIN CALCIUM EQ 25MG BASE	WELLCOVORIN (TABLET; ORAL)	BURROUGHS WELLCOME	18-342 07-08-83		NDF 09-24-86
LEUPROLIDE ACETATE 1MG/0.2ML	LUPRON (INJECTABLE; INJECTION)	TAP PHARMACEUTICALS	19-010 04-09-85		NCE 04-09-90
LITHIUM CARBONATE 450MG	ESKALITH CR (TABLET, CONTROLLED RELEASE; ORAL)	SK&F LABORATORIES	18-152 03-29-82		NS 09-24-86
LITHIUM CARBONATE 300MG	LITHIUM CARBONATE (TABLET; ORAL)	ROXANE LABORATORIES	18-558 01-29-82		
LITHIUM CARBONATE 300MG	LITHOBID (TABLET; CONTROLLED RELEASE; ORAL)	CIBA/CIBA-GEIGY	18-027 04-27-79	4264573 04-28-98	
LOPERAMIDE HYDROCHLORIDE 2MG	IMODIUM (CAPSULE; ORAL)	JANSSEN PHARMA	17-694 12-28-76	3714159 01-30-90	I-30 09-24-86

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
LOPERAMIDE HYDROCHLORIDE 1MG/5ML	IMODIUM (SOLUTION; ORAL)	JANSSEN PHARMA	19-037 07-31-84	3714159 01-30-90	NDF 09-24-86
LORAZEPAM 2MG/ML	ATIVAN (INJECTABLE; INJECTION)	WYETH LABS/AMHO	18-140 07-25-80	4017616 04-12-94	
LORAZEPAM 4MG/ML	ATIVAN (INJECTABLE; INJECTION)	WYETH LABS/AMHO	18-140 07-25-80	4017616 04-12-94	
LOXAPINE HYDROCHLORIDE EQ 50MG BASE/ML	LOXITANE (INJECTABLE; INJECTION)	LEDERLE LABS/AM CYAN	18-039 10-26-79	3546226 12-08-87	
LOXAPINE HYDROCHLORIDE EQ 25MG BASE/ML	LOXITANE (CONCENTRATE; ORAL)	LEDERLE LABS/AM CYAN	17-658 05-04-76	3546226 12-08-87 4049809 09-20-94	
LOXAPINE SUCCINATE EQ 5MG BASE	LOXITANE (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	17-525 10-25-77	3546226 12-08-87	
LOXAPINE SUCCINATE EQ 10MG BASE	LOXITANE (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	17-525 02-25-75	3546226 12-08-87	
LOXAPINE SUCCINATE EQ 25MG BASE	LOXITANE (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	17-525 02-25-75	3546226 12-08-87	
LOXAPINE SUCCINATE EQ 50MG BASE	LOXITANE (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	17-525 02-25-75	3546226 12-08-87	
MAFENIDE ACETATE EQ 85MG BASE/GM	SULFAMYLON (CREAM; TOPICAL)	WINTHROP LABS/STERL	16-763 01-24-69	3497599 01-26-88	
MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE 32MG/100ML; 128MG/100ML; 234MG/100ML	PLASMA-LYTE 56 IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-047 06-15-84		NC 09-24-86
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE 30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML	ISOLYTES PH 7.4 IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-006 04-04-84		NC 09-24-86

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	PHYSIOSOL IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	ABBOTT LABORATORIES	17-637 07-08-82		NC 09-24-86
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	PHYSIOSOL IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	ABBOTT LABORATORIES	18-406 07-08-82		NC 09-24-86
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	PHYSIOLYTE IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	AM MCGAW/AM HOSP	19-024 06-08-84		NC 09-24-86
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	SYNOVALYTE IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	19-326 01-25-85		
MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE 20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML	TIS-U-SOL (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-508 02-19-82		NC 09-24-86
MALATHION 0.5%	PRIODERM (LOTION; TOPICAL)	PURDUE FREDERICK	18-613 08-02-82		NCE 08-02-92
MAPROTILINE HYDROCHLORIDE 25MG	LUDIOMIL (TABLET; ORAL)	CIBA/CIBA-GEIGY	17-543 12-01-80	3399201 08-27-85	
MAPROTILINE HYDROCHLORIDE 50MG	LUDIOMIL (TABLET; ORAL)	CIBA/CIBA-GEIGY	17-543 12-01-80	3399201 08-27-85	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
MAPROTILINE HYDROCHLORIDE 75MG	LUDIOMIL (TABLET; ORAL)	CIBA/CIBA-GEIGY	17-543 09-30-82	3399201 08-27-85	NS 09-24-86
MAZINDOL 1MG	SANOREX (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	17-247 06-14-73	3763178 10-02-90	
MAZINDOL 2MG	SANOREX (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	17-247 06-14-73	3763178 10-02-90	
MAZINDOL 2MG	MAZANOR (TABLET; ORAL)	WYETH LABS/AMHO	17-980 08-28-80	3763178 10-02-90	
MAZINDOL 1MG	MAZANOR (TABLET; ORAL)	WYETH LABS/AMHO	17-980 02-11-81	3763178 10-02-90	
MEBENDAZOLE 100MG	VERMOX (TABLET, CHEWABLE; ORAL)	JANSSEN PHARMA	17-481 06-28-74	3657267 04-18-89	
MEDROXYPROGESTERONE ACETATE 100MG/ML	DEPO-PROVERA (INJECTABLE; INJECTION)	UPJOHN	12-541 01-16-76	4038389 07-26-94	
MEDROXYPROGESTERONE ACETATE 400MG/ML	DEPO-PROVERA (INJECTABLE; INJECTION)	UPJOHN	12-541 01-16-76	4038389 07-26-94	
MEGLUMINE; METRIZOIC ACID 140.1MG/ML; 461.8MG/ML	ISOPAQUE-280 (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	17-506 04-30-74	3476802 11-04-86	
METAPROTERENOL SULFATE 20MG	ALUPENT (TABLET; ORAL)	BOEHRINGER INGELHEIM	15-874 05-13-74	3422196 01-14-86	
METAPROTERENOL SULFATE 10MG	ALUPENT (TABLET; ORAL)	BOEHRINGER INGELHEIM	15-874 08-08-77	3422196 01-14-86	
METAPROTERENOL SULFATE 0.65MG/INH	ALUPENT (AEROSOL; INHALATION)	BOEHRINGER INGELHEIM	16-402 07-31-73	3422196 01-14-86	
METAPROTERENOL SULFATE 10MG/5ML	ALUPENT (SYRUP; ORAL)	BOEHRINGER INGELHEIM	17-571 05-23-75	3422196 01-14-86	
METAPROTERENOL SULFATE 5%	ALUPENT (SOLUTION; INHALATION)	BOEHRINGER INGELHEIM	17-659 09-18-80	3422196 01-14-86	

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
METAPROTERENOL SULFATE 0.6%	ALUPENT (SOLUTION; INHALATION)	BOEHRINGER INGELHEIM	18-761 06-30-83	3422196 01-14-86	
METHYLDOPA 250MG	METHYLDOPA (TABLET; ORAL)	CORD LABORATORIES	18-934 06-29-84		
METHYLDOPA 500MG	METHYLDOPA (TABLET; ORAL)	CORD LABORATORIES	18-934 06-29-84		
METHYLDOPA 250MG/5ML	ALDOMET (SUSPENSION; ORAL)	MS&D/MERCK	18-389 08-28-81	4404193 09-13-00	
METHYLPHENIDATE HYDROCHLORIDE 20MG	RITALIN-SR (TABLET, CONTROLLED RELEASE; ORAL)	CIBA/CIBA-GEIGY	18-029 03-30-82		NDF 09-24-86
METOCLOPRAMIDE EQ 5MG BASE/5ML	REGLAN (SYRUP; ORAL)	AH ROBINS	18-821 3-25-83		NDF 09-24-86
METOCLOPRAMIDE HYDROCHLORIDE EQ 5MG BASE/ML	REGLAN (INJECTABLE; INJECTION)	AH ROBINS	17-862 02-07-79		I-12; I-13; I-14 09-24-86
METOCLOPRAMIDE HYDROCHLORIDE EQ 10MG BASE	REGLAN (TABLET; ORAL)	AH ROBINS	17-854 12-30-80		I-4 09-24-86
METOPROLOL TARTRATE 50MG	LOPRESSOR (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-963 08-07-78	3876802 04-08-92 3998790 12-21-93	
METOPROLOL TARTRATE 100MG	LOPRESSOR (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-963 08-07-78	3876802 04-08-92 3998790 12-21-93	
METOPROLOL TARTRATE 1MG/ML	LOPRESSOR (INJECTABLE; INJECTION)	GEIGY/CIBA-GEIGY	18-704 03-30-84	3876802 04-08-92 3998790 12-21-93	NDF 09-24-86

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
METRIZAMIDE 3.75GM/VIAL	AMIPAQUE (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	17-982 08-23-78	3701771 10-31-89	I-26 09-24-86
METRIZAMIDE 6.75GM/VIAL	AMIPAQUE (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	17-982 08-23-78	3701771 10-31-89	I-26 09-24-86
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	ZENITH LABORATORIES	18-517 05-05-82		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	CHELSEA LABORATORIES	18-599 09-17-82		
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	CHELSEA LABORATORIES	18-599 02-13-84		
METRONIDAZOLE 250MG	METRYL (TABLET; ORAL)	DRUMMER/PHOENIX	18-620 03-04-82		
METRONIDAZOLE 500MG	METRYL 500 (TABLET; ORAL)	DRUMMER/PHOENIX	18-620 06-02-83		
METRONIDAZOLE 500MG/100ML	METRO I.V. (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-674 08-31-82		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	CORD LABORATORIES	18-740 10-22-82		
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	CORD LABORATORIES	18-740 10-22-82		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	DANBURY PHARMACAL	18-764 09-17-82		
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	DANBURY PHARMACAL	18-764 12-20-82		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	BARR LABORATORIES	18-818 02-16-83		

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	BARR LABORATORIES	18-818 02-16-83		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	PAR PHARMACEUTICAL	18-845 08-18-83		
METRONIDAZOLE 250MG	PROTOSTAT (TABLET; ORAL)	ORTHO PHARMACEUTICAL	18-871 03-02-83		
METRONIDAZOLE 500MG	PROTOSTAT (TABLET; ORAL)	ORTHO PHARMACEUTICAL	18-871 03-02-83		
METRONIDAZOLE 500MG/100ML	METRONIDAZOLE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-889 11-18-83		
METRONIDAZOLE 500MG/100ML	METRONIDAZOLE IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-890 11-18-83		
METRONIDAZOLE 500MG/100ML	METRO I.V. IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-900 09-29-83		
METRONIDAZOLE 500MG/100ML	METRONIDAZOLE (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-907 03-30-84		
METRONIDAZOLE 500MG/100ML	FLAGYL I.V. RTU (INJECTABLE; INJECTION)	SEARLE PHARMS	18-353 05-29-81		I-11 12-20-87
METRONIDAZOLE 500MG/100ML	FLAGYL I.V. RTU IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	SEARLE PHARMS	18-657 12-24-81		I-11 12-20-87
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	PAR PHARMACEUTICAL	18-930 08-18-83		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	LNK INTERNATIONAL	19-029 04-10-84		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
METRONIDAZOLE HYDROCHLORIDE EQ 500MG BASE/VIAL	FLAGYL I.V. (INJECTABLE; INJECTION)	SEARLE PHARMS	18-353 11-28-80		I-11 12-20-87
MICONAZOLE 10MG/ML	MONISTAT (INJECTABLE; INJECTION)	JANSSEN PHARMA	18-040 10-04-78	3717655 02-20-90 3839574 10-01-91	I-27 09-24-86
MICONAZOLE NITRATE 2%	MONISTAT 7 (CREAM; VAGINAL)	ORTHO PHARMACEUTICAL	17-450 01-30-74	3717655 02-20-90 3839574 10-01-91	
MICONAZOLE NITRATE 2%	MONISTAT-DERM (CREAM; TOPICAL)	ORTHO PHARMACEUTICAL	17-494 01-30-74	3717655 02-20-90 3839574 10-01-91	
MICONAZOLE NITRATE 2%	MONISTAT-DERM (LOTION; TOPICAL)	ORTHO PHARMACEUTICAL	17-739 12-16-75	3717655 02-20-90 3839574 10-01-91	
MICONAZOLE NITRATE 100MG	MONISTAT 7 (SUPPOSITORY; VAGINAL)	ORTHO PHARMACEUTICAL	18-520 03-15-82	3717655 02-20-90 3839574 10-01-91	NDF 9-24-86
MICONAZOLE NITRATE 200MG	MONISTAT 3 (SUPPOSITORY; VAGINAL)	ORTHO PHARMACEUTICAL	18-888 08-15-84	3717655 02-20-90 3839574 10-01-91	NS 09-24-86
MINOXIDIL 2.5MG	LONITEN (TABLET; ORAL)	UPJOHN	18-154 10-18-79	3461461 08-12-86	

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
MINOXIDIL 10MG	LONITEN (TABLET; ORAL)	UPJOHN	18-154 10-18-79	3461461 08-12-86	
MOLINDONE HYDROCHLORIDE 5MG	MOBAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	17-111 07-03-74	3491093 01-20-87	
MOLINDONE HYDROCHLORIDE 10MG	MOBAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	17-111 07-03-74	3491093 01-20-87	
MOLINDONE HYDROCHLORIDE 25MG	MOBAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	17-111 07-03-74	3491093 01-20-87	
MOLINDONE HYDROCHLORIDE 50MG	MOBAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	17-111 01-05-81	3491093 01-20-87	
MOLINDONE HYDROCHLORIDE 100MG	MOBAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	17-111 01-05-81	3491093 01-20-87	
MOLINDONE HYDROCHLORIDE 20MG/ML	MOBAN (CONCENTRATE; ORAL)	DUPONT PHARMS/DUPONT	17-938 12-28-79	3491093 01-20-87	
MORPHINE SULFATE 0.5MG/ML	DURAMORPH PF (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-565 09-18-84		NR; D-8 09-24-86
MORPHINE SULFATE 1MG/ML	DURAMORPH PF (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-565 09-18-84		NR; D-8 09-24-86
NADOLOL 40MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-063 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 80MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-063 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 120MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-063 12-10-79	3982021 09-21-93 3935267 01-27-93	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
NADOLOL 160MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-063 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 40MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-064 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 80MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-064 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 120MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-064 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 160MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-064 12-10-79	3982021 09-21-93 3935267 01-27-93	
NALBUPHINE HYDROCHLORIDE 10MG/ML	NUBAIN (INJECTABLE; INJECTION)	DUPONT PHARMS/DUPONT	18-024 05-15-79	3393197 07-16-85	
NALBUPHINE HYDROCHLORIDE 20MG/ML	NUBAIN (INJECTABLE; INJECTION)	DUPONT PHARMS/DUPONT	18-024 05-27-82		NS 09-24-86
NALIDIXIC ACID 250MG	NEGGRAM (TABLET; ORAL)	WINTHROP LABS/STERL	14-214 12-27-67	3590036 06-29-88	
NALIDIXIC ACID 500MG	NEGGRAM (TABLET; ORAL)	WINTHROP LABS/STERL	14-214 03-06-64	3590036 06-29-88	
NALIDIXIC ACID 1GM	NEGGRAM (TABLET; ORAL)	WINTHROP LABS/STERL	14-214 03-06-64	3590036 06-29-88	

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
NALIDIXIC ACID 250MG/5ML	NEGGRAM (SUSPENSION; ORAL)	WINTHROP LABS/STERL	17-430 04-17-73	3590036 06-29-88	
NALOXONE HYDROCHLORIDE 0.4MG/ML	NARCAN (INJECTABLE; INJECTION)	DUPONT PHARMS/DUPONT	16-636 04-13-71		NS, D-9, D-10, D-11, I-33 09-24-86
NALOXONE HYDROCHLORIDE 1MG/ML	NARCAN (INJECTABLE; INJECTION)	DUPONT PHARMS/DUPONT	16-636 06-14-82		NS, D-9, D-10, D-11 I-33 09-24-86
NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE 0.5MG; EQ 50MG BASE	TALWIN NX (TABLET; ORAL)	WINTHROP LABS/STERL	18-733 12-16-82	4105659 08-08-95	NC 09-24-86
NALTREXONE HYDROCHLORIDE 50MG	TREXAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	18-932 11-20-84		NCE 11-20-89
NAPROXEN 125MG	NAPROSYN (TABLET; ORAL)	SYNTEX PR	17-581 03-11-76	3904682 09-09-92 3998966 12-21-93 4001301 09-09-92 4009197 09-09-92	NS 09-24-86
NAPROXEN 250MG	NAPROSYN (TABLET; ORAL)	SYNTEX PR	17-581 03-11-76	3904682 09-09-92 3998966 12-21-93 4001301 09-09-92 4009197 09-09-92	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
NAPROXEN 375MG	NAPROSYN (TABLET; ORAL)	SYNTEX PR	17-581 07-18-80	3904682 09-09-92 3998966 12-21-93 4001301 09-09-92 4009197 09-09-92	
NAPROXEN 500MG	NAPROSYN (TABLET; ORAL)	SYNTEX PR	17-581 04-15-82	3904682 09-09-92 3998966 12-21-93 4001301 09-09-92 4009197 09-09-92	NS 09-24-86
NAPROXEN SODIUM 275MG	ANAPROX (TABLET; ORAL)	SYNTEX PR	18-164 09-04-80	3998966 12-21-93 4001301 09-09-92 4009197 09-09-92	
NICLOSAMIDE 500MG	NICLOCIDE (TABLET, CHEWABLE; ORAL)	MILES PHARMS/MILES	18-669 05-14-82		NCE 05-14-92
NICOTINE RESIN COMPLEX EQ 2MG BASE	NICORETTE (GUM, CHEWING; ORAL)	MERRELL DOW/DOW CHEM	18-612 01-13-84		NCE 01-13-94
NIFEDIPINE 10MG	PROCARDIA (CAPSULE; ORAL)	PFIZER LABS/PFIZER	18-482 12-31-81	3644627 02-22-89	
NITROGLYCERIN 0.5MG/ML	TRIDIL (INJECTABLE; INJECTION)	AM CRITICAL CARE/AHS	18-537 06-16-83		NDF 09-24-86
NITROGLYCERIN 5MG/ML	NITROSTAT (INJECTABLE; INJECTION)	PARKE-DAVIS/W-L	18-588 12-23-83		NDF 09-24-86

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
NITROGLYCERIN 5MG/ML	NITRO-BID (INJECTABLE; INJECTION)	MARION LABORATORIES	18-621 01-05-82		NDF 09-24-86
NITROGLYCERIN 1MG/ML	NITRONAL (INJECTABLE; INJECTION)	G POHL-BOSKAMP	18-672 08-30-83		NDF 09-24-86
NITROGLYCERIN 5MG/ML	NITRONAL (INJECTABLE; INJECTION)	G POHL-BOSKAMP	18-672 08-30-83		NDF 09-24-86
NITROGLYCERIN 0.8MG/ML	NITROL (INJECTABLE; INJECTION)	KREMERS-URBAN	18-774 01-19-83		NDF 09-24-86
NOMIFENSINE MALEATE 25MG	MERITAL (CAPSULE; ORAL)	HOECHST-ROUSSEL	18-224 12-31-84		NCE 12-31-89
NOMIFENSINE MALEATE 50MG	MERITAL (CAPSULE; ORAL)	HOECHST-ROUSSEL	18-224 12-31-84		NCE 12-31-89
NORETHINDRONE ACETATE 5MG	AYGESTIN (TABLET; ORAL)	AYERST LABS/AMHO	18-405 04-21-82		
NORGESTREL 0.075MG	OVRETTE (TABLET; ORAL)	WYETH LABS/AMHO	17-031 10-23-73	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91	
NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE	AVENTYL HCL (CAPSULE; ORAL)	ELI LILLY	14-684 11-06-64	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 25MG BASE	AVENTYL HCL (CAPSULE; ORAL)	ELI LILLY	14-684 11-06-64	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE/5ML	AVENTYL HCL (SOLUTION; ORAL)	ELI LILLY	14-685 11-06-64	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE/5ML	PAMELOR (SOLUTION; ORAL)	SANDOZ PHARMS/SANDOZ	18-012 08-01-77	3922305 11-25-92	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE	PAMELOR (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	18-013 08-01-77	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 25MG BASE	PAMELOR (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	18-013 08-01-77	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 75MG BASE	PAMELOR (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	18-013 06-14-79	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 50MG BASE	PAMELOR (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	18-013 06-14-79	3922305 11-25-92	
OXAMNIQUINE 250MG	VANSIL (CAPSULE; ORAL)	PFIZER LABS/PFIZER	18-069 07-23-80	3903283 09-02-92 3821228 06-28-91 3925391 12-09-92	
OXPRENOLOL HYDROCHLORIDE 20MG	TRASICOR (CAPSULE; ORAL)	CIBA/CIBA-GEIGY	18-166 12-28-83	3483221 12-09-86	NCE 12-28-93
OXPRENOLOL HYDROCHLORIDE 40MG	TRASICOR (CAPSULE; ORAL)	CIBA/CIBA-GEIGY	18-166 12-28-83	3483221 12-09-86	NCE 12-28-93
OXPRENOLOL HYDROCHLORIDE 80MG	TRASICOR (CAPSULE; ORAL)	CIBA/CIBA-GEIGY	18-166 12-28-83	3483221 12-09-86	NCE 12-28-93
OXPRENOLOL HYDROCHLORIDE 160MG	TRASICOR (CAPSULE; ORAL)	CIBA/CIBA-GEIGY	18-166 12-28-83	3483221 12-09-86	NCE 12-28-93
PANCURONIUM BROMIDE 2MG/ML	PAVULON (INJECTABLE; INJECTION)	ORGANON/AKZONA	17-015 10-24-72	3553212 01-05-88	
PANCURONIUM BROMIDE 1MG/ML	PAVULON (INJECTABLE; INJECTION)	ORGANON/AKZONA	17-015 09-14-73	3553212 01-05-88	
PARAMETHASONE ACETATE 1MG	HALDRONE (TABLET; ORAL)	ELI LILLY	12-772 04-17-61	3499016 03-03-87	

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
PARAMETHASONE ACETATE 2MG	HALDRONE (TABLET; ORAL)	ELI LILLY	12-772 04-17-61	3499016 03-03-87	
PENTAGASTRIN 0.25MG/ML	PEPTAVLON (INJECTABLE; INJECTION)	AYERST LABS/AMHO	17-048 07-26-74	3896103 07-22-92	
PENTAMIDINE ISETHIONATE 300MG/VIAL	PENTAM 300 (INJECTABLE; INJECTION)	LYPHOMED	19-264 10-16-84		
PENTAZOCINE LACTATE EQ 30MG BASE/ML	TALWIN (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	16-194 07-24-67	4105659 08-08-95	
PENTETATE INDIUM DISODIUM, IN-111 1MCI/ML	MPI INDIUM DTPA IN 111 (INJECTABLE; INJECTION)	MEDI-PHYSICS	17-707 02-18-82		NCE 02-18-92
PENTOXIFYLLINE 400MG	TRENTAL (TABLET, CONTROLLED RELEASE; ORAL)	HOECHST-ROUSSEL	18-631 08-30-84	3737433 06-05-90 4189469 02-02-97	NCE 08-30-94
PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE 5MG/5ML; 6.25MG/5ML	PHENERGAN VC (SYRUP; ORAL)	WYETH LABS/AMHO	08-604 04-02-84		
PILOCARPINE HYDROCHLORIDE 4%	PILOPINE HS (GEL; OPHTHALMIC)	ALCON LABORATORIES	18-796 10-01-84		NDF 10-01-87
PIMOZIDE 2MG	ORAP (TABLET; ORAL)	MCNEIL PHARM	17-473 07-31-84		NCE 07-31-94
PINDOLOL 5MG	VISKEN (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	18-285 09-03-82	3471515 10-07-86	NCE 09-03-92
PINDOLOL 10MG	VISKEN (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	18-285 09-03-82	3471515 10-07-86	NCE 09-03-92

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
PINDOLOL 15MG	VISKEN (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	18-285 09-03-82	3471515 10-07-86	NCE 09-03-92
PIROXICAM 10MG	FELDENE (CAPSULE; ORAL)	PFIZER LABS/PFIZER	18-147 04-06-82	3591584 07-06-88 3674876 07-04-89 3862319 01-21-92 4100347 07-11-95 3927002 12-16-92 RE29668 12-10-91	NCE 04-06-92
PIROXICAM 20MG	FELDENE (CAPSULE; ORAL)	PFIZER LABS/PFIZER	18-147 04-06-82	3591584 07-06-88 3674876 07-04-89 3862319 01-21-92 4100347 07-11-95 3927002 12-16-92 RE29668 12-10-91	NCE 04-06-92
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE 236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	GOLYTELY (POWDER FOR RECONSTITUTION; ORAL)	BRAINTREE LABS	19-011 07-13-84		

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE 120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET	COLYTE (POWDER FOR RECONSTITUTION; ORAL)	EDLAW PREPARATIONS	18-983 10-26-84		
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE 227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	COLYTE (POWDER FOR RECONSTITUTION; ORAL)	EDLAW PREPARATIONS	18-983 10-26-84		
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE 360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET	COLYTE (POWDER FOR RECONSTITUTION; ORAL)	EDLAW PREPARATIONS	18-983 10-26-84		
POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE 0.5MG; 1MG	MINIZIDE (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-986 06-13-80	3511836 05-12-87 3663706 05-16-89 4130647 12-19-95	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE 0.5MG; 2MG	MINIZIDE (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-986 06-13-80	3511836 05-12-87 3663706 05-16-89 4130647 12-19-95	
POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE 0.5MG; 5MG	MINIZIDE (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-986 06-13-80	3511836 05-12-87 3663706 05-16-89 4130647 12-19-95	
POTASSIUM ACETATE 2MEQ/ML	POTASSIUM ACETATE IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-896 07-20-84		NDF 09-24-86
POTASSIUM CHLORIDE 10MEQ	KLOTRIX (TABLET, CONTROLLED RELEASE; ORAL)	MEAD JOHNSON/B-M	17-850 05-22-80	4140756 02-20-96	
POTASSIUM CHLORIDE; SODIUM CHLORIDE 150MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-630 02-17-83		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 300MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-630 02-17-83		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 150MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-630 02-17-83		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 300MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-630 02-17-83		

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
POTASSIUM CHLORIDE; SODIUM CHLORIDE 75MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-722 11-09-82		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 150MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-722 11-09-82		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 220MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-722 11-09-82		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 300MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-722 11-09-82		
PRALIDOXIME CHLORIDE 300MG/ML	PROTOPAM CHLORIDE (INJECTABLE; INJECTION)	AYERST LABS/AMHO	18-799 12-13-82	3629425 12-21-88	NDF 09-24-86
PRALIDOXIME CHLORIDE 300MG/ML	PRALIDOXIME CHLORIDE (INJECTABLE; INJECTION)	SURVIVAL TECHNOLOGY	18-986 12-13-82		NDF 09-24-86
PRAZEPAM 20MG	CENTRAX (CAPSULE; ORAL)	PARKE-DAVIS/W-L	18-144 05-10-82		NS 09-24-86
PRAZIQUANTEL 600MG	BILTRICIDE (TABLET; ORAL)	MILES PHARMS/MILES	18-714 12-29-82	4001411 01-04-94	NCE 12-29-92
PRAZOSIN HYDROCHLORIDE 5MG	MINIPRESS (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-442 06-23-76	3511836 05-12-87 3663706 05-16-89 4092315 05-30-95 4130647 12-19-95	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
PRAZOSIN HYDROCHLORIDE 1MG	MINIPRESS (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-442 06-23-76	3511836 05-12-87 3663706 05-16-89 4092315 05-30-95 4130647 12-19-95	
PRAZOSIN HYDROCHLORIDE 2MG	MINIPRESS (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-442 06-23-76	3511836 05-12-87 3663706 05-16-89 4092315 05-30-95 4130647 12-19-95	
PROBUCOL 250MG	LORELCO (TABLET; ORAL)	MERRELL DOW/DOW CHEM	17-535 02-01-77	3576883 04-27-88 3862332 01-21-92	
PROCARBAZINE HYDROCHLORIDE EQ 50MG BASE	MATULANE (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	16-785 07-22-69	3520926 07-21-87	
PROPRANOLOL HYDROCHLORIDE 10MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 11-13-67		I-15 09-24-86
PROPRANOLOL HYDROCHLORIDE 20MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 10-16-74		I-15 09-24-86
PROPRANOLOL HYDROCHLORIDE 40MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 11-13-67		I-15 09-24-86
PROPRANOLOL HYDROCHLORIDE 60MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 10-18-82		NS 09-24-86 I-15 09-24-86
PROPRANOLOL HYDROCHLORIDE 80MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 10-16-74		I-15 09-24-86

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
PROPRANOLOL HYDROCHLORIDE 80MG	INDERAL LA (CAPSULE, CONTROLLED RELEASE; ORAL)	AYERST LABS/AMHO	18-553 04-19-83	4138475 02-06-96	NDF 09-24-86
PROPRANOLOL HYDROCHLORIDE 90MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 10-18-82		NS 09-24-86 I-15 09-24-86
PROPRANOLOL HYDROCHLORIDE 120MG	INDERAL LA (CAPSULE, CONTROLLED RELEASE; ORAL)	AYERST LABS/AMHO	18-553 04-19-83	4138475 02-06-96	NDF 09-24-86
PROPRANOLOL HYDROCHLORIDE 160MG	INDERAL LA (CAPSULE, CONTROLLED RELEASE; ORAL)	AYERST LABS/AMHO	18-553 04-19-83	4138475 02-06-96	NDF 09-24-86
PROTEIN HYDROLYSATE 5%	AMINOSOL 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	05-932 01-31-85		
PROTAMINE SULFATE 250MG/VIAL	PROTAMINE SULFATE (INJECTABLE; INJECTION)	UPJOHN	07-413 08-02-84		NS 09-24-86
PROTIRELIN 0.5MG/ML	THYPINONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	17-638 11-05-76	3746697 07-17-90	
PROTIRELIN 0.5MG/ML	RELEFACT TRH (INJECTABLE; INJECTION)	HOECHST-ROUSSEL	18-087 07-18-78	3746697 07-17-90	
PYRANTEL PAMOATE EQ 250MG BASE/5ML	ANTIMINTH (SUSPENSION; ORAL)	ROERIG/PFIZER	16-883 12-30-71	3644624 02-22-89 3549624 12-22-87	
RANITIDINE HYDROCHLORIDE EQ 150MG BASE	ZANTAC (TABLET; ORAL)	GLAXO	18-703 06-09-83	4128658 12-05-95	NCE 06-09-93 I-35 06-28-88
RANITIDINE HYDROCHLORIDE EQ 25MG BASE/ML	ZANTAC (INJECTABLE; INJECTION)	GLAXO	19-090 10-19-84	4128658 12-05-95	NCE 06-09-93

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
RITODRINE HYDROCHLORIDE 10MG	YUTOPAR (TABLET; ORAL)	ASTRA PHARM PRODS	18-555 12-12-80	3410944 11-12-85	
RITODRINE HYDROCHLORIDE 10MG/ML	YUTOPAR (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	18-580 12-12-80	3410944 11-12-85	
RITODRINE HYDROCHLORIDE 15MG/ML	YUTOPAR (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	18-580 09-27-84	3410944 11-12-85	
SAFFLOWER OIL; SOYBEAN OIL 10%; 10%	LIPOSYN II 20% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-991 08-27-84		NP 09-24-86
SAFFLOWER OIL; SOYBEAN OIL 5%; 5%	LIPOSYN II 10% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-997 08-27-84		NP 09-24-86
SARALASIN ACETATE EQ 0.6MG BASE/ML	SARENIN (INJECTABLE; INJECTION)	NORWICH EATON/P&G	18-009 05-29-81	3932624 01-13-93 3886134 05-27-92	
SCOPOLAMINE 1.5MG	TRANSDERM-SCOP (FILM, CONTROLLED RELEASE; PERCUTANEOUS)	CIBA/CIBA-GEIGY	17-874 12-31-79	4031894 06-28-94 4262003 04-14-98 4436741 04-14-98	
SELENIUM SULFIDE 2.5%	SELSUN (SHAMPOO/LOTION; TOPICAL)	ABBOTT LABS	07-936 05-17-51		I-3 09-24-86
SILVER SULFADIAZINE 1%	SILVADENE (CREAM; TOPICAL)	MARION LABORATORIES	17-381 11-26-73	3761590 09-24-90	
SILVER SULFADIAZINE 1%	SSD (CREAM; TOPICAL)	TRAVENOL LABS	18-578 02-25-82		

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
SINCALIDE 0.005MG/VIAL	KINEVAC (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-697 07-21-76	3839315 10-01-91	
SODIUM ACETATE, ANHYDROUS 2MEQ/ML	SODIUM ACETATE IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-893 05-04-83		PP 09-24-86
SODIUM CHLORIDE 450MG/100ML	SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-497 02-19-82		
SODIUM CHLORIDE 9MG/ML	BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-800 10-29-82		
SODIUM CHLORIDE 9MG/ML	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-803 10-29-82		
SODIUM CHLORIDE 2.5MEQ/ML	SODIUM CHLORIDE IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-897 07-20-84		
SODIUM CHLORIDE 3GM/100ML	SODIUM CHLORIDE 3% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-022 11-01-83		
SODIUM CHLORIDE 5GM/100ML	SODIUM CHLORIDE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-022 11-01-83		
SODIUM CHLORIDE 9MG/ML	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-217 07-13-84		
SODIUM CHLORIDE 9MG/ML	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-218 07-13-84		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
SODIUM CHLORIDE 900MG/100ML	SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	19-319 05-17-85		
SODIUM IODIDE, I-123 100 UCI	SODIUM IODIDE I 123 (CAPSULE; ORAL)	BENEDICT NUCLR PHARM	18-671 05-27-82		
SODIUM IODIDE, I-123 200 UCI	SODIUM IODIDE I 123 (CAPSULE; ORAL)	BENEDICT NUCLR PHARM	18-671 05-27-82		
SODIUM IODIDE, I-123 400 UCI	SODIUM IODIDE I 123 (CAPSULE; ORAL)	BENEDICT NUCLR PHARM	18-671 05-27-82		
SODIUM LACTATE 5MEQ/ML	SODIUM LACTATE IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-947 09-05-84		NS 09-24-86
SODIUM NITROPRUSSIDE 50MG/VIAL	SODIUM NITROPRUSSIDE (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-581 07-28-82		
SODIUM PHOSPHATE, DIBASIC; SODIUM PHOSPHATE, MONOBASIC 142MG/ML; 276MG/ML	SODIUM PHOSPHATES IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-892 05-10-83		NP 09-24-86
SOMATROPIN 2 IU/VIAL	ASELLACRIN 2 (INJECTABLE; INJECTION)	SERONO LABS	17-726 07-21-83		NS 09-24-86
SORBITOL 3GM/100ML	SORBITOL 3% IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-512 05-27-82		
SOYBEAN OIL 10%	SOYACAL 10% (INJECTABLE; INJECTION)	ALPHA THERAPEUTIC	18-465 06-29-83		
SOYBEAN OIL 10%	TRAVAMULSION 10% (INJECTABLE; INJECTION)	TRAVENOL LABS	18-660 02-26-82		
SOYBEAN OIL 20%	TRAVAMULSION 20% (INJECTABLE; INJECTION)	TRAVENOL LABS	18-758 02-15-83		

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
SOYBEAN OIL 20%	SOYACAL 20% (INJECTABLE; INJECTION)	ALPHA THERAPEUTIC	18-786 06-29-83		
SOYBEAN OIL 10%	LIPOSYN III 10% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-969 09-24-84		
SOYBEAN OIL 20%	LIPOSYN III 20% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-970 09-25-84		
STANOZOLOL 2MG	WINSTROL (TABLET; ORAL)	WINTHROP LABS/STERL	12-885 11-30-61	3704295 11-28-89	I-28 09-24-86
STREPTOZOCIN 1GM/VIAL	ZANOSAR (INJECTABLE; INJECTION)	UPJOHN	17-961 05-07-82		NCE 05-07-92
SUCRALFATE 1GM	CARAFATE (TABLET; ORAL)	MARION LABORATORIES	18-333 10-30-81	3432489 03-11-86	
SUFENTANIL CITRATE EQ 0.05MG BASE/ML	SUFENTA (INJECTABLE; INJECTION)	JANSSEN PHARMA	19-050 05-04-84	3998834 12-21-93	NCE 05-04-94
SULFAMETHOXAZOLE; TRIMETHOPRIM 400MG; 80MG	BACTRIM (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-377 07-30-73	RE28636 06-02-87	
SULFAMETHOXAZOLE; TRIMETHOPRIM 800MG; 160MG	BACTRIM DS (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-377 03-01-78	RE28636 06-02-87	
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	BACTRIM (SUSPENSION; ORAL)	HOFFMANN-LA ROCHE	17-560 04-16-75	RE28636 06-02-87	I-21 09-24-86
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	BACTRIM PEDIATRIC (SUSPENSION; ORAL)	HOFFMANN-LA ROCHE	17-560 12-10-79	RE28636 06-02-87	I-21 09-24-86
SULFAMETHOXAZOLE; TRIMETHOPRIM 80MG/ML; 16MG/ML	BACTRIM (INJECTABLE; INJECTION)	HOFFMANN-LA ROCHE	18-374 06-23-81	3551564 12-29-87 RE28636 06-02-87	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
SULFAMETHOXAZOLE; TRIMETHOPRIM 400MG; 80MG	SULFAMETHOXAZOLE AND TRIMETHOPRIM (TABLET; ORAL)	DRUMMER/PHOENIX	18-598 05-19-82		
SULFAMETHOXAZOLE; TRIMETHOPRIM 800MG; 160MG	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH (TABLET; ORAL)	DRUMMER/PHOENIX	18-598 05-19-82		
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	SULFATRIM PEDIATRIC (SUSPENSION; ORAL)	NATL PHARM MFG/BARRE	18-615 01-07-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	SULFATRIM (SUSPENSION; ORAL)	NATL PHARM MFG/BARRE	18-615 01-07-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	SMZ-TMP (SUSPENSION; ORAL)	BIOCRAFT LABS	18-812 01-28-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	SMZ-TMP PEDIATRIC (SUSPENSION; ORAL)	BIOCRAFT LABS	18-812 06-10-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 400MG; 80MG	SULFAMETHOXAZOLE AND TRIMETHOPRIM (TABLET; ORAL)	DANBURY PHARMACAL	18-852 05-09-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 800MG; 160MG	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH (TABLET; ORAL)	DANBURY PHARMACAL	18-854 05-09-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 400MG; 80MG	SULFAMETHOXAZOLE & TRIMETHOPRIM (TABLET; ORAL)	HEATHER DRUG	18-946 08-10-84		
SULFAMETHOXAZOLE; TRIMETHOPRIM 800MG; 160MG	SULFAMETHOXAZOLE & TRIMETHOPRIM (TABLET; ORAL)	HEATHER DRUG	18-946 08-10-84		
SULFAMETHOXAZOLE; TRIMETHOPRIM 400MG; 80MG	SEPTRA (TABLET; ORAL)	BURROUGHS WELLCOME	17-376 07-30-73	4209513 06-24-97	
SULFAMETHOXAZOLE; TRIMETHOPRIM 800MG; 160MG	SEPTRA DS (TABLET; ORAL)	BURROUGHS WELLCOME	17-376 02-12-76	4209513 06-24-97	

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
SULFASALAZINE 500MG	AZULFIDINE (TABLET, ENTERIC COATED; ORAL)	PHARMACIA/PHARMACIA	07-073 04-06-83		NDF 09-24-86
SULFASALAZINE 500MG	SULFASALAZINE (TABLET, ENTERIC COATED; ORAL)	BOLAR PHARMACEUTICAL	88-052 05-24-83		NDF 09-24-86
SULINDAC 150MG	CLINORIL (TABLET; ORAL)	MS&D/MERCK	17-911 09-27-78	3654349 04-04-89 3725548 04-03-90	
SULINDAC 200MG	CLINORIL (TABLET; ORAL)	MS&D/MERCK	17-911 09-27-78	3725548 04-03-90 3654349 04-04-89	
SUTILAINS 82,000 UNITS/GM	TRAVASE (OINTMENT; TOPICAL)	TRAVENOL LABS	12-828 06-12-69	3409719 11-05-85	
TECHNETIUM, TC-99M SODIUM PERTECHNETATE GENERATOR 0.22-2.22CI/GENERATOR	MINITEC (SOLUTION; INTRAVENOUS, ORAL)	ER SQUIBB AND SONS	17-339 06-03-74		I-31 09-24-86
TECHNETIUM, TC-99M, ALBUMIN COLLOID KIT N/A	MICROLITE (INJECTABLE; INJECTION)	MED DIAG/NE NUCLEAR	18-263 03-25-83		
TECHNETIUM, TC-99M, DISOFENIN KIT N/A	HEPATOLITE (INJECTABLE; INJECTION)	MED DIAG/NE NUCLEAR	18-467 03-16-82		NP 09-24-86
TECHNETIUM, TC-99M, GLUCEPTATE KIT N/A	TECHNESCAN GLUCEPTATE (INJECTABLE; INJECTION)	MS&D/MERCK	18-272 01-27-82		
TECHNETIUM, TC-99M, MEDRONATE N/A	OSTEOLITE (INJECTABLE; INJECTION)	MED DIAG/NE NUCLEAR	17-972 12-16-77		
TECHNETIUM, TC-99M, MEDRONATE N/A	AMERSCAN (INJECTABLE; INJECTION)	AMERSHAM/RADIOCHEM	18-335 08-05-82		
TECHNETIUM, TC-99M, SUCCIMER KIT N/A	MPI DMSA KIDNEY REAGENT (INJECTABLE; INJECTION)	MEDI-PHYSICS	17-944 05-18-82	4208398 06-17-97 4233285 11-11-97	NP 09-24-86

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
TERBUTALINE SULFATE 0.2MG/INH	BRETHAIRE (AEROSOL; INHALATION)	GEIGY/CIBA-GEIGY	18-762 08-17-84	3937838 02-10-93 4011258 03-08-94	NDF 09-24-86
TERBUTALINE SULFATE 0.2MG/INH	BRICANYL (AEROSOL; INHALATION)	MERRELL DOW/DOW CHEM	18-000 03-19-85	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 1MG/ML	BRICANYL (INJECTABLE; INJECTION)	MERRELL DOW/DOW CHEM	17-466 03-25-74	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 2.5MG	BRICANYL (TABLET; ORAL)	MERRELL DOW/DOW CHEM	17-618 04-22-75	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 5MG	BRICANYL (TABLET; ORAL)	MERRELL DOW/DOW CHEM	17-618 04-22-75	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 2.5MG	BRETHINE (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-849 05-17-76	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 5MG	BRETHINE (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-849 05-17-76	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 1MG/ML	BRETHINE (INJECTABLE; INJECTION)	GEIGY/CIBA-GEIGY	18-571 11-30-81	3937838 02-10-93 4011258 03-08-94	

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
TERFENADINE 60MG	SELDANE (TABLET; ORAL)	MERRELL DOW/DOW CHEM	18-949 05-08-85	3806526 04-23-91 3878217 04-15-92 3965257 06-22-93 3966949 06-29-93 4254129 03-03-98 4285957 08-25-98	NCE 05-08-90
THALLOUS CHLORIDE, TL-201 2MCI/ML	THALLOUS CHLORIDE TL 201 (INJECTABLE; INJECTION)	MEDI-PHYSICS	18-110 02-01-82		NS 09-24-86
THALLOUS CHLORIDE, TL-201 1MCI/ML	THALLOUS CHLORIDE TL 201 (INJECTABLE; INJECTION)	AMERSHAM/RADIOCHEM	18-548 12-30-82		
THEOPHYLLINE 300MG	QUIBRON-T/SR (TABLET, CONTROLLED RELEASE; ORAL)	MEAD JOHNSON/B-M	87-563 06-21-83	4465660 08-14-01	
TIMOLOL MALEATE 5MG	BLOCADREN (TABLET; ORAL)	MS&D/MERCK	18-017 11-25-81	3655663 04-11-89	
TIMOLOL MALEATE 10MG	BLOCADREN (TABLET; ORAL)	MS&D/MERCK	18-017 11-25-81	3655663 04-11-89	
TIMOLOL MALEATE 20MG	BLOCADREN (TABLET; ORAL)	MS&D/MERCK	18-017 11-25-81	3655663 04-11-89	
TIMOLOL MALEATE EQ 0.25% BASE	TIMOPTIC (SOLUTION; OPHTHALMIC)	MS&D/MERCK	18-086 08-17-78	4195085 03-25-97 3655663 04-11-89	
TIMOLOL MALEATE EQ 0.5% BASE	TIMOPTIC (SOLUTION; OPHTHALMIC)	MS&D/MERCK	18-086 08-17-78	4195085 03-25-97 3655663 04-11-89	

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
TOCAINIDE HYDROCHLORIDE 400MG	TONOCARD (TABLET; ORAL)	MS&D/MERCK	18-257 11-09-84	4218477 08-19-97 4237068 12-02-97	NCE 11-09-89
TOCAINIDE HYDROCHLORIDE 600MG	TONOCARD (TABLET; ORAL)	MS&D/MERCK	18-257 11-09-84	4218477 08-19-97 4237068 12-02-97	NCE 11-09-89
TOLAZAMIDE 100MG	TOLAZAMIDE (TABLET; ORAL)	ZENITH LABORATORIES	18-894 11-02-84		
TOLAZAMIDE 250MG	TOLAZAMIDE (TABLET; ORAL)	ZENITH LABORATORIES	18-894 11-02-84		
TOLAZAMIDE 500MG	TOLAZAMIDE (TABLET; ORAL)	ZENITH LABORATORIES	18-894 11-02-84		
TOLAZOLINE HYDROCHLORIDE 25MG/ML	PRISCOLINE (INJECTABLE; INJECTION)	CIBA/CIBA-GEIGY	06-403 02-22-85		
TOLMETIN SODIUM EQ 200MG BASE	TOLECTIN (TABLET; ORAL)	MCNEIL LABORATORIES	17-628 03-24-76	3752826 08-14-90	
TOLMETIN SODIUM EQ 400MG BASE	TOLECTIN DS (CAPSULE; ORAL)	MCNEIL LABORATORIES	18-084 10-30-79	3752826 08-14-90	
TRAZODONE HYDROCHLORIDE 150MG	DESYREL (TABLET; ORAL)	MEAD JOHNSON/B-M	18-207 03-25-85		
TRETINOIN 0.05%	RETIN-A (SOLUTION; TOPICAL)	ORTHO PHARMACEUTICAL	16-921 10-20-71	3729568 04-24-90	
TRETINOIN 0.1%	RETIN-A (CREAM; TOPICAL)	ORTHO PHARMACEUTICAL	17-340 01-26-73	3729568 04-24-90 3906108 09-16-92	
TRETINOIN 0.05%	RETIN-A (CREAM; TOPICAL)	ORTHO PHARMACEUTICAL	17-522 07-19-74	3729568 04-24-90 3906108 09-16-92	

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
TRETINOIN 0.01%	RETIN-A (GEL; TOPICAL)	ORTHO PHARMACEUTICAL	17-955 10-05-78	3729568 04-24-90 4247547 01-27-98	
TRETINOIN 0.025%	RETIN-A (GEL; TOPICAL)	ORTHO PHARMACEUTICAL	17-579 04-18-75	3729568 04-24-90 4247547 01-27-98	
TRIAMCINOLONE ACETONIDE 0.25MG/INH	AZMACORT (AEROSOL; INHALATION)	WILLIAM H RORER	18-117 04-23-83	3897779 08-05-92 3927806 12-23-92	NDF 09-24-86
TRIAMCINOLONE ACETONIDE 0.1%	KENALOG-H (CREAM; TOPICAL)	ER SQUIBB AND SONS	86-240 06-22-78	4048310 09-13-94	
TRIAZOLAM 0.125MG	HALCION (TABLET; ORAL)	UPJOHN	17-892 04-26-85	3980790 09-14-93 3987052 10-19-93	NCE 11-15-92
TRIAZOLAM 0.25MG	HALCION (TABLET; ORAL)	UPJOHN	17-892 11-15-82	3980790 09-14-93 3987052 10-19-93	NCE 11-15-92
TRIAZOLAM 0.5MG	HALCION (TABLET; ORAL)	UPJOHN	17-892 11-15-82	3980790 09-14-93 3987052 10-19-93	NCE 11-15-92
TRILOSTANE 30MG	MODRASTANE (CAPSULE; ORAL)	WINTHROP LABS/STERL	18-719 12-21-84		NCE 12-21-89
TRILOSTANE 60MG	MODRASTANE (CAPSULE; ORAL)	WINTHROP LABS/STERL	18-719 12-21-84		NCE 12-21-89
TRIMETHOPRIM 200MG	PROLOPRIM (TABLET; ORAL)	BURROUGHS WELLCOME	17-943 07-14-82		NS 09-24-86
TRIMETHOPRIM 200MG	TRIMPEX 200 (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-952 11-09-82		NS 09-24-86

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Generated for Shearrer, Cynthia D (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google
Digitized by Google
Original from UNIVERSITY OF MICHIGAN

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
TRIMETHOPRIM 100MG	TRIMETHOPRIM (TABLET; ORAL)	BIOCRAFT LABS	18-679 07-30-82		
TRIMIPRAMINE MALEATE EQ 100MG BASE	SURMONTIL (CAPSULE; ORAL)	IVES LABS/AMHO	16-792 09-15-82		NS 09-24-86
VECURONIUM BROMIDE 10MG/VIAL	NORCURON (NC-45) (INJECTABLE; INJECTION)	ORGANON/AKZONA	18-776 04-30-84	3553212 01-05-88 4237126 12-02-97 4297351 10-27-98	NCE 04-30-94
VERAPAMIL HYDROCHLORIDE 80MG	ISOPTIN (TABLET; ORAL)	KNOLL PHARMACEUTICAL	18-593 03-08-82		NR 09-24-86
VERAPAMIL HYDROCHLORIDE 120MG	ISOPTIN (TABLET; ORAL)	KNOLL PHARMACEUTICAL	18-593 03-08-82		NR 09-24-86
VERAPAMIL HYDROCHLORIDE 80MG	CALAN (TABLET; ORAL)	SEARLE/SEARLE PHARMS	18-817 09-10-84		NR 09-24-86
VERAPAMIL HYDROCHLORIDE 120MG	CALAN (TABLET; ORAL)	SEARLE/SEARLE PHARMS	18-817 09-10-84		NR 09-24-86
VERAPAMIL HYDROCHLORIDE 2.5MG/ML	CALAN (INJECTABLE; INJECTION)	SEARLE PHARMS	18-925 03-30-84		
VERAPAMIL HYDROCHLORIDE 2.5MG/ML	CALAN (INJECTABLE; INJECTION)	SEARLE PHARMS	19-038 03-30-84		
WATER FOR INJECTION, STERILE 100%	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER (LIQUID; N/A)	TRAVENOL LABS	18-595 01-17-83		
WATER FOR INJECTION, STERILE 100%	STERILE WATER IN PLASTIC CONTAINER (LIQUID; N/A)	TRAVENOL LABS	18-632 06-30-82		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 6-30-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
WATER FOR INJECTION, STERILE 100%	STERILE WATER IN PLASTIC CONTAINER (LIQUID; N/A)	ABBOTT LABORATORIES	18-801 10-27-82		
WATER FOR INJECTION, STERILE 100%	BACTERIOSTATIC WATER IN PLASTIC CONTAINER (LIQUID; N/A)	ABBOTT LABORATORIES	18-802 10-27-82		
WATER FOR INJECTION, STERILE 100%	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER (LIQUID; N/A)	AM MCGAW/AM HOSP	19-077 03-02-84		
XENON, XE-127 5MCI/VIAL	XENON XE 127 (GAS; INHALATION)	MALLINCKRODT	18-536 10-01-82		NCE 10-01-92
XENON, XE-127 10MCI/VIAL	XENON XE 127 (GAS; INHALATION)	MALLINCKRODT	18-536 10-01-82		NCE 10-01-92
XENON, XE-133 10MCI/VIAL	XENON XE 133 (GAS; INHALATION)	MALLINCKRODT	18-327 03-09-82		
XENON, XE-133 20MCI/VIAL	XENON XE 133 (GAS; INHALATION)	MALLINCKRODT	18-327 03-09-82		

Digitized by Google
Original from UNIVERSITY OF MICHIGAN
Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 19:31 GMT / http://hdl.handle.net/2027/mdp.39015072931762
Public Domain, Google-digitized / http://www.hathitrust.org/access_use#pd-google

UNIVERSITY OF MICHIGAN
3 9015 07293 1762

Digitized by Google
Original from UNIVERSITY OF MICHIGAN